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Thesis Summary 
Traumatic spinal cord injury (SCI) is a devastating event. It causes severe damage to the 
nervous tissue which can be associated with partial or complete loss of movement and 
sensation. Recent studies suggested that the benefits of stem cell transplants for SCI may not 
be restricted to cell restoration alone, e.g. to replace damaged neurons, but also may be due 
to their capacity to stimulate endogenous cells at wound sites through paracrine activity. 
Mesenchymal stem/stromal cells (MSCs), in particular, are thought to have anti-
inflammatory, neuroprotective, neurotrophic and angiogenic effects and may thus reduce 
secondary damage and promote neuroregeneration and wound healing after their 
administration. Experimental studies of small rodent SCI models are currently being used to 
investigate the MSCs as a promising option for treatments that repair damaged neuronal 
tissue. However, translation to human patients is still a challenging step. Dogs represent a 
good large animal model as the causes of SCI in dogs occur naturally and traumatically, and 
because of the similar scale and heterogeneity of the lesions formed. Therefore, this study 
aimed to investigate and compare the effects of canine and human MSCs, focused on the 
effects of MSC conditioned medium (MSC CM) on neurogenesis and angiogenesis using 
established responder cell lines, i.e. SH-SY5Y neuronal cells and EA.hy926 endothelial 
cells. All of the MSCs were derived from adipose tissue, and CD271 was used to isolate 
subset populations from human MSCs. The study has demonstrated for the first time the 
potentially beneficial effects of canine MSC CM in promoting SH-SY5Y neurite outgrowth 
and cell proliferation, as well as EA.hy926 endothelial cell proliferation, cell migration and 
the formation of endothelial tubules. Further experimentation demonstrated that canine and 
human adipose-derived MSCs exhibited such neurotrophic and angiogenic effects to a 
similar extent. This may have important implications for the pre-clinical assessment of MSC 
paracrine activity in the development of cell transplantation protocols both for dogs and 
humans. Finally, the study compared the neurotrophic and angiogenic effects of MSC CM 
from selected subpopulations of human MSCs, i.e. CD271+ versus CD271- and plastic 
adherent MSCs; this was with a view to establishing whether a more homogeneous MSC 
population might differ in their paracrine activity. There was no significant difference in the 
neurogenic effects of these various secretomes; however, MSC CM from human 
CD271+MSCs was found to be significantly less pro-angiogenic than human CD271- MSCs 
or non-selected human MSCs. In conclusion, the study supports the use of MSCs to treat 
naturally occurring SCI in dogs, and suggests that there is no evidence herein to support pre-
selecting CD271+ cells.  
Key words: human MSCs, canine MSCs, MSC CM, SCI, CD271, neurogenic, angiogenic.
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1. Introduction 
 
This chapter explores the problem area that inspired the hypothesis which was tested in this study. 
This chapter covers several topics including; the stem cells and their different types, in particular, the 
MSCs and their therapeutic role in treating spinal cord injury (SCI). This chapter also explains the 
role of the large animal model in translating SCI research.  At the end of the chapter, the aim of the 
study is presented. This thesis is organised as follows:  chapter two discusses the chosen 
methodology, chapter three to five set out the results obtained by this study and chapter six discusses 
the results and draws conclusions. 
 
1.1 Stem Cells 
Stem cells are undifferentiated cells found in multicellular organisms. Although they make up a small 
portion of the body mass, their properties and capacities of developing into a variety of cell types in 
the body are remarkable. Stem cells can divide through mitosis and differentiate into a variety of 
specialised cell types. Moreover, stem cells can self-renew to produce more stem cells (Lin, 2008). 
Also, under certain physiological conditions in vitro, stem cells can differentiate into different mature 
cell types with specialised functions (Wells, 2002). The ability to differentiate into diverse cell types 
allows stem cells to serve as a repair system to continuously replenish other cells (Li and Xie, 2005). 
Once, a stem cell divides, each new cell has the potential to either remain as a stem cell or become 
another mature cell type with new specific functions (Lechler and Fuchs, 2005). In fact, it is still a 
challenge to understand the underlying mechanisms of stem cells to differentiate and develop into 
various types of cells, which in turn have important biological functions (Feng and Wang, 2012, Xu 
et al., 2014).  However, all stem cells, regardless of their origin, have three features. Firstly, one of 
the fundamental properties of stem cells is they are unspecialised cells, not allowed to perform 
specific functions as they do not have any tissue-specific structures (Melton, 2014).
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For example, a stem cell cannot work with its neighbors to pump blood through the body (like a heart 
muscle cell)  ; it cannot carry molecules of oxygen through the bloodstream (like a red blood cell);  
it cannot fire electrochemical signals to other cells that allow the body to move or speak like a nerve 
cell (Zapata et al., 2012). However, unspecialised stem cells can give rise to specialised cells, 
including heart muscle cells, blood cells, or nerve cells (Kehat et al., 2001, Wichterle et al., 2002, 
Novotny et al., 2009). Secondly, stem cells have the capacity for dividing and renewing themselves 
for long periods. Stem cells may replicate many times in contrast with other mature cells such as 
muscles, red blood cells and nerve cells which do not usually replicate themselves (Clatworthy and 
Subramanian, 2001).  
Proliferation is the term which describes the repeated self-replication. The in vitro experimental 
studies showed that the stem cells can replicate many times, and can yield millions of cells. These 
studies have used the cell doubling time assay and cell proliferation assay to show the proliferative 
potential of the stem cells(Bruder et al., 1997, Baksh et al., 2007). If these cells resulting from 
proliferation continue to be unspecialised, like their original parent stem cells, then the cells will also 
be capable of long-term self-renewal (Park et al., 2008). Thirdly, stem cells can give rise to 
specialised cells. Differentiation is the term which describes the process by which unspecialized stem 
cells result in specialised cells through distinctive differentiation pathways controlled by internal and 
external signals. Researchers in their studies are just beginning to understand the internal signals and 
external signals that trigger the differentiation of stem cells. The internal signals are controlled by a 
cell's genes, which are interspersed across long strands of DNA, and carry coded instructions for all 
the structures and functions of a cell. The external signals for cell differentiation include chemicals 
secreted by other cells, physical contact with neighbouring cells, and certain molecules in the 
microenvironment (Tosh and Horb, 2014). These characteristics make stem cells a good target in 
regenerative medicine as they hold promise in the repair and regeneration of damaged tissue (Kimbrel 
and Lanza, 2015). Fighting diseases is a fundamental battle, stem cells present a powerful therapy to 
repair injured tissue by cell therapy and tissue regeneration (Trounson and DeWitt, 2016).
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There are a variety of sources of stem cells, based on the type of tissue origin. Mammalian stem cells 
can be classified into embryonic stem cells (ESCs), which can form specialised cells of all three germ 
layers, i.e., ectoderm, mesoderm and endoderm,  and adult stem cells, which are more restricted in 
their differentiation potential (Fortier, 2005). 
 
1.2 Types of stem cells  
The potency of stem cells can be defined as the capacity to differentiate into specialised cell types 
(Polejaeva and Mitalipov, 2013). During adulthood life and growth of each organism, stem cells have 
an increased potential to develop into many different cell types in the body. They have a crucial role 
in replenishing other cells in the body (Avasthi et al., 2008). Stem cell potency can be classified 
according to the differentiation extent of stem cells to give rise to different cell types. There are three 
main classifications for stem cell potency; these are: totipotent, pluripotent or multipotent (Sharma 
et al., 2012). Totipotent stem cells are stem cells that have the ability to differentiate into all possible 
cell types.  
The first few cells that result from the division of the zygote, which formed by the fusion of sperm 
cell with an egg cell,  are considered as totipotent stem cells. They have the potential capacity to give 
rise to the whole embryo and extra embryonic structures (Figure 1.1) (Martín and Menéndez, 2012). 
Pluripotent stem cells are stem cells that have the ability to give rise and differentiate into almost all 
cell types. An example of pluripotent stem cells is ESCs that are isolated from the inner cell mass 
(ICM) which can give rise to all cell types that are derived from the mesoderm, endoderm, and 
ectoderm germ layers (Figure 1.2). Induce pluripotent stem cells (iPSCs) are another example of 
pluripotent stem cells (Thomson et al., 1998, Sharma et al., 2012). Multipotent stem cells are stem 
cells that have the capacity to differentiate and give rise to several cell types. Haematopoietic stem 
cells (HSCs) and mesenchymal stem cells (MSCs) are examples of multipotent stem cells (Figure1.5) 
(Uccelli et al., 2008).
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Figure 1:1 Early developmental stages of a human zygote as an example for totipotent stem 
cells.  
Schematic illustration showing the stages of division of a fertilised egg as an example for totipotent 
stem cells. Each cell is capable of giving rise to a complete organism, plus the extraembryonic 
placental cells. Image adapted (Shutterstock, 2003).
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Figure 1:2 Embryonic stem cells derived from the inner cell mass as an example of pluripotent 
stem cells.  
Schematic illustration showing the developmental stages of embryonic stem cells which are derived 
from the ICM and their differentiation capacity into any of the three germ layers ectoderm, mesoderm 
and endoderm. They do not have the ability to give rise to the extraembryonic structures the umbilical 
cord and placenta. Image adapted from (Chial, 2008). 
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1.2.1 Embryonic stem cells  
In 1981, Evans and Kaufman were the first to isolate embryonic stem cells from mouse, which can 
be isolated from the ICM of the blastocyst at early stages of embryonic development (4-5 days after 
fertilisation), i.e., before implantation in the uterine wall  (Evans and Kaufman, 1981).  In the same 
year Martin, 1981 named them as ESCs (Martin, 1981). This finding led to an interest in an in vitro 
isolation of human ESCs and cell culturing by James Thomson and co-workers (Figure1.3) 
(Thomson et al., 1998). ESCs can be classified as pluripotent stem cells. They can be maintained and 
expanded in culture indefinitely under optimal conditions. As stated earlier, ESCs have the capacity 
to differentiate into all three embryonic germ layers endoderm, mesoderm and ectoderm which, 
subsequently can differentiate into different tissues (Evans and Kaufman, 1981). Thomson et al. 
(1998) and Odorico et al. (2001) suggested that ESCs can propagate for about 300 population 
doublings when growing in culture and that they can be passaged for over a year in culture (Thomson 
et al., 1998, Odorico et al., 2001).  
ESCs  have the potential uses in cell replacement therapy for transplantation medicine  as they have 
the capacity to differentiate into cells or tissues that have been damaged by disease or injury 
(Thomson et al., 1998, McDonald et al., 1999, Odorico et al., 2001, Menasche et al., 2015). Thus, 
ESCs may represent great promise in the future in various research areas, such as human 
developmental biology and cell-based therapies. However, despite these advantageous characteristics 
of ESCs, they have disadvantages as well. One of these disadvantages is the ethical issues 
surrounding ESCs since, to isolate ESCs, the destruction of the human embryo is required. Also, the 
other disadvantage of using ESCs is the possibility of tumour formation. Many animal experiments 
have shown that embryonic stem cells form tumours after transplantation (Master et al., 2007). 
Moreover, transplantation of ESCs requires either a histocompatibility match or the patient needs to 
be immunosuppressed (Swijnenburg et al., 2008).
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However, Schwartz et al., 2012 showed in their preliminary report the safety of treating patients with 
Stargardt's macular dystrophy and dry age-related macular degeneration by transplantation of human 
ESC-derived retinal pigment epithelium (RPE). They reported in their study that transplantation of 
ESC-derived RPE cells showed no signs of hyperproliferation, tumorigenicity, ectopic tissue 
formation, or apparent rejection after four months. They claimed that the pre-differentiation of ESCs 
into RPE cells before their transplantation could reduce the chances of the formation of a tumour or 
being rejected by host tissues  (Schwartz et al., 2012). 
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Figure 1:3 In vitro isolation of human embryonic stem cells.  
The schematic illustration showing the steps from a fertilised egg obtained by IVF to the culture of 
ESCs are depicted. A few-celled embryo later gives rise to the blastocyst, a structure comprised of 
an outer cell layer, the trophectoderm, and ICM. The ICM is harvested and plated on feeder cells, to 
yield a population of ESCs. Image adapted from (Landry and Zucker, 2004). 
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1.2.2  Induced pluripotent stem cells  
iPSCs are in fact adult somatic cells that have regained their pluripotency state by genetic engineering 
mechanisms (Takahashi and Yamanaka, 2006). These reprogrammed adult cells are similar to ESCs 
in that they are pluripotent and capable of differentiating to produce all of the different cells and 
tissues in the adult body (Okita et al., 2007). In brief, iPSCs can be generated by treating somatic 
cells with a combination of four reprogramming factors, including Oct4 (Octamer-binding 
transcription factor 4), Sox2 (Sex-determining region Y)-box2, Klf4 (Kruppel like factor-4), and c-
Myc (Figure 1.4) (Takahashi and Yamanaka, 2006). The iPSCs may overcome the various ethical 
issues regarding the use of embryos in research and clinical medicine. Also, immune rejection is not 
a concern since the body considers the introduction of iPSCs as an autologous transplantation (Guha 
et al., 2013). However, they also have the capacity to form tumours similar to ESCs (Howe et al., 
2008). Despite all the limitations and controversy, both ESCs and iPSCs are already used in ongoing 
clinical treatments of spinal cord injury, macular degeneration of the retina, type 1 diabetes and heart 
failure (Table 1.1) (reviewed in Ilic et al., 2015). 
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Figure 1:4 Generation of iPS cells.  
The schematic illustration showing the reprogramming of adult fibroblast cells in iPS cells mediated 
by Oct-4, Klf4, Sox2 and c-Myc give rise to cells that resemble ESCs with embryonic potential. In 
2006, Kazutoshi Takahashi and Shinya Yamanaka reprogrammed mice fibroblast cells into iPS and 
in 2007 they have reprogrammed human fibroblast cells into iPS. Image adapted from (Yamanaka, 
2009). 
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Table 1: The current clinical trial using ESCs and iPSCs. 
The table shows most of the current studies ongoing or recently closed. Most of these studies have demonstrated the safety of using ESCs and iPSCs 
rather than efficacy. The table is adapted from (Ilic et al., 2015). 
Indication Cell source Institution Country Start date Finish date Subjects 
Spinal cord injury  hESC  Geron USA October 2010 July 2013 5  
Asterias USA March 2015 June 2018 13       
Immunotherapy vaccine 
for lung cancer 
hESC Asterias UK Not defined Not defined Not defined       
      
Geographic atrophy 
secondary to myopic 
macular degeneration 
hESC Ocata USA April 2014 April 2015 Not defined       
      
       
Stargardt macular 
degeneration of retina 
hESC Ocata USA July 2012 December 2030 13   
UK November  2011 December 2015 16       
Dry macular degeneration 
of retina 
hESC Ocata USA July 2012 December 2030 13  
Cell Cure 
Neurosciences 
Israel April 2015 August 2017 15      
 
iPSC RIKEN CBD Japan October 2013 Not defined 6        
Wet macular degeneration 
of retina 
hESC The London 
Project 
to Cure Blindness 
UK August 2015 October 2016 10      
      
Diabetes type I hESC ViaCyte USA September 2014 August 2017 40 
Heart failure hESC APHP France June 2013 June 2017 6 
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1.2.3 Adult stem cells 
Most human body tissues have a stem cell population; these cells are called an adult or somatic stem 
cells. Adult stem cells are responsible for the replenishment of cells of the tissue or organ where they 
reside as well as undergoing self-renewal (Goodell et al., 2015). Adult stem cells can be found in all 
part of the body tissues. For example, they can be found in the brain, bone marrow, adipose tissue, 
peripheral blood and blood vessels, skeletal muscle, skin, teeth, heart, gut, liver, ovarian epithelium, 
and testis (Zuk et al., 2002, Avgustinova and Benitah, 2016). Commonly, the beneficial and 
therapeutic usage of adult stem cells is considered more acceptable than that of ESCs, as there are 
fewer ethical considerations and less controversy on the usage of adult stem cells in comparison with 
ESCs. This is because the isolation of adult stem cells and culture does not require the destruction of 
an embryo (Bongso and Richards, 2004, Larijani et al., 2012).  
However, the therapeutic use of adult stem cells faces several challenges. These include issues that 
may be related to donor source, e.g. a genetic pre-disposition to disease. Also, limitations in the 
differentiation potential of the somatic stem cells (which are multipotent rather than pluripotent) 
compared to ESCs (Mariano et al., 2015). Also, since adult stem cells are present in small numbers 
within the tissues they reside, this means few cells can be released, and as high numbers of cells are 
needed for stem cell replacement therapies, this is another challenge of using adult stem cells 
(Spradling et al., 2001). Finally, during cell culture, the capacity of adult stem cells to renew 
themselves are not as great as with ESCs. Adult stem cells also tend to undergo senescence after 
long-term culture (Zimmermann et al., 2004).  
Example of adult stem cells which are common in use in research is HSCs and MSCs which the later 
has discussed in more details in next section.
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1.3 Mesenchymal stem cells 
1.3.1 Sources and main characteristic features of mesenchymal stem cells  
MSCs are multipotent stem cells that have the capacity to renew themselves and have the ability to 
differentiate into several lineages of cells including adipocytes, osteoblasts, chondrocytes, myocytes 
and fibroblasts (Pittenger et al., 1999).  MSCs were first identified in the late 1970s, by a group led 
by the Russian scientist, Alexander Friedenstein (Friedenstein et al., 1970). They showed in their 
study that bone marrow contains a population of cells that have the characteristic of being plastic 
adherent, highly proliferative, and have the capacity to form a colony of fibroblasts. Hence, these 
cells were named colony forming unit-fibroblasts (CFU-F) (Friedenstein et al., 1981, Friedenstein et 
al., 1982). Friedenstein and his group found that these CFU-F spontaneously formed bone, cartilage 
and fibrous tissue following transplantation in diffusion chambers (Friedenstein et al., 1987). This 
study suggested that these cells were multipotent and can form different mature cell types of 
mesenchymal lineages. In 1991, Arnold Caplan proposed the term ˝ mesenchymal stem cells˝ for the 
previously termed CFU-F (Caplan, 1991). Basically, MSCs are multipotent stem cells that have the 
capacity to renew themselves and have the ability to differentiate into several lineages of  cells 
including adipocytes and chondrocytes (Dennis et al., 1999), osteoblasts (Haynesworth et al., 1992), 
muscle (Wakitani et al., 1995, Gang et al., 2004), marrow stromal cells (Majumdar et al., 1998), 
tendon and ligament (Young et al., 1998, Kuo and Tuan, 2008), and other connective tissues 
(Studeny et al., 2004, Bhatia and Hare, 2005) (Figure 1.5). 
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Figure 1:5 Multipotent differentiation capacity of mesenchymal stem cells.  
The schematic illustration shows the differentiation capacity of MSCs into limited types of cells. 
Image adapted from (Das et al., 2013). 
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As mentioned previously, MSCs were identified for the first time in the early 1970s by Alexander 
Friedenstein using the bone marrow, these cells are now referred to as bone marrow-derived MSCs 
(BM MSCs) (Friedenstein et al., 1970). However, over the last decades many studies have 
demonstrated that MSCs can be found in other places in the body, e.g., brain, adipose tissue, liver, 
and lungs (Zuk et al., 2001, Zuk et al., 2002, Kang et al., 2010, Zou et al., 2010). The International 
Society for Cellular Therapy (ISCT) has suggested three minimum criteria that MSCs should display 
regardless of the tissue from which they are isolated. The isolated cells are termed mesenchymal 
stem cells if they demonstrate the following criteria; i) plastic adherence, ii) multipotent 
differentiation profile (i.e., adipogenic, osteogenic and chondrogenic differentiation capacity) iii) 
expression of a specific cell surface markers and the absence of others (Dominici et al., 2006). The 
cell surface markers that the isolated cells should express include; CD44, CD73, CD90 and CD105, 
more than 95 % of the MSC population must express these markers. Also, the isolated cells must 
lack expression of CD34, CD45, CD11b, CD14, CD79, CD19 and HLA class II (less than 2 % should 
express these markers (Horwitz et al., 2005, Dominici et al., 2006).  
CD44 is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration 
(Goodison et al., 1999, Ponta et al., 2003). CD73 is one of the several enzymes responsible for the 
production of extracellular adenosine, a signalling molecule that is involved in responses to 
inflammation and tissue injury (Hashikawa et al., 2003). CD90 also known as Thy1, is a 
glycosylphosphatidylinositol-linked protein involved in cell-cell and cell-matrix interactions (Rege 
and Hagood, 2006). CD105 also known as endoglin, is a type I membrane glycoprotein that functions 
as an accessory receptor for TGF-beta superfamily ligands (Varma et al., 2007). 
Whereas the cell surface markers that the isolated cells should lack are; CD34 is a member of a family 
of single-pass transmembrane sialomucin proteins that show expression on early haematopoietic and 
vascular-associated tissue (Nielsen and McNagny, 2009). CD45 is Protein tyrosine phosphatase, 
receptor type C (PTPRC). 
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It was originally called leukocyte common antigen, and it is specifically expressed in haematopoietic 
cells (Wu et al., 2002). CD11b is a macrophage-1 antigen (Mac-1) or complement receptor 3 (CR3). 
It is expressed on the surface of many leukocytes involved in the innate immune system, including 
monocytes, granulocytes, macrophages, and natural killer cells (Hickstein et al., 1987, Xu et al., 
2015). CD14 is a human gene also known as cluster of differentiation 14. The protein encoded by 
this gene is a component of the innate immune system. CD14 is expressed on the surface of various 
cells, including monocytes, macrophages, polymorphonuclear neutrophils and chondrocytes (Tobias 
and Ulevitch, 1993, Bas et al., 2004).  
CD79 is composed of two distinct chains called CD79A and CD79B (formerly known as Ig-alpha 
and Ig-beta); these form a heterodimer on the surface of a B cell stabilised by disulphide bonding. 
CD79a and CD79b are both members of the immunoglobulin superfamily (Chu and Arber, 2001, 
Matnani et al., 2013). CD19 is a protein that in humans is encoded by the CD19 gene. It is found on 
the surface of B-cells, a type of white blood cell. CD19 is a B lymphocyte cell-surface marker which 
is expressed early during pre-B-cell differentiation, and this expression remains until terminal 
differentiation into plasma cells (Zhou et al., 1992). The human leukocyte antigen (HLA) system or 
complex is a gene complex encoding the major histocompatibility complex (MHC) proteins in 
humans. The MHCs are responsible for the regulation of the immune system in humans. HLAs are 
the leading cause of organ transplant rejection (Taylor et al., 2011).  
 The MSCs are an attractive resource not only for autologous cell therapy but also for allogenic cell 
therapy, as they possess immune modulatory properties and a powerful immunosuppressive potential 
(Zhu et al., 2008). Zuk et al., 2001 was the first who identified adipose tissue-derived mesenchymal 
stem cells (AT MSCs). These cells have a multi-lineage potential differentiation profile since they 
are capable of differentiating into adipogenic, osteogenic, chondrogenic (Zuk et al., 2001) and 
myogenic cells (Mizuno et al., 2002). 
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Also, in culture AT MSCs are characterised by their expression of a panel of markers (i.e. CD44, 
CD73, CD90 and CD105) and the absence of others (i.e. CD34, CD45, CD11b, CD14, CD79, CD19 
and HLA class II). AT MSCs and BM MSCs are the main sources of MSCs, and they are widely 
used especially in autologous cell-based therapies (Hoogduijn and Dor, 2013). According to the 
website of (clinicaltrials.gov), there are around 369 clinical trials as of 20.03. 2017 on MSCs 
transplantation ranging from recruiting, enrolling by invitation to completed trails. In these studies, 
both autologous and allogenic MSCs have used for treating different conditions, these studies were 
based on showing the safety and efficacy of MSCs.  
However, AT MSCs have several biologic advantages over BM MSCs in term of regenerative 
application for repairing injured and damaged tissue. These benefits can be ascribed to the fact that 
adipose tissue is a more abundant tissue than bone marrow.  It is easy to access and the procedure to 
harvest adipose tissue has a low morbidity rate when compared with the harvesting of bone marrow 
(Padoin et al., 2008). Moreover, the yield of AT MSCs from adipose tissue is potentially higher than 
the yield from bone marrow. AT MSCs make up roughly 2% of the nucleated cells in processed 
lipoaspirate, wears BM MSCs constitute about 0.01% of the total nucleated cells in the bone marrow 
(Friedenstein et al., 1970, Li et al., 2015). 
The approximate CFU-F per gram of adipose tissue is around 5000, compared with CFU-F from 1 
ml of bone marrow MSCs which is around 100 to 1000 (Strem et al., 2005). Furthermore, AT MSCs 
have better performance in terms of proliferative capacity and secreted proteins (basic fibroblast 
growth factor, interferon-γ, and Insulin-like growth factor-1), and immunomodulatory effects (Li et 
al., 2015).  These differences between both BM MSCs and AT MSCs could be due to differences in 
tissues origin site. In fact, heterogeneity is found not only between two MSCs population from 
different tissues of origin but also can be found within the MSC population itself (Noer et al., 2006, 
Tallone et al., 2011). As AT MSCs were used in this study, the heterogeneity of this population is 
further considered in the next section.  
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1.3.2 Heterogeneity of MSCs 
Many studies suggested that MSCs are heterogeneous populations. This heterogeneity could stem 
from different reasons such as genetic, epigenetic, localization-relocalization, site of origin, and 
likely sex/gender factors (Pevsner-Fischer et al., 2011, Li et al., 2013, Hart, 2014). Therefore, using 
heterogeneous populations of MSCs with the presence of subpopulations could result in different 
outcomes. Thus, to emphasise the point, the therapeutic effect of MSCs could be achieved by using 
very well characterised subpopulations to lighten the variation (Phinney, 2012). AT MSCs are easily 
isolated from adipose tissue by collagenase digestion followed by centrifugation steps; the isolated 
fraction is called the stromal vascular fraction (SVF) (Zuk et al., 2001). This SVF is characterised by 
its highly heterogeneous nature since it has different stem cell subpopulations and more differentiated 
cells (differentiated endothelial cells, smooth muscle cells and pericytes) (Ho et al., 2008).  
The plastic adherent outgrowth from SVF is AT MSCs which in turn are considered to be a 
heterogeneous population as they comprise several subset populations (Noer et al., 2006, Tallone et 
al., 2011, Busser et al., 2015). There are several techniques used to isolate a specific subset population 
from heterogeneous populations of AT MSCs. Such isolation can be carried out either by using flow 
cytometric sorting or immunomagnetic separation (Griesche et al., 2010, Jiang et al., 2010). 
Flow cytometry is a powerful diagnostic technique which can measure the physical and chemical 
characteristics of single cells when they pass individually through a laser beam. Additionally, flow 
cytometers also have the ability to sort cells within a heterogeneous mixture. This type of flow 
cytometer device is known as a flow sorter and also known as fluorescence activated the cell sorting 
(FACS) device (Figure1.6) (Shapiro, 2004). Many studies have used FACS technology to purify 
MSCs from heterogeneous cell populations. Such purification is based on the identification of cell 
surface markers expressed by MSCs (Battula et al., 2009, Ramakrishnan et al., 2013).
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Figure 1:6 Cell sorting technique using fluorescence activated cell sorting FACS device. 
 Schematic illustration showing the steps required to isolate certain populations of cells using a FACS 
device as the cells were fluorescently labelled with a targeted marker resulting in highly pure 
population. Image adapted from (Techniques, 2004). 
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The immunomagnetic separation technique is the most common technique of sorting cells using 
magnetic forces named magnetic-activated cell sorting (MACS). The cells selected for isolation are 
labelled with 50 nm diameter superparamagnetic beads and sorted using a packed column (Miltenyi 
et al., 1990). To achieve the separation and purification of a specific subset of cells, one uses 
magnetic beads coated with an antibody that is known to bind to the selected cell type selectively. 
These magnetic beads are incubated with the sample. Once the cells- particles are formed, the mixture 
should pass through a small column under the influence of a strong magnetic force. In the column 
matrix, a high gradient magnetic field is induced as the mixture passes, leading to particle-bound 
cells to be retained while the untagged cells pass through (Figure 1.7). Before tagged cells can be 
eluted from the column and to ensure a proper purification, the column must be washed at least three 
times with buffer to remove all unwanted cells (Jones et al., 2002). In fact, subset isolation techniques 
have attracted attention in mesenchymal stem cells research; this is because the isolation of 
subpopulations from SVF could have potential benefit to repair specific damaged tissue.  
Miranville et al., 2004 isolated CD34+/CD31− cells from the SVF of human adipose tissue obtained 
from three different regions (subcutaneous gluteal, subcutaneous abdominal and visceral abdominal) 
undergoing either lipoaspiration or lipectomy. In their study, they demonstrated that the selected cells 
improved postnatal neovascularization in a mouse model with an ischemic limb (Miranville et al., 
2004). Boquest et al., 2005 also described the differences of AT MSCs stemness between two AT 
MSCs subpopulations, CD31+ cells and CD31- cells, isolated from adipose tissue which was obtained 
by liposuction from abdominal, hip, and thigh regions. In their study, they showed that the 
differentiation plasticity of CD31- was higher compared with CD31+ which most closely resembled 
microvascular cells (Boquest et al., 2005). 
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Figure 1:7 Cell sorting technique using magnetic-activated cell sorting (MACS).  
The schematic illustration shows the experimental strategy using magnetic MACS beads to isolate 
specific subtypes of cells from the mixed population. The principles behind this technique are based 
on labelling cell surface antigens with superparamagnetic microbeads specific for targeted 
populations and a magnetic column (Steinhauser et al., 2013). 
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As another example of MSC cell purification, Jones et al., 2002 reported a study in which they 
performed a cellular purification of MSCs or as Jones et al referred these cells as mesenchymal 
progenitor cells (PMCs) from bone marrow by positive selection with D7-conjugated magnetic 
microbeads. They claimed in their study that they were able to purify a Homogeneous population of 
PMCs from BM based on D7-FIB+, CD45low, LNGFR+ phenotype. They suggested that this 
population is distinctive from haematopoietic stem cells by their lack of expression CD45 and their 
large size, also they claimed that the Stro-1 marker was expressed on these cells. Their study 
suggested that the BM PMCs contained all the CFU-F activity, also these cells have the capacity to 
differentiate into adipocytes, osteoblasts, and chondrocytes (Jones et al., 2002).  
Interestingly, CD271  has been described as one of the most specific markers for the purification of 
human BM MSCs. CD271 also known as low-affinity nerve growth factor receptor (LNGFR), nerve 
growth factor receptor (NGFR), or p75NTR (neurotrophin receptor), belongs to the tumour necrosis 
factor superfamily (Quirici et al., 2002, Buhring et al., 2007). In 2002 Quirici et al., reported for the 
first time that the anti-CD271 antibody is specific for a subset population of multipotent BM cells. 
Also, they suggested in their study the use of CD271 as a marker for the selection of MSC from BM 
(Quirici et al., 2002, Jones and McGonagle, 2008). This finding was also supported by Jarocha et al., 
2006. They suggested that the purification strategy population based on CD271 expression resulted 
in obtaining a subpopulation of cells that have a higher number of CFU-F colonies with higher 
enrichment for molecular markers of early osteogenic and adipogenic progenitors (Jarocha et al., 
2008). 
Moreover, CD271 is not only a marker for a specific subset of MSCs in bone marrow, but it also has 
been used to isolate CD271 subpopulations from other tissues sources for MSCs successfully, for 
example, adipose tissue, dental pulp and placenta (Álvarez-Viejo et al., 2015). Furthermore, several 
studies suggested that the CD271 positively selected cells have demonstrated a higher differentiation 
potential.  
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Mifune et al., 2013 demonstrated in their study that CD271 selected MSCs to have a greater 
differentiation potential for chondrogenesis in vitro and in vivo than plastic adherent MSCs (PA 
MSCs) (Mifune et al., 2013). Similarly, Alvarez et al., 2015 have successfully isolated three different 
subpopulations from the dental pulp using three different combinations of surface markers 
(CD51/CD140a, CD271, and STRO-1/CD146). They reported in their study that the isolated CD271 
cells from the dental pulp displayed the greatest odontogenic potential. The isolation of CD271 
positive MSCs from adipose tissue has received increased attention and favour in regenerative 
research. Such preferences can be ascribed to the fact that AT MSCs are isolated from fat tissue 
easily, have a high yield and also, these cells are easily cultured and have the capacity to differentiate 
into various cell lines (Zuk et al., 2002). Moreover, Cuevas-Diaz Duran et al., 2013 reported in their 
study that although the amount of CD271 positive MSCs decreased with age, the CD271 positive 
cells isolated from adipose tissue were present in all age groups and their frequency was higher than 
what has been found in BM. Therefore, they suggested that the CD271 positive cells selected from 
adipose tissue were proposed as the primary choice for tissue regeneration and autologous stem cell 
therapies in older subjects (Cuevas-Diaz Duran et al., 2013). 
In summary, from all the above it can be concluded that MSCs are not a homogeneous population of 
cells. Several studies suggested that there are several stem cell subpopulations within SVF, each 
population could have potential benefit to repair specific damaged tissue (Calabrese et al., 2015, 
Latifi-Pupovci et al., 2015). Moreover, it is worth mentioning that up till now; all these previous 
studies have focused on and demonstrated the potential of MSC subpopulations only; no study has 
explored the secretomes activity of these cells. Thus, in this study and as a part of this project, the 
potential paracrine action of CD271 isolated cells has been examined. 
 
1.4 The Role of the MSCsʼ Secretomes in Regenerative Medicine 
 As stated previously MSCs are characterised by their multipotent capacity. One of the most 
characteristic features of MSCs is their potent effect on the immune system; it is well known that 
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MSCs have an excellent capability to suppress immune responses (Jiang et al., 2005, Corcione et al., 
2006, Casiraghi et al., 2008, Jarvinen et al., 2008). Also, one of the most distinguishing features of 
MSCs compared to most other cell types is that MSCs retain the ability to migrate into damaged 
tissues so that they can differentiate. In the other word, MSCs are clearly remarkable in possessing 
several regenerative properties including the homing ability to the site of damaged tissue, 
immunosuppressive capacity and multiple differentiation capacities as well as secreting growth 
factors (Figure 1.8) (Deng et al., 2011). In the past, the effective and most common accepted concept 
about the regenerative therapeutic effects of transplanted MSCs was by their migration and 
integration into the damaged tissue and differentiation into specialised cells (Kapur and Katz, 2013, 
Collawn and Patel, 2014). However, many experimental studies showed that only a small proportion 
of locally or systemically administered MSCs have participated in the healing of injured tissues 
(Baglio et al., 2012).  
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Figure 1:8 Regenerative properties of MSCs.  
Schematic diagram showing the main properties that make MSCs a potential therapy for human 
degenerative diseases. The image is adapted from (Kim et al., 2013a). 
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Thus, the scientists are currently suggesting that the beneficial effects in tissue repair and 
regeneration are more likely indirect and depend on the paracrine activity of MSCs and not on their 
engraftment. Several studies proposed secretomes as the main pathway through which MSCs exert 
their therapeutic effects in the central nervous system (CNS) (Drago et al., 2013, Teixeira et al., 2013, 
Konala et al., 2016) this will be described later in this section. Interestingly, this hypothesis opens 
the window on novel therapeutic applications involved in the development of cell-free strategies 
based on the use of MSCs secretomes. The development of such strategies can ensure a treatment 
that is free of immune rejection and tumour formation risks and maybe even potentially better in 
some cases than the application of cell therapy (Kim et al., 2013a). MSCs’ secretomes can be defined 
as a rich complex set of molecules secreted by living cells or shed from the cell surface. It is believed 
that the MSCs’ secretomes are composed of soluble factors, cytokines, chemokines, micro-RNA 
(miRNA), exosomes and microvesicles (Skalnikova et al., 2011). 
These secreted trophic and immunomodulatory/anti-inflammatory factors function together in a co-
operative manner to generate tissue microenvironments that are ideal for repair/regeneration (Figure 
1.9) (Madrigal et al., 2014). The fully characterised profile of secretomes is required for better 
application in regenerative medicine. Therefore, different proteomic approaches have been applied 
to address the characterization of growth factors, cytokines and other molecules secreted by stem 
cells (Skalnikova et al., 2011). Classical proteomic techniques such as 1-D or 2-D gel-based and 
chromatographic fractionation and protein identification using mass spectrometry, along with recent 
advancements in proteomic tools including protein microarrays, quantitative mass spectrometry and 
bioinformatics also highly sensitive antibody-based techniques are expected to enable mapping of 
the stem cell secretomes (Potian et al., 2003, Wang et al., 2006, Chiellini et al., 2008, Hoch et al., 
2012, Kim et al., 2013b).
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Figure 1:9 MSCs secretomes potential activities. 
 Schematic diagram showing a summary of the potential therapeutic roles attributed to the 
mesenchymal stem cells secretomes. Image adapted from (Lavoie and Rosu-Myles, 2013). 
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All biological functions of cells such as growth, division, differentiation, apoptosis and signalling 
are regulated and coordinated by secreted proteins (Skalnikova et al., 2011). Similarly, the tissue 
repair process requires several factors including; regulating extracellular matrix deposition, collagen 
synthesis, fibroblast proliferation, platelet activation, fibrinolysis and angiogenesis. Also, the tissue 
repair process requires immunomodulatory factors,  this are often involved in suppressing T cells, 
activating macrophages and potentially recruiting neutrophils (Krafts, 2010). 
MSCsʼ trophic properties have been studied for wound healing. MSCs can be recognised by their 
ability to secrete many vital growth factors and chemokines to induce cell proliferation and 
angiogenesis. These factors include; transforming growth factor-alpha (TGF-α), transforming growth 
factor-beta (TGF-β), hepatocyte growth factor (HGF), epithelial growth factor (EGF), basic 
fibroblast growth factor (bFGF) and Insulin-like growth factor-1(IGF-1) to increase fibroblast, 
epithelial, and endothelial cell division (Haynesworth et al., 1996, Caplan and Bruder, 2001, Collawn 
and Patel, 2014). Vascular endothelial growth factor (VEGF), IGF-1, EGF and angiopoietin-1 are 
also released to recruit endothelial lineage cell and initiate vascularization (Chen et al., 2008).  
Interestingly, there is growing evidence that MSCs’ secretomes also include neuroregulatory 
molecules such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) 
(Teixeira et al., 2013, Teixeira et al., 2016). Wilkins et al. (2009) in their study showed that MSCs 
secreted several neurotrophic factors such as BDNF. In their study, they demonstrated that exposure 
of neurones to BDNF secreted by MSCs increased activation of AKT pathways and protected 
neurones from trophic factor withdrawal (Wilkins et al., 2009). 
Similarly, Egashira et al., (2012) have suggested that murine and human adipose-derived MSCs have 
neuroprotective effects against experiment models of stroke, both in vivo and in vitro (Egashira et 
al., 2012).
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Also, Teixeria et al., 2016, has investigated the effect of human MSCsʼ secretomes on neural 
progenitor cells in an in vitro and in vivo studies. They claimed that MSCsʼ secretomes prepared 
either in dynamic or static condition both improved proliferation and differentiation of neural 
progenitor cells (Teixeira et al., 2016). Although a significant part of the trophic effect of the MSCsʼ 
secretomes are due to growth factors and cytokines, recently it has also become evident that the 
extracellular vesicles (EVs) including exosomes (40–100 nm) and microvesicles (MVs) (100–1000 
nm) have been shown to play a vital role in tissue repair (Konala et al., 2016). 
 The molecular composition of EVs are mainly proteins including; endosome-associated proteins 
(e.g., Rab GTPase, SNAREs, Annexins, and flotillin), proteins involved in biogenesis (e.g., Alix and 
Tsg101) and some membrane proteins including tetraspanins (e.g., CD63, CD81, CD82, CD53, and 
CD37) (Hemler, 2003, van Niel et al., 2006, Zoller, 2009). Additionally, the EVs are highly enriched 
in lipids (e.g., cholesterol, sphingomyelin, and hexosylceramides) (Brouwers et al., 2013). Moreover, 
EVs are also enriched with a cargo of both mRNA and miRNA (Valadi et al., 2007). Several studies 
have examined the regenerative therapeutic effect of EVs derived from MSCs for different diseases 
for example cardiovascular disease, neurological diseases and other diseases (Bian et al., 2014, 
Jarmalavičiūtė and Pivoriūnas, 2016). Feng et al., 2014, reported in their study where they use mouse 
myocardial infarction model that the delivery of miR-22, which was released by MSCs, reduced 
apoptosis in ischemic cardiomyocytes, reduced fibrosis and promoted cardiac function post-
myocardial infarction (Feng et al., 2014).  
Exosomes are fitting for neurological diseases as lipid-bound nano-vesicles exosomes act as 
liposomes which can cross the blood-brain barrier (Konala et al., 2016). However, MSCs’ paracrine 
actions also have limitations that must be addressed. For example, some cytokines or chemokines, 
such as TNF-α and IL-6 released from MSCs may be harmful (Ward, 2009). Nevertheless, exploring 
the MSCsʼ secretomes holds great promise as a more controllable, manageable and sensible 
therapeutic strategy than cell-therapy. 
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Since MSCs have emerged in the field, intensive research has been explored on the MSCsʼ potential 
for therapy for different conditions including; cardiovascular diseases, autoimmune diseases, and 
liver diseases, orthopaedic injuries, and spinal cord injury (Wright et al., 2011, Kim and Cho, 2013). 
Many animal experiments have recorded an improvement in locomotor function after transplantation 
of MSCs in SCI (Ankeny et al., 2004, Ohta et al., 2004, Deng et al., 2006, Geffner et al., 2008). The 
main mechanism of effect in cell transplantation has been ascribed to their secretomes (Kanno et al., 
2014). The recent clinical trial phase I of SCI in human showed that the transplantation of MSCs was 
safe and feasible (Kakabadze et al., 2016). SCI is further explored in the next section.  
1.5  Spinal cord injury and regenerative medicine 
1.5.1  Gross anatomy of the spinal cord  
The spinal cord is a part of the central nervous system. The spinal cord is the long tubular bundle of 
nerves and neurones that extend from the medulla oblongata in the brainstem to the lumbar region of 
the vertebral column. Generally, spinal cords are characterised by their elaborate organisation and 
complexity. Its complexity is attributed to its critical functions. These include; sensation, autonomic 
and motor control (FintanSheerin, 2004). 
The spinal cord can be described as a complicated processor of sensory and motor information. It 
can regulate the sensory inflow and is involved in the control of movements. In other words, the 
spinal cord looks and also functions as a cable gathering sensory information from the body to the 
brain and sending movement orders from the brain to the body. The spinal cord also processes 
sensory and motor signals (Dikopolskaya and Makarenko, 2014). 
1.5.2 Causes and pathophysiology of spinal cord injury  
SCI is one of the most devastating injuries that can affect the CNS. SCI causes severe damage to the 
nerve tissue in the spinal cord leading to a block in the communication between the brain and the 
body. Before proceeding onto the further explanations regarding SCI, it is worth highlighting the fact 
that the clinical presentation and syndromes of SCI do not necessarily correlate with the pathological 
findings (El Masri, 2006, Ecker et al., 2008).
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A person with SCI, loses sensory, motor and reflex messages, which may not be able to get past the 
damage to the spinal cord (Mothe and Tator, 2012).The most common causes of traumatic SCI are 
motor vehicle accidents, falls at home or work-related injuries, acts of violent crime, and sports-
related injuries (Devivo, 2012). Most clinicians classify the level of injuries of the spinal cord as 
either complete or incomplete. Simply, the fully compressed or severed spinal cord is classified as 
complete spinal cord injury in which the brain's ability to send signals below the point of damage is 
eliminated. Incomplete spinal cord injuries occur when the spinal cord is partially compressed or 
injured, and the brain's ability to send signals below the site of the injury is not completely removed 
(Kirshblum et al., 2011). However, the severity of damage or injury in the spinal cord can be 
classified based on the amount of spinal cord tissue damage or density of the lesion.   Regardless of 
the cause the mechanisms underlying injury after spinal cord trauma results from, primary and 
secondary injury mechanisms (Webb et al., 2010).  
The primary mechanism of spinal cord trauma is a mechanical injury to the spinal cord. This 
mechanical injury occurs as a result of impact and compression (due to column fracture and 
dislocation) against the spinal cord. This leads to several pathological changes at the site of injury 
including; severe damage to the axon, mechanical trauma causing damage to the cells, and damage 
to the small intramedullary vessels causing haemorrhage (Rowland et al., 2008). The primary injury 
leads to the secondary mechanism. The secondary mechanism of injury results in several events. 
These include first, electrolyte shifts in which changes in local ionic concentration occur. Second, 
vascular dysfunction this includes; disturbance in local and systemic blood pressure, reduction in 
spinal blood flow and rupture of the blood-brain barrier. Third, the release of free radicals and finally, 
immune system response inflammation, and apoptotic cell death (Dumont et al., 2001, Oyinbo, 
2011). However, these two mechanisms are involved in four biological phases as a response to a 
spinal cord injury. The immediumte phase (0-2 hours) is the immediumte result of the injurious event 
itself.  
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It begins at the time of injury and lasts ~ 2 hours.  This phase represents the primary mechanism of 
injury and is accompanied by the phenomenon of spinal shock leading to loss of function at and 
below the level of injury for complete injuries (Dumont et al., 2001). 
The acute phase in which the secondary injury processes become dominant and can be subdivided 
into two stages; early acute stage (2-48 hours) which is characterised by continuing haemorrhage, 
increasing oedema and inflammation. Subacute stage (2 days to 2 weeks) this stage represents the 
most favourable time for repair mechanisms, in particular for the strategies based on cell therapies. 
Many experimental studies showed that active functional recovery could happen after cell 
transplantation during this stage compared with immediate treatment or at later time point (Keirstead 
et al., 2005, Karimi-Abdolrezaee et al., 2006).  
The intermediate phase (2 weeks to 6 months) is characterised by the continued maturation of the 
glial scar and by regenerative axonal sprouting. Finally, the chronic phase (more than 6 months) takes 
over. This phase begins at 6 months following injury and continues throughout the lifetime of the 
patient. The main characteristic features of this phase are the maturation and stabilisation of the lesion 
through the continuation of scar formation and the development of cysts, and alterations in neural 
circuitries (Dumont et al., 2001). 
 
1.5.3 The importance of nerve regeneration and revascularization in SCI recovery 
Anatomically the spinal cord can be divided into five regions. The nerves in the cervical region 
control the muscles and glands and receive sensory input from the neck, shoulder, arm and hand. The 
thoracic region nerves are associated with the chest and abdominal walls. The lumbar region nerves 
are associated with the hip and leg. In the sacral region, the nerves are associated with the genitals 
and lower digestive tract. Coccygeal region nerves supply the skin over the coccyx. Spinal cord 
regions do not necessarily correspond to the bony regions of the spinal column (Figure 1.10) (Silva 
et al., 2014).  
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Nerve regeneration after SCI is very limited, however, a team led by Rosenzweig in California San 
Diego in 2010 performed an incomplete hemisection spinal cord injury on adult rhesus monkeys, 
administered at C7 of the spinal cord. They investigated the mechanisms underlying natural recovery 
after such injury. Their findings suggested that the connections between circuits in the spinal cord 
grew again, considerably and spontaneously, and after only 24 weeks following the mild spinal cord 
injury, 60 percent of the connections were fully recovered (Rosenzweig et al., 2010). Also, El Masri 
and colleagues demonstrated that early simultaneous active physiological conservative management 
of the injured spine in patients with complete motor paralysis but with sparing of pinprick sensation, 
70% of those patients revealed in the first 72 h of injury recovered motor power to ambulate without 
surgical, pharmacological, cellular or biological intervention. Thus, based on their studies they 
suggested that surgical intervention is not recommended at the early stages of SCI (El Masri and 
Kumar, 2017).This may be due to the fact that surgical intervention at early stages of SCI may add 
extra trauma to the already injured tissue.  
When CNS patients undergo injury, several factors are required to reconstruct neuronal circuit 
including; synaptic reorganisation, axonal sprouting and neurogenesis. Under the effect of injury 
environment, the nervous system reveals plasticity property to adapt the environmental changes 
(Celnik and Cohen, 2004).  Particularly, the undamaged neurones and collateral axon branches can 
grow into the injured regions to re-establish the neuronal circuit. Although this plasticity is limited 
due to inhibitory factors released at the site of injury, increasing numbers of studies showed that a 
cell transplantation strategy could improve neuronal plasticity (Darian-Smith, 2009, Liu et al., 2012).
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Figure 1:10 Spinal cord regions.  
The schematic illustration shows the five regions of the spinal cord which are not related to the bony 
structure of the vertebra. Image adapted from (System, 2016). 
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Based on several studies either in vitro (Wright et al., 2007, Liu et al., 2010) or in vivo (Ribeiro et 
al., 2011, Neirinckx et al., 2015), MSCs transplantation or conditioned medium exhibited 
neurological effects by improving neurite outgrowth or neuronal axon sprouting from surviving 
axons.  
Angiogenesis plays a critical role in SCI recovery by reducing secondary axonal damage due to 
ischaemia and also by the delivery of oxygen and nutrients to the site of regeneration and removal of 
metabolic waste (Loy et al., 2002, Lutton et al., 2012). Migration and proliferation of endothelial 
cells are important in the angiogenic process. In the spinal cord, blood vessel distribution is based on 
the area of supply, grey matter is characterised by its high vascularisation compared with white 
matter. Such variation in blood supply reflects the metabolic activity of individual areas as the grey 
matter is the aggregation of nerve cells bodies where the metabolic activity is very high whereas 
white matter is an aggregation of axons (Mautes et al., 2000).  The vertebral arteries are the main 
source of blood to the spinal cord which undergoes a series of branching, ending in terminal capillary 
beds that establish the blood-spinal cord barrier (BSCB) (Fenstermacher et al., 1988). The anatomical 
structure of BSCB is composed of several components including; a capillary wall of endothelial cells, 
pericytes, astrocytes and the extracellular matrix (Mautes et al., 2000). The endothelial cells of BSCB 
are unlike those in the peripheral circulation (Figure 1.11). Endothelial cells of BSCB are 
characterised by their non-fenestrated membrane. Instead, the endothelial cells overlap and seal the 
paracellular spaces with tight junctions (Ng et al., 2011). Pericytes surround the endothelial cells and 
separate from endothelial cells by the basal lamina. Pericytes have a significant role in endothelial 
cellsʼ proliferation, migration, and differentiation. Both endothelial and pericyte cells are wrapped 
within a layer of the basal lamina which provides physical support for the vessel wall. Astrocytes 
foot processes, which are juxtaposed against the basal lamina, surround the outer surface of these 
capillaries. 
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Figure 1:11 Basic cellular constituents of the BSCB. 
 Schematic illustration showing the basic composition of BSCB which is formed from an overlapped 
endothelial cell that has tightened by tight junction surrounded with pericyte, and the whole structure 
is wrapped with feet processes of astrocytes. Image adapted from (Abbott et al., 2006). 
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Astrocytes have a critical role in the formation and maintenance of the BSCB (Bartanusz et al., 2011). 
This concrete structure of BSCB reflects the effective role of this barrier to protect spinal cord by 
preventing passage of any molecules apart from the required nutrients. Therefore, lack of such 
protective barrier results in the influx of cellular toxic molecules including; calcium, excitatory 
amino acid neurotransmitters. A high concentration of glutamine and glycine can be toxic to cells. 
Free radicals, erythrocytes, leukocytes, and inflammatory mediators can also be toxic (Bartanusz et 
al., 2011, Ng et al., 2011). In fact, there is an angiogenic response that occurs after SCI in which new 
blood vessels are formed (Oudega, 2012). However, Whetstone et al., 2003 has reported in their 
study that BSCB lost its permeability and the regenerated blood vessels after injury of spinal cord do 
not display a typical barriers’ properties (Whetstone et al., 2003). Therefore, there is a need to 
develop a strategy to ensure the restoration of fully functional nerves and BSCB. The restoration of 
a complete structural and functional BSCB may enhance the improvement of neuronal tissue as the 
BSCB can prevent infiltration of unwanted particles.  
In fact, the cellular and molecular changes that occur during the secondary processes of SCI have a 
significant role in the development of pathophysiology of the lesion. Many studies claimed that the 
intervention may reduce secondary injury of the spinal cord by reducing the series of cascade events 
after spinal cord trauma and thus, an improvement in spinal cord functionality may be achieved 
(Dasari et al., 2014). Since the emerging of stem cells as cell-based therapy, many studies have 
investigated their potential activities to modulate the cascade of events of secondary injury after 
spinal cord trauma. For example, transplantation of MSCs in animal model studies has been shown 
to increase the repair of the injured spinal cord tissues (Park et al., 2011). Although, a full 
determination of the in vivo MSCs functional roles and involved molecular regulatory mechanisms 
are not yet completed. However, several studies suggested that the possible mechanisms through 
which MSCs may ameliorate the secondary injury of SCI may be due to the main characteristic 
features of MSCs biological activities including; migration to the damaged neuronal tissue, neuronal 
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differentiation, and releasing survival factors that could play a role in neuronal protection (Qu and 
Zhang, 2017). 
Cancer cell lines are widely used as models to investigate broad biological activities. Therefore, to 
achieve the goals raised by this study, two cell line models have been adapted to investigate the 
neurogenic and angiogenic effects of MSCs conditioned medium.  
These models include: SH-SY5Y human neuroblastoma cell line, SH-SY5Y human neuroblastoma 
cell line is one of the cell lines which have been widely used to understand neurogenic properties. It 
is the third successive subclone from the original cell line, called SK-N-SH, which was isolated from 
a bone marrow biopsy taken from a four-year-old female with neuroblastoma. SH-SY5Y has been 
extensively used as a neuronal model in most in vitro neurological experiments. This was conferred 
due to first, their ability to differentiate into a functionally mature neuronal phenotype when they are 
differentiated by exposure to retinoic acid followed by brain-derived neurotrophic factor in serum-
free medium. Second, due to the experimental limitation of gaining primary neurone cells in vitro, 
SH-SY5Y cells considered as an alternative source for neuron cells (Yusuf et al., 2013). 
EA.hy926 Human endothelial cell line, a hybrid cell line that was established by fusion of A549 
cells (human cell lung carcinoma) with human umbilical vein endothelial cells (HUV-EC). Note that 
HUVEC is primary cells (Edgell et al., 1983). This cell line displays structural and functional 
characteristic features of vascular endothelial cells (Edgell et al., 1990, Bauer et al., 1992, Rieber et 
al., 1993). This study has adopted EA.hy926 cell line over the primary HUVECs for the following 
reasons, i) long life span of EA.hy926 cells compared with HUVECs as they have a short life span 
ii) reducing individual variation as the primary cells HUVECs are multi-donor of origin adding 
variability to the variability  from the conditioned medium used in this study that has been also 
derived from different donor. Thus, using a cell line model can minimise the risk of the donor to 
donor variations (Bouïs et al., 2001). 
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1.5.4 Strategies for SCI treatment 
As stated above, SCI results from severe damage to neuronal tissue resulting in dramatic disability 
represented in the loss of motor and sensory functions. The primary aim for SCI management is 
avoidance of secondary injury. Thus, the recent therapeutic strategies are aimed to reduce and control 
any further damage to the spinal cord after injury (Martin et al., 2015). Currently, no treatment is 
effective at obtaining a full recovery of function of the damaged tissue of spinal cord after injury. 
However, there are several strategies that claim to improve some of the functions of the spinal cord 
after injury. These strategies include; spinal cord decompression, spinal cord stabilisation, 
neuroprotective strategies and regenerative therapies. The surgical intervention to decompress spinal 
cord after injury within the first 24 h claim to increase the chances of improvement in motor function 
at later stages of injury (Dvorak et al., 2015). Similarly, spinal cord stabilisation is at least as 
important as spinal cord decompression. Spinal cord stabilisation may involve different surgical 
interventions for example; anterior and posterior surgical approaches, halo-vest cervicothoracic 
orthosis and external bracing or rigid collar. The surgical interventions are based on the severity of 
damage in ligaments and bone (Krengel et al., 1993, Furlan et al., 2011). 
Neuroprotective strategies include hypothermia and pharmaceutical therapy. Several studies showed 
that systemic hypothermia in acute SCI has contributed to improving neurological functions. 
However further studies are needed before hypothermia is adopted widely (Wang and Pearse, 2015).  
The evidence based on research studies suggested administration of some pharmaceutical drugs may 
have a beneficial effect on either minimising the secondary injury mechanism or facilitate the 
neurological recovery after injury. Methylprednisolone (MP) is a potent corticosteroid that inhibits 
inflammation and membrane lipid peroxidation. It was widely used by SCI clinicians previously. 
However, this drug classifies as an optional treatment as there is a controversy about the high dose 
of MP (Hugenholtz, 2003, Evaniew et al., 2015, Martin et al., 2015). However, several drugs are in 
development for treating spinal cord injury. They are either neuroprotective or neuroregenerative 
agents targeting specific pathological mechanisms. Riluzole is considered as one of the 
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neuroprotective agents which slow degeneration of motor neurones and prolongs survival (Fehlings 
et al., 2012). Another neuroprotective agent is minocycline which has an effect by reducing 
microglial activation and TNF-alpha secretion (Festoff et al., 2006). Pre-clinical studies suggested 
that improvement in motor function, reduction in lesion size, and preservation of axons have been 
achieved after the administration of minocycline after SCI attributing this improvement to its 
neuroprotective effects (Wells et al., 2003, Casha et al., 2012). The regenerative approaches can be 
achieved not only by halting secondary injury but also by inducing and amplifying repair 
mechanisms. Cethrin is a bacterial-derived toxin that blocks signalling from inhibitory proteins 
released by myelin debris present at the site of injury and promotes axonal growth in vitro (Fehlings 
et al., 2011). Protein nogo-A is one of the myelin proteins which act as an inhibitor of nerve growth 
factor (NGF). Recently, applying a biological strategy of neutralising monoclonal antibodies that are 
selective for Nogo-A has been shown to enhance the regeneration and reorganisation of the injured 
spinal cord (Liebscher et al., 2005, Zhao et al., 2013b). 
These advances in both the understanding of spinal cord pathological mechanisms of injuries and 
developing therapies have shown promising results at the preclinical stage of study but failed to 
translate into clinic Since each therapy focuses on one specific mechanism, therefore, a combination 
of therapies is needed (Martin et al., 2015). Thus, various aspects of stem cells therapy for SCI have 
attracted research as they exert a multiple or a combination of therapeutic and trophic activities.   
MSCs account for a large share of investigations for their therapeutic activities for SCI; this can be 
attributed to their main characteristic features including; freedom from concern about ethical issues, 
ease of access and lack of tumour formation after transplantation (Li and Lepski, 2013, Dasari et al., 
2014). Several new studies have investigated the therapeutic potential of AT MSCs by targeting a 
different aspect of injury mechanisms (Kolar, 2014, Hur et al., 2016). AT MSCs hold significant 
promise for SCI, most of the animal studies showed MSCs could contribute to repair spinal cord 
tissue after injury by several mechanisms. These mechanisms include; replacement of damaged 
nerves as a result of injury, generation of new supporting cells that are capable of formation of 
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myelin, reduction of the damaging inflammation that can occur after injury and secretion of 
protective substances as trophic factors to protect the cell from further damage at the site of injury 
and also absorption of free radicals (Dasari et al., 2014). However, further investigation is still 
required to understand the underlying mechanisms of the therapeutic effects of MSCs and to optimise 
the roles of MSCs in repairing SCI.  
 
1.6 The importance of a large animal model in translating regenerative therapy for 
SCI 
As stated above the strategy of using stem cell transplantation for SCI is rapidly evolving in 
regenerative medicine.  However, the absence of animal models fully reflecting the phenotype of the 
human experience of SCI is still a challenging step in bridging the gap between translation research 
and human clinical trials (Harding et al., 2013). 
Although, rodents represent the most traditional animal models for preclinical studies, in cell-based 
therapies they have their limitations. On the one hand, rodents have the advantage in experimental 
studies of easier management and relatively inexpensive cost. On the contrary, they have a short 
lifespan which does not fit with observation experiments over long periods, small organ sizes and 
marked physiologic differences (Cibelli et al., 2013). Rodent models do not reproduce full in certain 
aspects of SCI in human, as the injury is induced in the lab and it is not spontaneously and natural in 
occurrence. Large animal models could be the best option to investigate and translate the outcome of 
cell-based therapies into human clinical trials. The large animals are anatomically and 
physiologically similar to human in comparison with rodents which have small body size and 
substantially different physiology (Casal and Haskins, 2006). For example, the neuropathological 
sequences following SCI in human are characterised by cystic cavitation whereas in murine the lesion 
site is filled with non-neuronal cells (Fujiki et al., 1996, Guth et al., 1999, Byrnes et al., 2010). 
Large animals like rabbits, cats, dogs, pigs, goats, sheep, and non- human primates often represent 
better models than rodents. The use of dogs as large animal models can bring benefits for both human 
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and veterinary medicine. Besides, dogs among other large animals faithfully mirror most of the 
disease in humans (Starkey et al., 2005). The domestic dogs share common similar features in 
diseases including; physiology, disease presentation and clinical response.  About 400 inherited and 
naturally occurring diseases in dogs are similar to those found in human (Khanna et al., 2006). 
Diabetes, epilepsy, asthma and cancer are the most common inherited diseases. These diseases occur 
as a result of complex interactions between multiple genes and environmental factors, interestingly, 
these characteristics are shared by both human and dogs (Schneider et al., 2008). In 2005 Toh et al., 
announced the publication of a complete map of the dog genome. The availability of this genome 
map provides the opportunity to explore the genetic basis of disease susceptibility and may provide 
insights into disease mechanism. This may lead to the possibility of clinical trials in dogs with genetic 
diseases to develop new therapeutics that would improve health in both dogs and humans (Switonski 
and Szczerbal, 2001, Lindblad-Toh et al., 2005). Indeed, the availability of canine DNA and protein 
sequence make dogs a more relevant model to translate the genetic mechanisms underlying the 
occurrence of some genetic diseases in human than mice (Kirkness et al., 2003, Lindblad-Toh et al., 
2005). 
Similarly, in stem cell transplantation dogs have a crucial role as a model for many transplantation 
research studies (Abkowitz et al., 1996, Wagner and Storb, 1996, Horn et al., 2004). Moreover, 
canine SCI represents perfect models for spontaneous SCI in human. The common reasons for SCI 
in canine are similar to human; that can either be traumatic injury as a result of motor accidents or 
non-traumatic injury due to Intervertebral disc disease (IVDD) (McMahill et al., 2015). There are 
three methods of inducing SCI in the lab which is frequently used for experimental animal models 
including; transection model, compression model, and contusion model (Rosenzweig and McDonald, 
2004). Each method addresses a specific question thus each one has its advantages and disadvantages. 
Briefly, the transection model is either a complete or partial section of the spinal cord involving an 
opening within the dura to induce this injury. The advantages of this method are that it provides a 
good setting for axon regeneration experiments and it is a suitable method for the implantation of 
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specific devices. The disadvantage of this method is that transection in spinal injury is very rare in 
humans (Zorner et al., 2010). The contusion model is induced without any disruption of the dura by 
instead directly hitting the spinal cord. There is a specific tool that is controlled by a computer called 
the impactor to generate this model. The advantage of this method is that it provides valuable 
information on several biomechanical parameters. The disadvantage is that it is difficult to 
distinguish between the survived tissue (i.e., spared tissue) and the newly regenerated tissue, as the 
survival tissue has a marked contribution to the recovery process of the spinal cord. Thus the moral 
value of this model could be to assess the safety of interventions but not to establish an efficacy 
(Salegio et al., 2016). 
Whereas, the compression model allows for a prolonged spinal cord compression using a clip or 
forceps compression technique. The advantages of this model are that it is simple, inexpensive, and 
limited resources are necessary. The disadvantages are the lack of an acute injury to study (Cheriyan 
et al., 2014). 
Nonetheless, the clinical lesion in human and dogs usually occur due to a mixture of both forces, 
contusive and compressive, which affect multiple regions of the spinal cord. While in rodents’ 
experimental model's the lesion is only one type either contusive or compressive which are created 
on a single side of the spinal cord (Jeffery et al., 2006a). Also, the immune response in rodents after 
SCI differs compared with human and dogs. Both canine and human inflammation are dominated by 
microglia cells (Schmitt et al., 2000, Spitzbarth et al., 2011). In contrast, inflammation in injured 
rodents is dominated by T-lymphocyte  (Popovich et al., 1997).  Thus SCI in canine is more closely 
mimics the pathophysiology of SCI in human compared to rodents.  Canine could be a promising 
model to bridge that gap between research and human clinical trials. 
Although dogs may consider as better large animal model for human SCI, there are several limitations 
should be taken in a count as dog is quadruped that has less motor dominance by the pyramidal 
(corticospinal) tract, in this aspect it is difficult to use dog as model for human SCI also, difficulties 
in interpreting outcomes measured in animals (Jeffery et al., 2006b, McMahill et al., 2015). 
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1.7 Aims and objectives of the study  
The major aim of this study was to investigate the regenerative activities of MSCs’ secretomes and 
their potential benefit for SCI repair in both human and veterinary regenerative medicine. The reason 
for focusing on secretomes rather than the cells themselves was to establish and develop a new 
strategy of cell-free therapy that will be ready to use at any time, without needing to wait for two or 
three weeks as is the case with using the cells. As it was explained previously in the Introduction 
(Section 1.5.3) neurogenesis and angiogenesis play a critical role in spinal cord recovery and repair. 
Therefore, the thesis has firstly, investigated the regenerative activities (i.e. neurogenesis and 
angiogenesis activities) of canine MSCs secretomes. Secondly, the aim was to investigate the 
differences in these regenerative activities between human and canine MSCs secretomes. Such 
studies could bridge the gap between translating research into preclinical studies and clinical trials 
on SCI in human. Thirdly, the aim was to investigate the differences in regenerative activities among 
MSC subpopulation secretomes. Such investigating could explore the differences in biological 
actions within heterogeneous populations, which may lead to the identification of differences that 
can be employed to develop a specific application of treatment. 
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2  Chapter Two:  Materials and Methods 
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2.1  Tissue culture regime and management  
2.1.1 Isolation and culture of canine adipose-derived mesenchymal stem cells 
Canine adipose-derived mesenchymal stem cells (cMSCs) were kindly provided by the Veterinary 
Tissue Bank Limited (VTB Ltd., Chirk, UK.) (Table 2.1). These cells were isolated from the inguinal 
fat pads of dogs undergoing MSCs transplantation in the treatment of joint pathology. Fat samples 
were dissected, minced and washed in phosphate buffered saline (PBS) (Gibco®, Life 
Technologies™, Paisley, UK). Then each sample was digested with collagenase solution (0.2% 
Collagenase type A, Worthington Biochemical Corporation. USA) where the sample was placed in 
an incubator at 37 ºC with gentle shaking for 2hrs. An equal amount of standard culture medium, i.e., 
DMEM/F-12 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/ 
streptomycin (all from Gibco®) was added to stop the action of collagenase, then the digested sample 
was filtered through a 40µm cell strainer (BD Biosciences) to remove any large debris. Following 
two cycles of centrifugation at 1,200 rpm for 4 minutes and resuspension of the resultant cell pellet 
in standard culture medium to wash away any remaining collagenase, the obtained cells were seeded 
in T75 tissue culture flasks (Sarstedt AG & Co. Germany) and incubated in a humidified incubator 
with 5% CO2 at 37ºC. Any non-adherent cells were removed by discarding the medium at 24-72 
hours post-seeding, and the adherent cells cultured as monolayer cultures through to passaging by 
trypsinisation into fresh T75 flasks. The culture-cMSCs at passages II-III was delivered to the 
research laboratories at Aston University. These cells were further cultured with standard culture 
medium, where they were kept incubated at 37ºC in a humidified atmosphere of 5% CO2.  
It may cross the mind how old is a dog in the human year, actually, dogs mature more quickly than 
human do early on. In fact, dog size and breed play a role. Smaller dogs tend to live longer than 
larger ones, but they may mature more quickly in the first few years of life. Table 3 shows the dog 
age compared to a human. Also, it is worth to mention that age and gender of donors have an 
influence on the potency of MSCs (Sotiropoulou et al., 2006, Duggal and Brinchmann, 2011). Donor-
to-donor variation and gender-related variation have a significant impact on phenotype features and 
functional properties of MSCs (Siegel et al., 2013). 
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2.1.2  Isolation and culture of human adipose-derived mesenchymal stem cells 
Following ethical approval and informed consent (LREC number 12/EE/0136), human adipose-
derived mesenchymal stem cells (hMSCs) were harvested from the excised infrapatellar fat pad of 
the knee joints of patients having a knee replacement surgery (Table 2.1). The MSCs were isolated 
from adipose tissue samples following the protocol described previously by (Bunnell et al., 2008). 
Initially, adipose tissue samples were minced and incubated with 0.3 U/ml of collagenase type I 
(Sigma, Dorset, UK) for 3-4hrs in a humidified incubator at 37°C and 5% CO2, with gentle shaking. 
Following collagenase digestion, an equal amount of DMEM/F-12 medium supplemented with 20% 
FBS and 1% penicillin/streptomycin was added to stop the reaction of collagenase. Then the digested 
tissue was centrifuged at 1000 rpm for 10 minutes. After removing the supernatant, the resultant cell 
pellet was washed in DMEM/F-12 containing 20% FBS and 1% penicillin/ streptomycin followed 
by further centrifugation at 1000 rpm for 10 minutes. The resultant cell pellet was resuspended and 
filtered through 70µm cell strainers (BD Biosciences) to remove any debris. The cells obtained 
following this filtering were then cultured in DMEM/ F-12 containing 20% FBS and 1% penicillin/ 
streptomycin in a humidified atmosphere in an incubator at 37 °C and 5% CO2 and after 24-72 hours 
of incubation and non-adherent cells were washed off by a complete change of medium and the 
adherent cells remaining were subsequently culture expanded in T75 flasks until they reached 70%-
80% confluence. The cultured adherent cells were further cultured expanded by passaging through 
trypsinisation and re-seeding into fresh T75 flasks, as described (Kohli et al., 2015). 
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Table 2: MSCs donor details.  
The table shows the MSCs used in this study. Human MSCs were provided by the Royal Orthopaedic 
Hospital, Birmingham whereas the canine MSCs were provided by the Veterinary Tissue Bank 
Limited. 
  
 
MSC ID Tissue of origin Sex Age 
MSC from human 
MSC101 The infrapatellar fat pad of the knee joints Female 27 
MSC110 The infrapatellar fat pad of the knee joints Female  49 
MSC105 the infrapatellar fat pad of the knee joints Male 69 
MSC123 The infrapatellar fat pad of the knee joints Female 59 
MSC126 The infrapatellar fat pad of the knee joints Female 60 
MSC from canine 
 Breed  
MSC012 The inguinal fat pads Labrador Female 7 
MSC014 The inguinal fat pads Labrador Female 8 
MSC017 The inguinal fat pads Spaniel Male 2 
MSC018 The inguinal fat pads Not specified Female 8 
MSC020 The inguinal fat pads Doberman Male 6 
MSC028 The inguinal fat pads Plummer terrier Female 9 
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Size of dogs Small 
20 Ibs or less 
Medium  
21-50 Ibs 
Large  
More than 50 Ibs 
Age of dog (year) Age in human years 
1 15 15 15 
2 24 24 24 
3 28 28 28 
4 32 32 32 
5 36 36 36 
6 40 42 45 
7 44 47 50 
8 48 51 55 
9 52 56 61 
10 56 60 66 
11 60 65 72 
12 64 69 77 
`13 68 74 82 
14 72 78 88 
15 76 83 93 
16 80 87 120 
 
Table 3: Dog age in human years. 
The table shows dogs’ age in human years based on their body mass. This table adapted from 
(WebMD, 2017). 
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2.1.3 Isolation and culture of CD271+ and CD271- human adipose-derived 
mesenchymal stem cells 
MSCs were harvested from the excised infrapatellar fat pad of the knee joints of patients having a 
knee replacement surgery after the ethical approval and informed consent (LREC number 
12/EE/0136) by collagenase digestion, as described above. Following two steps of washing and 
centrifugation to remove collagenase, the resultant cell pellet was re-suspended with 10ml of 
DMEM/F-12 containing 20% FBS and 1% penicillin/ streptomycin and passed through A 100µm 
cell strainer (BD Biosciences). The filtered cell suspension was collected in a 15ml conical centrifuge 
tube and centrifuged at 600g for 10 minutes. Then the cell pellet was re-suspended in 5ml of 
DMEM/F-12 containing 20% FBS and 1% penicillin/ streptomycin and passed through a 40μm cell 
strainer (BD Biosciences). After that, the number of cells was determined by counting viable and 
non-viable cells using the method of trypan blue exclusion and a haemocytometer. Some cells were 
then cultured in T25 flasks to isolate MSCs based on their adherence on tissue culture plastic (PA 
MSCs), as described above, whilst the rest were processed for isolation based on their 
immunopositivity for CD271 using immunolabelling with an antibody for CD271 and magnetic 
beads, as described previously (Jones et al., 2002) and by the manufacturers protocol for CD271+ 
cell isolation (Miltenyi Biotec Inc. USA). In brief, this was as follows: 1. cells were centrifuged at 
300g for 10 minutes and then the supernatant completely removed; 2. any erythrocytes were lysed 
by treatment of the resultant cell pellet with 1ml of 1x erythrocyte lysis buffer (provided with the kit) 
and incubation for 10 minutes at room temperature, then the solution was further centrifuged at 300g 
for 10 minutes; 3. next, the supernatant was removed completely, and cells were re-suspended with 
80µl of buffer (PBS pH 7.2%, 0.5% bovine serum albumin (BSA) and 2 mM of EDTA) ; 4. 10µl of 
FcR blocking reagent and 10µl of CD271-APC was added to the cell suspension, mixed well, and 
the cells were incubated at 2-8 ºC for 10 minutes; 5. at the end of the incubation period, cells were 
washed by adding a further 1ml of buffer and centrifuged at 300g for 10 minutes; 
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6. the supernatant was completely removed, the resultant cell pellet was re-suspended with 10µl of 
FcR blocking reagent and 20µl of anti-APC microbeads and incubated at 2-8 ºC for 15 minutes; 7. 
the washing step was repeated by adding 1ml of the buffer to the cells and centrifugation at 300g for 
10 minutes; 8. finally, the supernatant was completely removed, and the cell pellet was re-suspended 
with 500µl of the buffer, preparing them for magnetic separation. 9. based on the total number of 
cells obtained following this procedure the appropriate MACS column and MACS separator were 
chosen and placed in the magnetic field. 10. the column was rinsed three times with buffer solution, 
then 500µl of the cell suspension was loaded onto the column. 11. unlabelled cells were collected by 
applying 3x3 ml of buffer to the column and eluting each time; these cells were used for this study 
as CD271- cells. 12. after the third buffer wash, the column was removed from the magnetic field, 
placed into new collection tube and a further 5ml of buffer applied onto the column and the 
magnetically labelled cells were immediately flushed out by firmly pushing the plunger into the 
column and collecting the eluent; these collected cells have been referred to as CD271+ cells. 13. 
after this final separation and isolation procedure, all collected cells were pelleted by centrifugation 
and re-suspended with 5ml of DMEM/F-12 containing 20% FBS and 1% penicillin/ streptomycin 
and seeded in a T25 flask at 37 ºC with 5% CO2. 
 
2.1.4 Cell culture expansion and storage 
2.1.4.1 Passaging cells 
Monolayer cells in tissue culture flasks were washed with PBS and incubated with 0.25% trypsin 
(w/v)/EDTA (Gibco®) for 5 minutes at 37 °C with 5% CO2. After the detachment of cells, trypsin 
activity was neutralised by adding an equal volume of standard medium containing 10% FBS. Then 
this cell suspension was centrifuged for 10 minutes at 1000 rpm to make a cell pellet. The supernatant 
was removed, and the pellet was re-suspended in the culture medium. A viable cell count was 
performed using trypan blue exclusion.
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The cells were then seeded into new fresh flasks at a desired density ranging from 5000-20000 cells 
per cm2 according to the experimental protocol. 
 
2.1.4.2  Cell cryopreservation and re-culture from storage 
Cells were harvested by trypsinisation following the method described above and the cell pellet after 
centrifugation was resuspended in cold freezing mix (10% dimethyl sulphoxide (DMSO) in FBS). 
The cell suspension in freezing mix was transferred into cryovials (containing 1-2 ml per vial), which 
were then stored overnight in a designated cryofreezing container that contained isopropyl alcohol at 
-80°C before transfer to storage containers at the same temperature or in liquid nitrogen. Cells were 
returned to culture from -80°C storage by rapidly thawing cryovials under running warm/hot tap 
water. Then the cells in freezing mix were transferred to a 15ml centrifuge tube, and 1ml of ice-cold 
standard culture medium was added to the cell suspension dropwise over one minute. The cells were 
left to stand for one minute at room temperature. After that, 10ml of room temperature standard 
culture medium was added drop-wise over 5 minutes. Then the cell suspension was centrifuged for 
10 minutes at 1000 rpm. The pellet was re-suspended in the warm standard culture medium, a viable 
cell count was performed using trypan blue stain, and then the cells were cultured in T25/T75 flasks 
at 37 °C with 5% CO2 at the desired cell density for each experiment. 
 
2.1.4.3  Screening for mycoplasma contamination in tissue culture 
Regular testing of cell cultures to ensure the absence of mycoplasma infections was performed, in 
conjunction with good aseptic technique, as strongly recommended (Barile et al., 1973). Mycoplasma 
screening was performed on every new donor cell sample received from VTB Ltd, as well as on 
maintained cultures routinely every 3-6 months using a commercial kit by following the 
manufacturer’s instructions (EZ-PCR mycoplasma test kit; Geneflow, Lichfield, Staffordshire, UK). 
In brief, 0.5-1ml of the medium was harvested from the supernatant of each cell culture to be tested 
and transferred into a 2ml micro-centrifuge tube. The supernatant was centrifuged at 250g for 3 
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minutes to remove cellular debris, then collected into a new micro-centrifuge tube and centrifuged at 
15,000g for 10 minutes. Then the supernatant was removed carefully and completely and the resultant 
pellet was re-suspended in 50µl of the commercial buffer solution provided, mixed thoroughly with 
a micro-pipette and heated to 95°C for 3 minutes. This is referred to as the “test sample”. Then 35µl 
of dH2O was mixed with 10µl of reaction mix and 5µl of the test sample in a sterile PCR tube. A 
positive template control was also prepared by adding 39µl of dH2O that was mixed with 10µl of 
reaction mix and 1µl of the positive template in sterile PCR tubes. All tubes were placed into a DNA 
thermal cycler (Thermo Fisher Scientific, UK) and the following parameters were set to amplify the 
DNA: 30 seconds at 94°C, then 35 cycles of; 30 seconds at 94°C then 120 seconds at 60°C then 60 
seconds at 72°C, followed by 30 seconds at 94°C, 120 seconds at 60°C and finally 5 minutes at 72°C. 
After that, the samples were used for agarose gel electrophoresis to determine if a PCR product had 
formed by loading 15µl of the sample in a 2% (w/v) agarose gel and applying 100 volts across the 
gel for 30-45minutes. A known DNA ladder of 100-1013 base pairs (HyperLadder™ 100bp, Bioline, 
London, UK) was also loaded. The gel was then visualised under UV light, and digitised images 
were captured using Syngene imaging software (Syngene, Cambridge, UK). The positive control for 
mycoplasma infection and any mycoplasma positive cultures gave a visible band at 270bp. Any 
mycoplasma positive MSC cultures were subsequently destroyed and all data omitted from this 
thesis. 
 
2.2 Mesenchymal stem cell phenotyping  
The ISCT (Dominici et al., 2006) has proposed three phenotypic criteria to define MSCs for 
laboratory investigations and preclinical studies, these are: (i) adherence to plastic and a stromal 
morphology; (ii) a CD profile that is immunonegative for CD34 and CD45, but immunopositive for 
CD44, CD73, CD90, CD105 and Stro-1; (iii) a multipotent differentiation capacity to form 
adipocytes, osteoblasts and chondrocytes after induction with appropriate induction medium. 
Therefore canine and human MSCs were examined for their capacity to meet these criteria. 
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2.2.1 Immunophenotypic characterization of MSCs using flow cytometry 
Canine and human MSCs were examined for their expression of specific CD markers on the cell 
surface by flow cytometry, according to the availability of commercial antibodies of published 
specificity. 
Canine MSC CD immunoprofiling. 
Immunolabeling of cMSCs was performed from passage III-V as described previously (Zhang et al., 
2013a). In brief; 3x105 cells were trypsinised, washed and pelleted by centrifugation, then re-
suspended in 200µL of 2% BSA/PBS containing 5µL of each one of the antibodies for each sample 
of cells prepared. Cells were incubated with each of the following antibodies conjugated to 
phycoerythrin (PE) or fluorescein (FITC): PE-CD34 (Cat No. 559369 BD Biosciences), FITC-CD44 
(Cat No. 115440 eBiosciences), PE-CD45 (Cat No. 125451 eBiosciences), and PE-CD90 (Cat No. 
125900 eBiosciences) or with antibodies that were not specific for mammalian antigens as isotype-
matched controls, i.e. IgG1 mouse (Cat No.12-4714-41 eBiosciences), IgG2a rat (Cat No.11-4321-
41 eBiosciences), IgG2b rat (Cat No. 11-4031-81 eBiosciences) and IgG2b rat (Cat No. 12-4031-81 
eBiosciences) (isotype control respectively for each CD marker), for 30 minutes at room temperature. 
The cells were then washed twice with 2% BSA/PBS. Immunoreactivity for each CD marker was 
assessed by flow cytometry using a Beckman Coulter FC500 Flow Cytometer and data was analysed 
using Kaluza® Analysis Software. 
Human MSC CD immunoprofiling 
Immunolabelling of human MSC was performed at passages II-V as described previously (Kohli et 
al., 2015).
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In brief, cells were harvested by trypsinisation, washed and centrifuged, and the resultant pellet re-
suspended in 2% BSA/ PBS. Initially, the cells were blocked with 10% normal human 
immunoglobulin (Grifols, Cambridge, UK) for 1hr on ice with shaking. Then cells were washed with 
1 ml of 2% BSA/PBS and centrifuged. Then 105 of cells were aliquoted and each of one of the 
following PE-conjugated mouse monoclonal anti-human antibodies: CD34, CD44, CD45, CD105 
(Immunotools, Friesoythe, Germany), CD73 or CD90 (BD Biosciences, UK), CD271 (Miltenyi 
Biotec Inc.) was added. Separate aliquots of 105 cells were also incubated with isotype-matched 
control PE-conjugated antibodies IgG2a and IgG1 (Immunotools) to detect levels of non-specific 
binding and fluorescence. The extent of immunoreactivity for each CD marker was performed by 
flow cytometry using a Beckman Coulter FC500 flow cytometer with data analysed using Kaluza® 
Analysis Software. 
 
2.2.2  Multipotential differentiation of MSCs 
Canine and human MSCs were induced to differentiate along multiple mesenchymal cell lineages, 
i.e. adipocytes, osteoblasts and chondrocytes, at passages III-V, as described previously by (Wright 
et al., 2008). This was performed as follows: 
Adipogenic Induction: Cells were seeded in triplicate wells at 104 cells per well in a 24 well plate 
and cultured for one week to reach confluence before starting adipogenic induction. Cells were then 
treated with adipogenic induction medium, which consisted of DMEM/F-12 culture medium 
supplemented with 10% FBS, 1% penicillin/streptomycin, 1µM dexamethasone, 1% 
insulin/transferrin/selenium (ITS), 0.5mM 3-isobutyl-1-methylxanthine (IBMX) and 100µM 
indomethacin. The medium was completely replaced with fresh induction medium every 2-3 days. 
Control medium consisted of the carriers alone, i.e., methanol and DMSO, at the same dilution as 
was used for the induction medium. 
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Osteogenic Induction: Cells were seeded into 24 well plates and cultured for one week as described 
for the adipogenic induction above. They were then treated with DMEM/F-12 medium supplemented 
with 10% FBS, 1% penicillin/streptomycin, 10µM beta-glycerophosphate, 50µM ascorbic acid and 
10nM dexamethasone. The medium was completely replaced with fresh induction medium every 2-
3 days. Control medium contained the carriers alone, i.e., methanol and cell culture water at the same 
dilution as was used for the induction medium. 
Chondrogenic Induction: Cells were aliquoted at 25 x 105 cells in 1 ml of DMEM/F-12 medium 
supplemented with 2% FBS and 1% penicillin/streptomycin into 1.5ml microfuge tubes. These were 
then centrifuged in a microcentrifuge at 500g for 5 minutes until they formed a small cell pellet. After 
that, the cell pellets were maintained in the same culture medium further supplemented with 10nm 
TGF-β and 50nm ascorbic acid with fresh medium changes every 2-3 days. All cultures were 
maintained in a humidified atmosphere of 5% CO2 at 37oC for 4 weeks after the initial addition of 
induction medium. 
2.2.3  Assessment of MSC differentiation  
Oil Red O staining and quantification of lipid vacuoles for adipogenic differentiation: The 
formation of lipid droplets was verified by Oil Red O staining and quantified by spectrophotometry, 
as described previously (Ramirez-Zacarias et al., 1992).  Briefly, the Oil Red O stock staining 
solution was prepared by dissolving 300mg of Oil Red O powder (Sigma) into 100ml of isopropanol. 
The stock solution can be stored for 1year at room temperature. The Oil Red O working solution was 
then prepared by dilution of 3 parts from the stock solution into 2 parts of distilled water; this was 
mixed well and left to stand for 10minutes, then filtered through Whatman paper (Whatman No.1 
filter paper, Maidstone, UK), and the filtered solution was used within 3hrs. The induced cell cultures 
were fixed in 10% neutral buffer formalin for 1hr, the 1ml from the working Oil Red O staining 
solution was added for 1hr. The stain was removed, and after 3-4 washing steps in PBS to remove 
any unbound stain, digitised images were captured with an inverted phase contrast microscope 
(CETI. Medline Scientific Ltd. UK). 
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The relative levels of Oil Red O accumulation in each culture were further measured by a 
spectrophotometer (Multiskan go, Thermo Scientific. UK) after treating the stained wells with 100µl 
of 100% isopropanol to extract the Oil Red O from the stained cells. The plates were incubated for 
15minutes on a plate shaker; then the 100µl isopropanol contained the Oil Red O stain was 
transferred into 96 well plates, and the absorbance (optical density - O.D.) was measured using a 
bench spectrophotometer at 540nm. 
Alkaline phosphatase staining and quantification for osteoblastic differentiation: 
Alkaline phosphatase activity is frequently used as a key marker of osteoblast differentiation 
(Štefková et al., 2015). To assess alkaline phosphatase activity by staining, cells were fixed with 10% 
neutral buffer formalin for 10 minutes. Meanwhile, staining solution was prepared by placing 25mg 
of naphthol-phosphate (Naphthol AS-MX phosphate: Sigma) in 0.5ml of dimethyl formamide. Then, 
this solution was mixed with 50ml of 0.2M Tris-HCl buffer containing 50mg of fast red TR (Sigma). 
After mixing well, the final solution was filtered using Whatman No. 1 filter paper (Whatman). The 
fixative solution was then removed, and cells were washed with PBS, then 1ml of the staining 
solution was added to each well for 1hr. Finally, the stain was removed, and digitised images were 
captured with an inverted microscope. 
For the purpose of quantification, a colourimetric assay kit (BioVision, USA) was also used to 
determine alkaline phosphatase activity. This was performed by following the manufacturer’s 
protocol as follows; in brief, cells were homogenised in the assay buffer. The homogenised cells were 
then centrifuged to remove insoluble material at 13,000g for 3minutes. Then 80µl of each of the 
samples was loaded into separate wells of a 96 well plate. Then 50µl of 5mM of the pNPP solution 
was added to each sample well. Following a mixing step by pipetting up and down, the wells were 
incubated at 25ºC for 60minutes. A standard curve was generated by diluting 40µl of 5mM of pNPP 
into 160µl of assay buffer to generate 1mM pNPP standard. 
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Then 0, 4, 6, 12, 16 and 20µl of this standard solution was loaded into a 96 well plate to generate 0-
20 nmol/ml pNPP standards that could be measured by spectrophotometry. Then, the volume of all 
wells was brought up to 120µl by adding required volumes of assay buffer solution. Then 10µl of 
alkaline phosphatase enzyme was added to each well containing the pNPP standard, and the plates 
were further incubated at 25ºC for 60minutes. Following this incubation period, 20µl of the stop 
solution was added into each standard and sample well to stop all the reactions. The levels of alkaline 
phosphatase activity in all wells were measured by O.D. at 405nm in a microplate spectrophotometer. 
Glycosaminoglycan staining and quantification for chondrogenic differentiation: 
Glycosaminoglycans (GAGs) are a major component of the extracellular matrix (ECM) of cartilage, 
and their generation is a key indicator of chondrogenic differentiation (Sasisekharan et al., 2006). 
The deposition of GAGs in the ECM in 3D chondrogenic-induced pellet cultures was demonstrated 
by harvesting and sectioning the cell pellets and toluidine blue staining for the metachromatic 
staining that demonstrates the presence of GAGs (Wright et al., 2008). Briefly, 3D pellet cultures 
were harvested at day 28 of differentiation and fixed with 10% neutral buffer formalin overnight 
followed with two steps of washing with PBS. After fixation, the 3D pellets were processed for 
histological sectioning as follows. The pellets were immersed in 70%, 90% and 100% solutions of 
ethanol (in water), respectively, for 30minutes per each concentration. Then the pellets were 
immersed in 100% xylene for 30 minutes. The pellets were carefully transferred to a base mould, 
which was then filled with melted paraffin wax (VWR International Ltd., Poole, UK) and left to 
stand at 60ºC for a minimum of 12hrs. After this time fresh, melted paraffin wax was added after 
aspiration of the old paraffin from the pellets, and embedding cassettes (Thermo Electron 
Corporation, Basingstoke, UK) were placed on top of the base moulds. The cassette and base moulds 
were transferred to an ice block and left to stand for 10 minutes. 
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Finally, the paraffin-embedded 3D pellet blocks were stored at room temperature for further 
histological purposes. Three-micron thick tissue sections were prepared using a standard rotary 
microtome (HM325, Thermo Scientific) placed on glass slides and allowed to dry using a hotbox at 
70ºC. 
Then the sections were dewaxed with 100% xylene for 5 minutes and rehydrated in serial dilutions 
of 100%, 90%, 70% ethanol (in water) for 2 minutes per each concentration, and then washed in tap 
water. These sections were then stained with 0.4% staining solution of toluidine blue (Sigma) in 
0.2M sodium acetate buffer (pH3.75-4.25), which was added to the sections for 10minutes. After 10 
minutes incubation, the sections were washed with tap water for 1minute, then again passed through 
a graded series of 70%, 90%, 100% of ethanol (in water) for dehydration, being immersed for 2 
minutes per each concentration. After a clearing step with 5 minutes in 100% xylene, the slides were 
mounted in Pertex mounting medium (Sigma). Digitised images of the toluidine blue stained sections 
were captured using an inverted microscope. 
The amount of GAGs in the 3D pellets was quantified using the 1, 9-dimethyl methylene blue 
(DMMB) dye binding spectrophotometric assay (Farndale et al., 1982, Farndale et al., 1986). In brief, 
this was performed, as more recently described (Wright et al., 2008). The 3D chondrogenic-induced 
pellet cultures and control pellet cultures were washed with PBS and digested overnight with papain 
at 60ºC. A DMMB solution was prepared as follows; 16mg of DMMB powder, 3.04g of glycine and 
1.6g of NaCl were dissolved in 95ml of 0.1M acetic acid, and the volume was increased to 1L with 
water, then filtered (0.45μm filter, Sigma) and stored in a brown bottle to protect the solution from 
light. A standard curve for GAG levels was prepared by dissolving 40µg/ml of chondroitin sulphate 
from shark cartilage (Sigma) to generate 0, 8, 16, 24, 32, 36, 40µg/ml chondroitin sulphate standards. 
In 96 well plates, 50µl of each standard and test samples were mixed each with 200µl of the DMMB 
solution; then absorbance was measured at 595nm after incubation of the plate for 5minutes at room 
temperature using a bench spectrophotometer.
  
74 
 
 
2.3 The generation of MSC culture-conditioned medium (MSC CM) 
Canine and human MSCs were seeded at a seeding density of 1.5x106 cells in T75 tissue culture 
flasks in DMEM/F-12 medium supplemented with 10% FBS and 1% penicillin/streptomycin for 
24hrs to permit cell adhesion. After this time, the standard culture medium was discarded, and the 
cultures were washed three times in PBS before feeding with 15ml of DMEM/F-12 culture medium 
supplemented with 1% ITS, 1% non-essential amino acids (NEAA) and 1% penicillin/streptomycin, 
but without any serum present. The MSC cultures were then incubated at 37ºC in a humidified 
atmosphere of 5% CO2 for 3 days. The MSC culture-conditioned medium (MSC CM) was collected 
and filtered through a sterile filter (0.20µm, Minisart® C€, Germany) to remove any cell debris or 
fragments. The MSC CM was aliquoted and stored at -80ºC for further experimentation. Control 
medium (i.e. serum-free DMEM/F-12 with the same supplements, but with no cells present) was 
similarly incubated in T75 culture flasks for 3 days, then harvested, filtered and stored. During culture 
under serum-free conditions, there was no evidence of loss of cell viability as determined by cells 
either losing plastic adherence or floating or becoming phase dark when examined under phase 
contrast microscopy. In Chapter Five, the conditioned medium prepared from three human MSC 
subpopulations examined have been referred to as PA MSC CM, CD271+ MSC CM, and CD271- 
MSC CM. 
 
2.4 Assessment of the paracrine activity of canine and human MSC CM on neuronal 
and endothelial cell cultures 
The effects of MSC CM on neurogenesis and angiogenesis were assessed since these two activities 
play a major role in SCI repair (Cantinieaux et al., 2013). The cell lines, SH-SY5Y neuronal cells 
and EA.hy926 endothelial cells were used as potential responder cells, as previous research has 
reported that MSC CM generated from bone marrow-derived MSC CM have been shown to induce 
differentiation of both cell lines (Wright et al., 2010, Walter et al., 2015).
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Both cell lines derived from tumour cells and are human in origin. As described in the Introduction 
(1.5.3.), SH-SY5Y and EA.hy926 cells have been widely used as models to investigate neuronal and 
endothelial biological activities. 
 
2.4.1 Assessment of neurogenesis using SH-SY5Y neuronal cells 
The SH-SY5Y cell line was used as a neuronal model to investigate and assess the paracrine activity 
of canine or human MSC CM, as discussed in the Introduction (Section 1.5.3) and reported 
previously (Wright et al., 2010). SH-SY5Y cells were routinely grown in DMEM/F-12 supplemented 
with 15% FBS, penicillin/streptomycin and 1% of NEAA and 1% of ITS. For each experiment, SH-
SY5Y cells were harvested at 70-80% confluence by treatment with 0.025% trypsin/EDTA, and then 
centrifuged at 1000rpm for 10 minutes prior to seeding the cells at a density of 1x104 cells per well 
in 24 well plates and incubated overnight at 37°C in a humidified atmosphere of 5% CO2 to allow 
the cells to adhere. The next day, the SH-SY5Y cells were treated either with 1ml of MSC CM or 
with serum-free control medium and the cultures incubated in the Cell IQ Imaging Platform (CM 
Technologies Ltd, Finland) for live cell digitised imaging and analysis, where at least 3 wells per 
sample were analysed and where one image/well was captured prior to and after incubation for a 
3day period. The growth and morphological differentiation of SH-SY5Y cells were determined using 
these captured images and the Cell IQ image analyser software, as described in more detail in Section 
2.5, but in brief this allowed for the determination of the total number of viable SH-SY5Y cells per 
image and the extent of SH-SY5Y neurite outgrowth, i.e. neurite length per cell. 
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2.4.2 Immunofluorescence staining of SH-SY5Y cells for β-III tubulin 
Beta-III tubulin is a marker of neuronal differentiation (Dwane et al., 2013) that was used to further 
examine the effects of MSC CM on SH-SY5Y cells. SH-SY5Y cells were seeded on sterilised glass 
coverslips at a density of 1x104 cells; one coverslip each was placed in a 6 well plate. Cells were 
allowed to adhere overnight by incubating the plates at 37 °C in a humidified atmosphere of 5% CO2. 
Then cells were then washed three times with serum-free DMEM/F-12 medium, and 1ml of MSC 
CM (from either canine or human MSC cultures) or 1ml of serum-free control medium was added. 
The plates were then further incubated at 37°C in a humidified atmosphere of 5% CO2 for three days 
after which the medium was removed, and the cells were fixed with 10% neutral buffer formalin for 
1hr. Then the cells were washed twice with PBS and blocked with a blocking solution of 2% BSA in 
PBS for 1hr before adding a primary antibody of mouse monoclonal anti-beta III tubulin (TU-20: 
Cat. No. ab7751, Abcam) at a 1:500 dilution in blocking buffer that also contained the 
permeabilisation reagent, 0.1% Triton X -100. The plates were incubated with the primary antibody 
for 2hrs at 4°C, and parallel plates were incubated in the same permeabilisation solution with no 
antibody present. After three steps of washing with PBS, the SH-SY5Y cells were then incubated 
with a secondary antibody, which was rhodamine Red-X-AffiniPure donkey anti-mouse IgG (H+L) 
(Cat. No. 715-295-150, Stratech Ltd, address) at a 1:200 dilution for 1hr at 4°C in a humidified 
container that was light protected. After three further washing steps with PBS, 20-30µl of the 
antifading agent Vectashield was pipetted onto clean glass slides. The coverslips were rinsed with 
distilled water and mounted with the cells facing down on the glass slides. Digitised images were 
acquired using a Leica DMI4000 digital microscope, as shown in Chapters 3-4. There was no 
immunopositivity seen in control coverslips of SH-SY5Y cells that were incubated in the absence of 
the primary antibody. 
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2.4.3 Assessment of angiogenesis using EA.hy926 endothelial cells 
2.4.3.1  Scratch assay using EA.hy926 endothelial cells 
Migration and proliferation of endothelial cells are necessary for the angiogenesis process (Norton 
and Popel, 2016). Scratch assays of  EA.hy926 cells combined with digitised image analysis have 
been used previously to examine the effects of bone marrow-derived MSC CM on both aspects of 
angiogenic activity (Walter et al., 2015). 
Therefore, a similar approach was adopted in this research. EA.hy926 cells were seeded in DMEM/F-
12 supplemented with 10% FBS and 1% penicillin/streptomycin in 24 well plates at a density of 
5x104 cells per well and incubated at 37 °C in a humidified atmosphere of 5% CO2 for 48hrs to permit 
the formation of 100% confluent monolayers. Then the culture medium was removed, and the 
monolayers were scratched with a 200µl sterile pipette tip to leave a scratch with a gap in the 
monolayer. The wells were then washed immediately with PBS to remove any non-adherent cells or 
debris and then 1ml of MSC CM or serum-free control medium was added into the wells. The plates 
were placed for live cell imaging in the Cell IQ platform to collect digitised images for 2 days. As 
described in more detail in Section 2.5.1, these digitized images were analyzed using the Cell IQ 
analyser software to measure (i) the rate of scratch wound closure, (ii) the number of dividing cells 
per image, (iii) the number of non-dividing cells per image, and (iv) to track the extent of cell 
migration of individual cells. 
 
2.4.3.2  Endothelial tubule formation assay 
The extent to which MSC CM promoted endothelial tubule formation was examined by culturing 
EA.hy926 cells on a substrate of Matrigel, which is a well characterised in vitro model of this aspect 
of angiogenesis (Donovan et al., 2001, Ponce, 2001, Guidolin et al., 2004, Khoo et al., 2011). 
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This was performed as follows. Growth factor-reduced Matrigel (Corning. USA) was kept on ice in 
the fridge at 4°C overnight, then 50μl aliquots were plated into 96-well plates and incubated for 
30minutes in a humidified atmosphere of 5% CO2 at 37°C. Stock cultures of EA.hy926 cells grown 
in DMEM/F-12 supplemented with 10% FBS and penicillin/streptomycin were washed with serum-
free DMEM/F-12 three times and then detached from tissue culture plastic with 0.25% 
trypsin/EDTA. Harvested cells were then centrifuged at 1000 rpm for 10minutes, and the resultant 
cell pellets were re-suspended in 1ml of serum-free DMEM/F-12 before counting by trypan blue 
exclusion in a haemocytometer. Then 2 x 104 viable cells per well were re-suspended in 200µl of 
MSC CM or serum-free control medium and loaded on the top of the aliquots of Matrigel. Following 
incubation in a humidified atmosphere at 37°C and 5% of CO2 for 1day, phase-contrast digitised 
images were captured from three different randomly selected positions in each well using the Cell 
IQ live imaging platform.  From these digitised images, image analysis was performed, as described 
in more detail in section 2.5.1, to determine the total tubule length per image and a total number of 
branching points per image was using the Cell IQ analyser software. 
 
2.4.4 Cell viability assessment using MTT assay  
The MTT assay is a colourimetric assay for assessing cell metabolic activity. The principle of this 
assay is based on the capability of NAD(P)H-dependent cellular oxidoreductase enzymes, which 
under defined conditions reflect the number of viable cells present, to reduce the tetrazolium MTT 
dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to its insoluble formazan, which 
has a purple colour. Thus, in this study, the MTT assay was performed to assess further the effects 
of MSC CM on SH-SY5Y and EA.hy926 cell proliferation, by determining the numbers of viable, 
i.e. metabolically active cells present. This was performed as follows: SH-SY5Y cells and EA.hy926 
cells were seeded at a density of 5x103 cells per well into 96 well plates and treated with 200µl of 
MSC CM or serum-free control medium for three or two days respectively.  
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Following the treatment period, 20µl of 5mg/ml MTT solution was added to each well and incubated 
for 3-4hrs at 37°C in a humidified atmosphere of 5% CO2. Then carefully and without disturbing the 
cells, the medium was removed. The plates were left for 10 minutes to dry then 100µl of DMSO was 
added. The MTT assay was performed in the dark since the MTT reagent is sensitive to light. The 
absorbance of each well, including blanks containing MTT alone (no cells), were measured at 492 
nm and background at 650nm a plate reader. 
 
2.5 Microscopy and Image Analysis   
2.5.1 The Cell IQ live cell imaging machine   
The Cell IQ is an automated live-cell imaging apparatus, which provides an environment that enables 
cells to remain viable, i.e. in an incubator at 37oC and atmosphere of 5% CO2, while also collecting 
digitised images of the cells, a single snapshot at a time. The system can provide for long-term 
analysis of cells, and its software can be applied to the digitised images collected automatically to 
identify and quantify changes in cell phenotype. The system can be used to collect both phase contrast 
data and fluorescence data in different wavelengths and combinations thereof. The accompanying 
analyser software is powerful and has been applied to examine multiple changes in cell phenotype, 
including cell viability (Cao et al., 2016), cell proliferation (Rämö et al., 2016), cell migration (Bray 
and Slevin, 2015), individual cell tracking (Jansson et al., 2012), and specific changes for different 
cell lineages, e.g. increases in neurite outgrowth from neurons (Palazzolo et al., 2012), and 
endothelial tubule formation (Bray and Slevin, 2015). Any morphological parameter that cannot be 
identified by the naked eye can be analysed and quantified by Cell-IQ analyser software. It is possible 
to analyse structures composed of groups of cells either in 2D or 3D in cell culture, e.g. scratch 
wound closure, endothelial tube length and branch points, embryo and oocyte tracking. Such analysis 
is achieved by using the software to develop an analysis protocol for each parameter to be quantified.
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Because of the advantages of using the Cell IQ platform, regarding accumulated extensive, accurate 
and objective data on changes in cell phenotype, the platform was used to examine the effects of 
MSC CM on SH-SY5Y neuronal cells and EA.hy926 endothelial cells. More routine examinations 
of stock cell cultures, e.g. for passaging cells and trypan blue exclusion measures of stock cell 
viability, were performed using an inverted phase contrast microscope. 
 
2.5.2 The Cell IQ analysis protocol for SH-SY5Y viable cell numbers and neurite 
outgrowth 
After treating SH-SY5Y cells with MSC CM or with serum-free control medium, the plates were set 
for imaging using the Cell IQ live cell imaging platform and digitised images captured under phase 
contrast using an X10 objective, where one image per well (in triplicate wells) was captured at the 
end of 3-day time courses. At the end of the incubation period, these images were processed for 
further analysis using the Cell IQ analyser software. Digitised images were uploaded and opened in 
the analyser software window. By following the steps provided in the Cell IQ analyser user manual, 
the protocol was developed using an initial sample “library” of morphological features of the imaged 
cells that were designated as neurites or viable neuronal cell bodies (distinguished as phase-bright) 
versus cell debris or non-cellular background (Figure 2.1). 
  
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:1 Digitised phase contrast images of SH-SY5Y neuronal cells used as a reference 
library for the image analysis software to distinguish morphological features.  
  Representative images are shown of the sample library through segmentation and classification 
based on morphological differences. The process of generating the image analysis protocol was 
performed initially by selecting the “cell classifier” + “neurite finder”. The classes identified were 
neurites (top panels), cell bodies and debris of background (bottom panels). These are magnified 
images derived from digitised images collected using a phase contrast  X10 objective, then 
further magnified using the image analysis software. 
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2.5.3 The Cell IQ analysis protocol for EA.hy926 viable cell numbers, scratch wound 
closure and individual cell migration  
EA.hy926 cells were treated with MSC CM after performing a scratch as described in section 2.4.2.1; 
then the plate was incubated in the Cell IQ platform for digitised image acquisition under phase 
contrast using the x10 objective. Images were generated by selecting at least one region of interest 
(RoI) per well and captured at the same RoI every 15minutes over a two-day period to the point of 
scratch wound closure. Measurements of wound closure, viable cell numbers (distinguished as phase 
bright cells) and cell migration/movement were obtained by using Cell IQ analyser software and 
following the instructions provided by the user manual guide. In brief, the scratch wound closure 
analysis was based on previously published protocols (Walter et al., 2010, Bray and Slevin, 
2015), which utilised threshold levels and selected parameters as shown in Figure 2.2. The Threshold 
tool selects the area that contains viable cells covering the entire digitised then the selected 
parameters can be set to identify and remove any debris from the scratch area or fill in gaps in the 
non-scratched area. The results generated for the scratch wound area have been indicated by the 
purple boundary line seen in Figure 2.2, while the width of the scratch at exactly the centre of the 
image is shown by a blue line. The results used were derived from the scratch area as a proportion of 
the original scratch wound area. This was to avoid the use of the scratch width, which varied along 
the scratch length. The measurement of cell proliferation was also performed using the Cell IQ 
analyser by counting the number of dividing and non-dividing cells in the digitised images collected 
for each of the scratch wounds over time. This measurement was achieved by generating a cell 
identification protocol based on a library of sample images, which were classified according to their 
morphological appearance (Figure 2.3). The same cell identification protocol was also used to track 
viable cell movement and to measure the total distance of cell migration from the edge of the scratch 
wound towards the wound centre. These measurements were quantified over the two days of imaging 
period.
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Figure 2:2 The imaging protocol used to measure EA.hy926 cell scratch wound closure. 
 Representative digitised images are shown of the processing steps undertaken for scratch wound 
area analysis that was used to measure the percentage of wound closure over time. This measurement 
was based on a “threshold level” that initially identified the area of the digitised image that was 
covered by cells. Images from the left panels indicate a representative scratch wound created at day 
0, while the images in the right panels are representative images of the same scratch at day 2. Images 
from top panels to the bottom panels represent the processing steps: i) setting the threshold ii); 
removing debris in the scratched area; iii) eliminating gaps from the non-scratched area; (iv) finally, 
the resultant images used to calculate the scratch wound area as a proportion of the original scratch 
area.
Original images  
Threshold  
Remove debris from 
scratched area 
Remove gaps in non-
scratched area 
Results – the scratch wound 
area indicated by purple  
 
  
84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:3 The imaging protocol used to measure viable EA.hy926 cell division and 
proliferation.  
Representative images are shown from the sample library that was used to identify and quantify the 
numbers of dividing and non-dividing cells present in each of the digitised images of EA.hy926 cells 
in the scratch wound assays. As illustrated above, the cells were classified as dividing and non-
dividing cells based on their morphological appearance, with dividing cells appearing phase bright 
and rounded up or undergoing mitosis, while non-dividing cells were also phased bright but flattened 
and without any clear mitotic changes taking place. 
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2.5.4 The imaging protocol used to measure EA.hy926 tube formation 
Digitised images were captured of EA.hy926 cells cultured on Matrigel in the presence of MSC CM 
versus serum-free control medium for 1day. These digitised images were then analysed to measure 
the total tubule length and total branch point count per image using the Cell IQ analyser software. 
For each well (there were 5 wells per sample tested), 3 images were captured randomly from the well 
and then the threshold tool and selected parameters enabled the required measurements to be 
determined (Figure 2.4). Initially, the threshold tool was used to identify areas of the images that 
contained cells. Then followed by removal of all debris or small single objects, including single cells 
or short lengths of connected cells in sequence, and the removal of cell connections that were less 
than the width of one cell. The numbers of branch points were counted whenever longer sequences 
of cells (classified as tubules) connected with shorter sequences of cells (tubules); these were only 
scored once per connection. 
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Figure 2:4 The imaging protocol used to measure EA.hy926 tube formation.   
Representative images show the processing steps that were applied to develop the analysis protocol 
for measuring endothelial tubule length and for counting the number of endothelial tubule branch 
points. The measurement was based on initially thresholding the areas that were covered by cells and 
that were connected to other cells. Top panels: A) original image; B) applied threshold to identify all 
cells; C) step required to identify debris, single cells and short lengths of unconnected cell sequences; 
D) identification of branch points and removal of small sequences of cells identified in the previous 
step; E) performing the branch counts; F) an optional step to classify the endothelial tubule as thin 
or thick; G) the resultant image that was used to determine the final measurement for tubule length 
and branch point count.
B A 
C D 
E F 
G 
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2.6 ELISA analysis 
Canine and human MSC CM were analysed for the presence of VEGF protein by enzyme-linked 
immunosorbent assay (ELISA) using a commercially available kit (R&D Systems; Minneapolis, 
MN, USA) according to the manufacturer's instructions. In brief, this involved bringing all the 
reagent to room temperature. The working standards were prepared by dilutions as 1000, 500, 250, 
125, 62.5, 31.3, 15.6, and 0 pg/ml after having reconstituted the VEGF in 2000 pg/ml with calibrator 
diluent. 50µl of assay diluent was added to each well coated with a monoclonal antibody against 
VEGF, followed by adding 200µl of standard or sample per well and the plate was incubated for 
2hrs. after incubation, each well was aspirated then washed three times with wash buffer after the 
last wash step a complete removal of any remaining wash buffer was performed by aspirating or 
decanting. Then 200µl of the anti-VEGF conjugate was added to each well and incubated for 2hrs at 
room temperature followed by repeating the same aspiration/ wash steps described earlier. This was 
followed by adding 200µl of substrate solution to each well and incubated for 20minutes protected 
from light. Finally, 50µl of stop solution was added to each well, and 450 nm optical density was 
determined using microplate reader.  
 
2.7 Statistical analysis 
At least three independent experiments were performed for all analysis, i.e. using canine and human 
MSCs and MSC CM that was derived from at least three different patients (for each species) versus 
at least three separately generated serum-free control medium. Data has presented as the mean ± the 
standard error of the mean (SEM). For one experimental readout, i.e. the quantitative determination 
of alkaline phosphatase activity shown in Chapter 5, it was only possible to measure levels in n=2 
MSC donors; therefore this data has been presented as the mean ± standard deviation (SD). All data 
were examined for normal distributions and then analysed using parametric tests (normally 
distributed data) or non-parametric tests (non-normally distributed data) accordingly. 
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The tests used were an independent samples t-test or Mann-Whitney U test, one-way ANOVAs and 
two-way ANOVAs. A p value below 0.05 was considered significant. Statistical analysis was 
performed using Prism software (GraphPad Software Inc., La Jolla, CA, USA). 
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3 Chapter 3: An in vitro investigation of the neurotrophic and 
angiogenic paracrine activities of cMSCs 
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3.1 Aim and background 
The most common causes for SCI in dogs are IVDD or vehicle accidents (Bonner and Smith, 2013). 
Regardless of the cause of the SCI in both cases, the resultant pathology will lead to primary and 
secondary injury. Excellent recovery after injury can be achieved by preventing secondary injury, 
promoting regeneration and sprouting of remaining axons, enhancing the remaining function of any 
preserved neural circuitry, replacing destroyed spinal cord tissue and promoting revascularisation 
(Thuret et al., 2006). However, the recovery level depends on the severity of the injury, the more 
severe the injury, the less efficient the recovery. Although cure from paralysis is still difficult to 
achieve, recent research studies have suggested novel methodologies for SCI treatment, one of which 
is the use of MSCs as a cell-based therapy (Park et al., 2012a). Different studies suggested that 
transplanted MSCs exert therapeutic activity through their secretomes (Drago et al., 2013, Neirinckx 
et al., 2015, Bollini et al., 2013).  
As described in Chapter 1, dogs represent an excellent opportunity in which it is possible to examine 
how cell therapies may benefit SCI patients. Given the evidence that rodent and human MSCs exert 
paracrine activity in promoting nerve growth and angiogenesis (Wright et al., 2007, Wright et al., 
2014, Walter et al., 2015). Therefore, this study has investigated the capacity of canine MSCs to 
exert paracrine activities on models of nerve growth and angiogenesis. As stated above, to achieve a 
good recovery the regeneration of destroyed axons and CNS tissue revascularization is required. This 
chapter reports on the initial characterisation of cMSCs according to the criteria of the ISCT 
(Dominici et al., 2006) and on the effects of canine MSC secretomes, in the form of culture 
conditioned medium, on the SH-SY5Y neuroblastoma cells and the EA.hy926 endothelial cells. 
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3.2 Phenotypic verification of cMSC by multipotential differentiation and 
immunophenotype 
Differentiation capacity of cMSCs 
Cells were originally provided by the Veterinary Tissue Bank at passage II-III, then culture expanded 
as monolayer cultures in standard culture medium (DMEM/F-12 supplemented with 10% FBS, and 
1% penicillin and streptomycin, as described in  Chapter 2(Section, 2.1.1). These cultures of culture 
expanded cMSCs were plastic-adherent and displayed a stromal appearance. At passages III-V, 
cMSC cultures were induced to undergo differentiation towards adipogenic, osteogenic and 
chondrogenic lineages. As shown in Figure 3.1, cMSCs were able to differentiate along all three 
lineages. For adipogenic and osteogenic differentiation there was no evident loss of cell viability. 
However, for chondrogenic pellet cultures some cell death was apparent (as determined by Live/Dead 
staining and confocal microscopy), but nonetheless, there was also clear evidence of extracellular 
metachromatic staining with toluidine blue, indicative of glycosaminoglycan deposition and 
chondrogenic differentiation (Figure 3.1). 
 
Immunophenotyping for CD markers 
The expression of a panel of CD markers was examined for cMSCs (n=4 dogs; passages III-V) by 
flow cytometry. The cMSCs were notably immunopositive for CD44 and CD90 while being 
immunonegative for CD34 and CD45.  This finding is in line with the minimal phenotypic CD pattern 
for the identification of MSCs (Figure 3.2) (Table 3.1) (Dominici et al., 2006). 
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Figure 3:1 Differentiation of cMSCs along mesenchymal lineages. 
 Representative images are shown of plastic adherent, fibroblastic cells under phase contrast 
microscopy before treatment with inducers of differentiation (top panel) and after induction to 
become Oil Red O-positive adipocytic cells, alkaline phosphatase-positive osteoblastic cells, and 
toluidine blue-stained cartilaginous extracellular matrix and cells, as indicated (bottom panels). There 
was an evident loss of cell viability during the chondrogenic differentiation of MSCs in 3D-pellet 
cultures (visualised following Live/Dead staining and confocal microscopy; inset, bottom left panel). 
Scale bars = 100µm.Original magnification X10 for plastic adherent, osteogenesis, and 
chondrogenesis images. Original magnification X40 for adipogenesis image. Data shown are 
representative of inductions of cMSCs from four separate dogs. 
Adipogenesis  Osteogenesis  Chondrogenesis  
Plastic adherent 
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Figure 3:2 Immunophenotypic verification of cMSCs following CD immunostaining.  
Representative histograms are shown flow cytometric analysis of cMSCs following 
immunocytochemical staining for CD34, CD44, CD45 and CD90.  Immunoreactivity following 
immunocytochemical staining with irrelevant isotype-matched control antibodies has been shown in 
blue, while immunoreactivity for each of the CD markers has been shown in red. Data shown are 
representative of the CD profiles of cMSCs from four separate dogs. 
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Table 4: CD immunopositivity of cMSCs.  
The percentages of cMSCs that were immunoreactive for specific CD markers. The cells were largely 
immunonegative for CD34 and CD45, but immunopositive for CD44 and CD90. Summative data 
has been shown as the mean±SEM of four independent experiments (i.e. 4 different donor dogs). 
 
Percentage expression of CD markers 
 
Cell type Patient ID CD34 CD44 CD45 CD90 
Canine MSCs  cMSC 012 0.6 99.31 0.1 96.3 
 
 cMSC 014 0.3 82.1 0.1 90.9 
 
 cMSC 017 0.1 81.7 0.1 92.7 
 
 cMSC 028 0.3 90.35 0.04 96.3 
Mean 
 
0.33 88.37 0.18 94.05 
SEM 
 
0.11 4.16 0.075 1.35 
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3.3 The effects of cMSC CM on SH-SY5Y neuronal cells 
Following cell characterisation for minimal criteria of MSCs phenotype, the investigation of 
paracrine activities was performed. The neurotrophic activity was examined using SH-SY5Y cells. 
 
3.3.1 cMSC CM enhanced SH-SY5Y cell proliferation and neurite outgrowth 
SH-SY5Y cells were seeded at 1x104 cells per well in triplicate wells of 24 well plates in DMEM/F-
12 containing 15% FBS and 1% penicillin and streptomycin and left overnight to allow for cell 
adherence. After removal of the serum containing medium and washes in serum-free medium, cells 
were treated with cMSC CM versus serum-free control medium. A single digitised phase contrast 
image of each well was generated after placing the culture plates in the Cell IQ live cell imaging 
platform at the end of the 3-day time course (see Figure 3.3 for representative images). These images 
were then used, along with the Cell IQ analyser software, to measure the number of viable cells 
present and the extent of neurite outgrowth per cell. As shown in Figure 3.4, there were significant 
increases in both the number of cells present and neurite outgrowth in cMSC CM when compared 
with control (p= 0.0036 for cell number and p= 0.0055 for neurite outgrowth/cell, respectively) 
(Figure 3.4). 
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Figure 3:3 The appearance of SH-SY5Y cells cultured for 3 days in the presence of cMSC CM 
versus control medium.  
Representative images show there was an apparent increase in SH-SY5Y cell numbers and increased 
neurite outgrowth (arrowed) in cMSC CM compared with control cultures. Scale bars = 200µm. 
These images were performed on cMSC CM from three separate donors.
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Figure 3:4 cMSC CM significantly increased SH-SY5Y cell proliferation and neurite 
outgrowth.   
SH-SY5Y cells were treated with cMSC CM or serum-free medium for 3 days when digitised phase 
contrast images were captured and analysed using the Cell IQ imaging platform and software. There 
was a significant increase in both the number of viable cells present and the extent of neurite 
outgrowth per cell in cMSC CM at the 3-day time point compared with the control cultures. Each 
bar represents the mean±SEM of 5 independent experiments (i.e. using cMSC CM from 5 separate 
dogs). **indicates p≤0.01.  Mann-Whitney U test used to determine the significant differences. 
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3.3.2 cMSC CM induced immunopositivity for the mature neuronal marker, βIII-
tubulin in SH-SY5Y cells 
To further examine the differentiation status of SH-SY5Y cells, the cells were tested for their 
immunopositivity for the mature neuronal marker, βIII-tubulin (Meyer et al., 2004). As shown in 
Figure 3.5, SH-SY5Y cells were βIII-tubulin immunopositive following their treatment with cMSC 
CM for 3 days but were largely immunonegative in control medium at the same time point. Figure 
3.6 demonstrates that there were significantly greater numbers of βIII-tubulin immunopositive SH-
SY5Y cells when cultured in the presence of cMSC CM compared with control cultures (p= 0.0002).
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Figure 3:5Treating SH-SY5Y human neuroblastoma cells with cMSC CM induced beta-III 
tubulin immunopositivity.  
Representative images are shown of SH-SY5Y cells following immunocytochemical staining for 
beta-III tubulin. As shown, there was a clear increase in immunopositivity in cells cultured in the 
presence of cMSC CM compared with control cultures.  Scale bar = 100µm. Original magnification 
X40. These images were performed on cMSC CM from 3 separate donors.
Beta-III tubulin / DAPI 
Beta-III tubulin / DAPI 
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Figure 3:6 cMSC CM significantly increased the proportion of SH-SY5Y neuronal cells that 
were beta-III tubulin immunopositive.  
As shown, there was a marked increase in the percentage of SH-SY5Y cells cultured in cMSC CM 
versus control medium that was beta-III tubulin immunopositive. The proportion of beta-III 
immunopositive SH-SY5Y cells present was determined by scoring a minimum of 500 cells from 
digitised images, each collected from 5 randomly selected fields in each of 3 wells per medium tested. 
Each bar represents mean±SEM from three independent experiments, i.e. after culturing cells in 
cMSC CM from 3 separate dogs versus control medium. ***indicates p≤0.001. Mann-Whitney U 
test used to determine the significant differences. 
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3.3.3 Assessment of SH-SY5Y viable cell numbers using the MTT assay 
The MTT assay was used to further examine the number of viable SH-SY5Y cells present in cMSC 
CM versus control medium in a 96 well plate format. As shown in Figure 3.7, there appeared to be 
more viable SH-SY5Y cells present after culturing in cMSC CM for 3 days compared with control 
medium. These cultures were subsequently processed to assess viable cell number using the MTT 
assay, which measures non-specific esterase activity in viable cells (Hansen et al., 1989, Denizot and 
Lang, 1986). As shown in Figure 3.8, there was a significantly greater level of absorbance, indicative 
of increased numbers of viable SH-SY5Y cells in cMSC CM versus control medium (p= 0.0009).
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Figure 3:7 The effects of cMSC CM on SH-SY5Y neuronal cell proliferation. 
 Representative images have been shown to the relative increase in SH-SY5Y cell numbers when 
cultured for 3 days in cMSC CM versus control medium. Scale bar = 100µm. Original magnification 
X10. These images were performed on cMSC CM from 3 separate donors. 
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Figure 3:8 The MTT assay confirmed that culturing SH-SY5Y neuronal cells in cMSC CM 
versus control medium significantly increased the number of viable SH-SY5Y cells present. 
 MTT assays were performed to assess viable cell numbers. The results showed a significant increase 
in the number of viable SH-SY5Y cells in cMSC CM versus control medium at 3 days. Each bar 
represents mean±SEM from three independent experiments, i.e. using cMSC CM from 3 separate 
dogs. ***indicates p≤0.001.  Mann-Whitney U test used to determine the significant differences. 
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3.4 The effects of cMSC CM on EA.hy926 endothelial cells 
3.4.1 cMSCs CM increased EA.hy926 endothelial cell migration and proliferation 
The effects of soluble factors secreted into the conditioned medium by cMSCs on EA.hy926 cells 
were examined using a scratch assay. Confluent layers of EA.hy926 endothelial cells were scratched 
using a yellow pipette tip, and the medium was replaced with either cMSC CM or serum-free control 
medium. Then, the rates of EA.hy926 endothelial cell migration and proliferation were monitored 
and quantified using the Cell IQ Imaging platform. Results showed that there was a significant 
increase in scratch wound closure (as a percentage of the original scratch width) when compared 
with control cultures (p=0.0409) (Figures 3.9 and 3.10).  To determine whether cMSC CM played a 
role in promoting cell migration to induce wound closure, cells from both sides of wound edges were 
tracked by using Cell IQ analyser software. A minimum of three cells for each of triplicate scratch 
wound from each of three independent experiments (i.e. testing cMSC CM from three separate dogs) 
was randomly selected. Their patterns of migration were tracked by collecting digitised images every 
15 minutes over a 2-day time course, after which the total distance that each cell had migrated during 
this period was measured. These results showed that there was a significant increase in the extent of 
cell migration in the closure wound area when the cells were treated with cMSC CM compared with 
control medium (p= 0.0001) (Figure 3.11).  
Additional analysis using the cell IQ analyser software was performed on tracked cells to determine 
the numbers of dividing, and non-dividing cells present within the scratch wound area in each image 
collected every 15 minutes over the two-day time course. This data showed that the number of both 
dividing and non-dividing EA.hy926 cells present within the scratch wound area were significantly 
higher when treated with cMSC CM compared with control medium (p= 0.0127 for dividing cells, p 
=0.0001 for non-dividing cells) (Figure 3.12). EA.hy926 cell proliferation was also determined using 
a 96 well plate format and the MTT assay. Representative images in Figure 3.13 show evidence of 
EA.hy926 endothelial cells proliferating to a greater extent after treatment with cMSC CM compared 
with control medium after 2 days of incubation. 
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The MTT assay of these cultures also showed a significant difference in the number of viable 
EA.hy926 cells present in cultures treated with cMSC CM compared with control medium after 2 
days of treatment (p= 0.0001) (Figure 3.14). 
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Figure 3:9 The effects of cMSC CM on EA.hy926 endothelial cells in scratch assays. 
 Representative images are shown EA.hy926 endothelial cell scratch assays, which were treated with 
cMSC CM or serum-free control medium for 2 days after scratching. EA.hy926 cells were seeded 
into multiple wells of 24 well plates and cultured in a standard culture medium until confluent and 
then scratched using a yellow pipette tip. After washing with PBS, the cultures were then fed with 
cMSC CM or serum-free control medium. Scale bars = 200µm. These images were performed on 
cMSC CM from 3 separate donors. 
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Figure 3:10 cMSC CM significantly increased the rate of wound closure in EA.hy926 
endothelial scratch assays.  
The Cell IQ platform was used for live imaging of wound closure in EA.hy926 endothelial cell 
scratch wound assays in the presence of cMSC CM versus serum-free control medium. Digitised 
images were generated over 2 days of incubation and the  Cell IQ imaging software used to measure 
the extent to which the wound had closed (as a proportion of its original scratch area). There was a 
significant increase in the rate of wound closure in cMSC CM compared to the control medium. Each 
bar represents mean±SEM of 3 independent experiments, i.e. using cMSC CM from 3 separate dogs. 
* (red start) indicates p≤0.05. Two-way ANOVA with a Sidak's multiple comparisons test used to 
determine the significant differences. 
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Figure 3:11 cMSC CM significantly increased EA.hy926 endothelial cell migration. 
 Image analysis of the collected digitised images was used to measure the distance that EA.hy926 
endothelial cells migrated from the edge of the scratch towards the centre of the wound over a period 
of 2 days in the presence of cMSC CM versus serum-free control medium. As shown, there was a 
significant increase in distance travelled in cMSC CM versus control medium during this time. Each 
bar represents the mean±SEM of 3 independent experiments (i.e. 3 different dog donors) of 3 
replicates per each experiment. ****indicates P≤ 0.0001. Mann-Whitney U test used to determine 
the significant differences. 
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Figure 3:12 The stimulatory effects of cMSC CM on EA.hy926 endothelial cell numbers in the 
scratch wound area resulted from increased cell migration and cell proliferation.  
The increased numbers of EA.hy926 endothelial cells present in the closure of scratch wounds, seen 
in Figures 3.9 and 3.10, could have been through increased cell migration (as shown in Figure 3.11) 
and increased cell proliferation. Therefore further analysis was performed to track the number of 
dividing and non-dividing cells present in the wound area. As shown, there was a significant increase 
in both cell populations, indicating that cMSC CM stimulated EA.hy926 endothelial cell migration 
and cell proliferation. Each bar represents mean±SEM from 3 independent experiments, i.e. using 
cMSC CM from 3 separate dogs. * (red star top panel) indicates P≤0.05 and **** (four red stars 
bottom panel) indicates P≤ 0.0001. Two-way ANOVA with a Sidak's multiple comparisons test used 
to determine the significant differences.
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Figure 3:13 cMSC CM promoted EA.hy926 endothelial cell proliferation in 96 well plates. 
  Representative images are shown of EA.hy926 cells cultured in cMSC CM or serum-free control 
medium. As shown, there was an apparent increase in the number of EA.hy926 cells present in cMSC 
CM versus control medium at 2 days of culture. Scale bars = 100µm. Original magnification X10. 
This analysis was performed on cMSCs from 3 separate donors.
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Figure 3:14 The MTT assay confirmed that culturing EA.hy926 endothelial cells in cMSC CM 
versus control medium significantly increased the number of viable EA.hy926 cells present.  
MTT assays were performed to assess viable cell numbers. The results showed a significant increase 
in the number of viable EA.hy926 cells in cMSC CM versus control medium at 2 days. Each bar 
represents mean±SEM from 3 independent experiments, i.e. using cMSC CM from 3 separate dogs 
of five replicates per each experiment. ****indicates p≤ 0.0001. Mann-Whitney U test used to 
determine the significant differences.
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3.4.2 The effects of cMSC CM on EA.hy926 endothelial tubule formation 
Angiogenesis is a normal and vital process in growth and development, as well as in wound healing. 
When a new tissue is formed, it is vital that it has blood supply for its growth and sustenance. For 
this, the formation of blood vessels or angiogenesis is important. The effect of cMSC CM was 
examined further using an in vitro assay for endothelial tubule formation. EA.hy926 endothelial cells 
were cultured on three-dimensional Matrigel (with reduced growth factors) in cMSC CM or serum-
free control medium. As shown in Figure 3.15, culturing EA.hy926 cells in cMSC CM induced the 
formation of tubule-like structures, with more of these structures present in the cMSC CM compared 
with control medium. After one day of treatment with cMSC CM or serum-free control medium, 
phase contrast images were captured and analysed using the Cell IQ cell imaging platform and 
software. As shown in Figure 3.16, there were significant increases in both the total tubule length per 
image (p= 0.0082) and the number of tubule branch points per image (p= 0.0307) in cMSC CM 
versus control medium. 
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Figure 3:15 The effects of cMSC CM on EA.hy926 endothelial cells cultured on Matrigel.  
Representative images are shown of EA.hy926 endothelial cells cultured on Matrigel in the presence 
of cMSC CM or serum-free control medium. These images were subsequently analysed using the 
Cell IQ imaging software to determine the length (indicated by green lines) and the number of branch 
points (indicated by blue dots) seen in endothelial tubule-like structures. Scale bars = 200µm. This 
analysis was performed on cMSCs from 3 separate donors. 
cMSC CM Control 
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Figure 3:16 cMSC CM significantly increased EA.hy926 endothelial tubule formation. 
 Image analysis of the collected digitised images (see Figure 3.15) was used to measure both the total 
length of tubules formed (per image) and the number of endothelial tubule branch points (per image). 
As shown, there were significant increases in both of these parameters when EA.hy926 cells were 
cultured on Matrigel for 2 days in cMSC CM versus control medium. Each bar represents the 
mean±SEM of 3 independent experiments, i.e. using cMSC CM from 3 separate dogs. Top panel: 
**indicates p≤0.01. Bottom panel: *indicates p≤0.05. Unpaired t-test with Welch's correction used 
to determine the significant differences.
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3.5  Discussion  
MSCs are traditionally characterised by their capacity for self-renewal and multipotent potential to 
differentiate into three lineages: adipocytes, osteoblasts and chondrocytes (Caplan, 1991). The rare 
population of MSCs established from bone marrow (BM) by their preferential adhesion to tissue 
culture plastic constitute only 0.001% -0.01% of the total nucleated cells in the bone marrow 
(Friedenstein et al., 1970). Adipose tissue (AT), like BM, is derived from mesenchyme and has 
supportive stroma that is easily isolated (Zuk et al., 2002). Throughout the last decade, AT MSCs 
have been achieving mounting attention in regenerative medicine (Zuk et al., 2001, Hong et al., 
2010). AT MSCs have similar characteristics to BM MSCs, which are the classical cells source for 
tissue regeneration, but AT MSCs may have advantages since they are more genetically stable in 
long-term culture than BM MSC (Fernyhough et al., 2008, Liu et al., 2011).  
The ISCT has proposed minimal criteria to define MSCs. These are adherence to plastic, specific 
surface antigen (Ag) expression for example CD73, CD90 and CD105, and low or no expression of 
CD34, CD45, CD11b, CD14, CD19, CD79a and HLA-DR., multipotent differentiation potential into 
the three mesenchymal lineage cell types of adipocytes, osteoblasts and chondrocytes, at least in vitro 
(Dominici et al., 2006). The immunophenotyping of the canine culture expanded and plastic adherent 
cells seen in this study was supportive of these cells being characterised as MSCs. They were positive 
for certain surface antigen markers specific for CD44 and CD90. Also, these cells showed negativity 
for the haematopoietic CD markers CD34 and CD45. The study has only examined these four canine 
specific CD markers as they were commercially available. However, this study showed that cMSCs 
poorly differentiate into adipocytes, this might be as a result of using an established protocol which 
was suitable for hMSCs, but might not be suitable for cMSCs. Recently, cell therapy has been 
considered as an efficient method to repair injuries such as SCI (Quertainmont et al., 2012). Different 
studies suggested that cell replacement is not the sole way for transplanted stem cells to boost tissue 
repair in vivo (Madrigal et al., 2014). 
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It is, in fact, becoming increasingly accepted that the mechanism of the therapeutic effect of MSC 
transplants in particular could be related to the ability of these cells to secrete a varied array of factors, 
including growth factors, cytokines, chemokines, metabolites and bioactive lipids, that have 
paracrine activity (Pluchino et al., 2005, Caplan and Correa, 2011, Paul and Anisimov, 2013). 
Moreover, several recent studies have suggested that the secretomes of AT MSCs can have a 
stimulatory effect on wound healing (Walter et al., 2010, Lopatina et al., 2011, Zhao et al., 2013a).  
Having established that canine MSCs could be culture expanded from adipose tissue, this study 
aimed to examine the potential neurotrophic effect and angiogenic effect of canine AT MSCs 
secreted factors in cMSC CM. The purposes of this study were first to determine the effects of cMSC 
CM on neurite growth and cell survival using the SHSY-5Y neuroblastoma cell line. Secondly, to 
identify effects of cMSC CM on endothelial cell migration, proliferation and tubule formation using 
the EA.hy926 endothelial cell line.  The Cell IQ live cell image capture platform and analysis 
software was used for these studies, as has been performed previously (Pandya et al., 2006, Ucuzian 
and Greisler, 2007, Bokara et al., 2016), along beta-III tubulin immunopositivity as a marker of 
neuronal differentiation (Brohlin et al., 2012) and MTT assays for viable cell numbers (Morgan, 
1998). The data obtained by this study showed that cMSC CM significantly increased SH-SY5Y 
neurite outgrowth, proliferation and differentiation when these cells were cultured in cMSC CM 
generated under serum-free conditions versus serum-free control medium. These findings support 
the hypothesis raised by this study, i.e., that the cMSCs secretomes are neurotrophic. Similarly, 
Neuhuber et al., 2005 in their study claimed that MSCs secreted factors which mediate the axonal 
outgrowth and enhance the recovery after SCI  (Neuhuber et al., 2005). Wright et al., 2014 presented 
in their MSCs as a suitable candidate and an option of treatment for chronic SCI as they claimed that 
MSCs encourage the neurite outgrowth overcoming the inhibitory factors which are common in the 
chronic lesion (Wright et al., 2014).
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Moreover, Pires et al. (2014), in their study, showed the secretomes of both BMSCs and Warton 
jelly-derived MSCs was capable of sustaining SH-SY5Y cell survival throughout their differentiation 
into a neuronal phenotype. Such finding can support the evidence on the capacity of AT MSCs to 
secrete neuroprotective and neurotrophic growth factors (Pires et al., 2014). 
When the spinal cord is injured, the local blood vascular supply also will be ruptured, and the primary 
injury mechanism leads further to haemorrhage at the site of injury. This disturbance in the 
vasculature of the spinal cord causes necrotic damage to the endothelial cells, and subsequently, there 
is a decrease in blood vessel density (Ng et al., 2011). This decreased vascularization may be 
considered detrimental to SCI recovery, as several studies have suggested that functional 
improvement after SCI might be related to increases in blood vessel density (Glaser et al., 2006, 
Kaneko et al., 2006, Rauch et al., 2009). Hence, this study also evaluated whether cMSC CM promote 
endothelial cell migration and blood vessel formation. A handful of studies has confirmed that AT 
MSC CM from other species promotes wound healing and formation of new blood vessels (Estrada 
et al., 2009, Ranganath et al., 2012). Also, in vitro studies demonstrated that MSCs from a variety of 
sources could secrete angiogenic, anti-apoptotic and mitogenic factors for endothelial cells such as 
VEGF, HGF, angiopoietin-1, adrenomedullin and IGF-1 (Kinnaird et al., 2004, Schinkothe et al., 
2008). In particular, this study showed the effect of cMSC CM on the proliferation, migration, and 
tube formation of EA.hy926 endothelial cells. The results showed that cMSC CM significantly 
increased the closure rate of scratch wounds compared to non-conditioned control medium. 
Furthermore, detailed live cell image analysis demonstrated that increased EA.hy926 endothelial cell 
proliferation and cell migration contributed to the wound closure process. The data also showed that 
cMSC CM induced the formation of endothelial tube-like capillaries in a Matrigel assay. These 
findings are supportive of the conclusion that cMSCs are also angiogenic. 
In summary, this study has used established in vitro models to examine the paracrine activity of 
cMSCs. It demonstrated that cMSC CM was both neurotrophic and angiogenic. Further studies are 
required to identify mechanisms of action, although a significant number of studies have already 
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shown that MSCs from a variety of different sources and across species secrete neurotrophic and 
angiogenic factors (Timmers et al., 2011, Cantinieaux et al., 2013, Sun et al., 2013, Zhang et al., 
2013b). Also, it would also be important to confirm that the canine MSCs exert similar trophic effects 
on canine neurones and canine endothelial cells, especially if cMSCs were to be used clinically. The 
stimulatory activities reported here support the application of cMSCs as a therapeutic option in 
veterinary regenerative medicine, e.g. to treat SCI. Furthermore, as discussed previously, the 
investigation of cMSC CM on these cell models and in the treatment of SCI in dogs could help to 
develop cell-based regenerative strategies for the treatment of humans. Since many aspects of canine 
diseases and injury are functionally and structurally similar to those described in humans (Starkey et 
al., 2005). A second important consideration, therefore, in this translational pathway, is to examine 
how the paracrine activity of canine MSC and human MSC compare, which is the focus of the next 
research chapter.  
 
 
 
 
  
119 
 
 
 
 
 
 
 
 
4 Chapter 4: An in vitro comparison of the neurogenic and 
angiogenic paracrine activities of human versus canine 
MSCs 
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4.1 Background and aims  
SCI can be a devastating condition in humans and other species since it causes direct damage to the 
neuronal tissue accompanied by the loss of motor and sensory function. Current treatments involve 
surgery to decompress and stabilise the spinal cord, treatments that avoid secondary complications 
and that may promote rehabilitation (Tator, 2006). However, functional neurological recovery after 
serious injury, i.e. injury involving chronic and complete loss of motor and sensory function, is still 
rare and effective treatment has not yet emerged. On the other hand, recent evidence, based on studies 
focused on stem cells as a therapy for SCI, have shown some promising results. For example, 
experimental and clinical studies demonstrated the possible use of ESC-derived oligodendrocyte 
precursor cells (Keirstead et al., 2005), neural stem/progenitor cells (NSPCs) (Tsuji et al., 2011), 
iPSCs (Oh et al., 2015, Salewski et al., 2015)or MSCs (Matos et al., 2016, Rathinasabapathy et al., 
2016) as a potential cell transplantation therapy for SCI.  
However, MSCs may be preferable over other stem cells for many strategies promoting tissue repair 
for a variety of reasons. First, there is less concern about the ethical issues of using MSCs in 
comparison with ESCs. Second, studies have suggested that MSCs are suitable for allogenic 
transplantation procedures since they are immuno-privileged, which make the risks of rejection and 
complications more unlikely (Gupta et al., 2013, Vega et al., 2015). Third, the possibility of obtaining 
MSCs in quantity required for clinical application in comparison with many other types of adult stem 
cells, e.g. neural stem cells or olfactory cells, make them preferable (Le Blanc and Pittenger, 2005, 
Morte et al., 2013). Fourth, MSCs do not carry the same risk of forming teratomas compared to ES 
cells (Tipnis et al., 2010, López-Iglesias et al., 2011, Rong et al., 2012). As stem cells emerge as 
potential cell-based therapies, pre-clinical assessment of their regenerative activity is required. 
Therefore, there is a clear awareness of the need for animal models that fully reflect the target 
diseases to be investigated by using stem cells (Plews et al., 2012). Different studies reported that 
the application of mouse models in regenerative medicine has many limitations (Cibelli et al., 2013).
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This could be because mice have short lifespans in comparison to humans and also there are 
significant anatomical and physiological differences between human and mouse (Schneider et al., 
2008). In contrast, large animal models more closely resemble important aspects of human anatomy, 
physiology and pathology than mouse models. In this regard, it may be considered that dogs represent 
a promising translational model for many human diseases (Qeska et al., 2013, Hicks et al., 2015, 
Park et al., 2016). Similarly to SCI in human, SCI in dogs may lead to severe neuronal tissue damage 
resulting in loss of motor and sensory functions (Starkey et al., 2005, McMahill et al., 2015). In 
addition, a number of studies have tested the safety and occasionally, efficacy of cell transplantation 
therapies in dogs with SCI, examining the outcome of different transplanted cell types, including 
autologous canine olfactory cells (Jeffery et al., 2006a, Granger et al., 2012) and canine MSCs (Jung 
et al., 2009, Sarmento et al., 2014). The mechanisms of action of canine MSCs in the treatment of 
dogs with SCI are currently unknown. For this reason, the previous chapter examined whether canine 
MSCs secrete factors that are neurotrophic and angiogenic, using established cell model systems. 
However, the longer term aim is to evaluate the potential of MSCs to treat humans with SCI, wherein 
the effects of canine MSCs in dogs with SCI would represent part of the translational pathway from 
evaluating cell phenotyping and reparative activity in vitro, through to clinical treatment. As a step 
along this pathway, it is worthwhile comparing the neurotrophic and angiogenic effects of canine 
MSCs with human MSCs. Such knowledge would be invaluable in trying to estimate their potential 
for regenerative effects when transplanted. 
This chapter aims to address and understand the differences in the behaviour of MSCs secretomes 
from both canine and human donors. Therefore, experiments were performed to investigate the 
neurotrophic and angiogenic activity for human MSCs in comparison with canine MSCs secretomes, 
where the cells were isolated and cultured from adipose tissue in both cases and all experimentation 
was performed independently of that shown in Chapter 2 and Chapter 3. Cell assays were undertaken 
to examine the effects of MSC CM on SH-SY5Y neuronal cells and EA.hy926 endothelial cells, 
following the methods established in Chapter 3.
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The outcome of these investigations might provide benefits for veterinary and human medicine and 
also might be helpful to bridge the gap between translational research and human clinical trials. 
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4.2 Characterisation of hMSCs and cMSCs  
4.2.1  Growth characteristic and differentiation capacity of hMSCs and cMSCs 
Human and canine MSCs were plastic adherent and displayed a spindle-shaped fibroblast-like 
morphology (Figure 4.1), matching the criteria for an MSC phenotype established by the ISCT 
(Dominici et al., 2006). Both hMSCs and cMSC were assessed for their ability to differentiate the 
following induction in culture into three mesodermal lineages, i.e. to form adipocytes, osteoblasts 
and chondrocytes. As shown in Figure 4.1, hMSCs and cMSCs demonstrated some differentiation 
capacity to form adipocytes (indicated by staining intracellular lipid droplets with Oil Red O), 
osteoblasts (indicated by staining for alkaline phosphatase activity) and chondrocytes (indicated by 
staining the paraffin sections of chondrogenic 3D cell pellets with toluidine blue for 
glycosaminoglycan deposition) (Figure 4.1). However, there was less evidence of greater lipid 
accumulation in the cMSCs compared with hMSCs. 
 
4.2.2 Immunophenotype 
According to the ISCT criteria, MSCs should be immunopositive for the cluster of differentiation 
(CD) markers, CD73, CD90 and CD CD105, and lack immunopositivity for CD11b, CD14, CD19, 
CD34, CD79α and HLA-DR (Dominici et al., 2006).  Some of these markers were included in this 
study, according to the availability of antibodies recognising the canine antigens, and the CD profiles 
were assessed using flow cytometry. The results showed that the large majority of cultured hMSCs 
and cMSCs were immunopositive for CD44 and CD90, but were immunonegative for haematopoietic 
markers, i.e. CD34 and CD45 (Figure 4.2). For hMSCs 91.83%±3.92% and 97.81%±0.52% of cells 
were CD44 and CD90 immunopositive, respectively, while only 1.14%±1.08% and 0.06%± 0.02% 
of cells were CD34 and CD45 immunopositive, respectively (mean±SEM).
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Similarly, cMSCs were 90.57%±1.52% immunopositive for CD44 and 99.20%±0.22% 
immunopositive for CD90, but only 5.79%±5.58% and 0.04%±0.00% of cells were immunopositive 
for CD34 and CD45, respectively (mean±SEM) (Table 4-1).  
In summary, this data demonstrated that the processes of isolating and culturing hMSCs and cMSCs 
from adipose tissue generated a population of cells that met with the ISCT criteria for being 
considered MSCs. 
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Figure 4:1 The appearance and differentiation potential of hMSCs and cMSCs.  
Representative images are shown of hMSCs (top panels A) and cMSCs (bottom panels B). Both cell 
types were plastic adherent and fibroblastic in appearance under phase contrast microscopy. 
Furthermore, hMSCs and cMSCs underwent differentiation into the mesodermal lineages, 
adipocytes, osteoblasts, and chondrocytes. Scale bars = 100µm with original magnification X10 for 
plastic adherent, osteogenesis, and chondrogenesis images. Scale bar = 50µm with original 
magnification X40 for adipogenesis image. This analysis was performed on hMSCs and cMSCs from 
3 separate donors of human or canine.
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Figure 4:2 Flow cytometry analysis of CD markers phenotypic for MSCs. 
 Representative histograms are shown of the extent of immunopositivity seen for CD34, CD44, CD45 
and CD90 in hMSCs (top panels A) and cMSCs (bottom panels B). As shown, both human and 
canine MSCs were immunonegative for CD34 and CD45, but they were immunopositive for CD44 
and CD90. Immunostaining for each CD marker is shown in red, whilst control staining with 
irrelevant isotype-matched antibodies (as described in chapter two, section 2.2.1) is shown in blue. 
This analysis was performed on hMSCs and cMSCs from 3 separate donors.
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Table 5: The proportions of hMSCs and cMSCs that were immunopositive for CD markers.  
The percentages of hMSCs (top panel) and cMSCs (bottom panel) for each of the CD markers. As 
shown, this analysis was performed on hMSCs and cMSCs from 3 different donors. 
Percentage expression of CD markers for hMSCs 
Cell type Patient ID CD34 CD44 CD 45 CD90 
Human MSC  hMSC101 0.04 83.99 0.04 97.54 
 
hMSC110 3.30 95.72 0.04 97.08 
 
hMSC123 0.09 95.78 0.10 98.83 
Mean  
 
1.14 91.83 0.06 97.81 
SEM 
 
1.08 3.92 0.02 0.52 
Percentage expression of CD markers of cMSCs 
Cell type Patient ID CD34 CD44 CD45 CD90 
Canine MSC cMSC 018 0.03 92.57 0.04 98.86 
 
cMSC 020 16.97 87.59 0.04 99.62 
 
cMSC 028 0.39 91.54 0.04 99.13 
mean 
 
5.79 90.57 0.04 99.20 
SEM 
 
5.58 1.52 0 0.22 
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4.3 A comparison of the neurotrophic effects of hMSCs and cMSCs conditioned 
medium 
4.3.1 Human and canine MSC CM promoted neurite outgrowth and neuronal cell 
proliferation of SH-SY5Y cells 
The effects of hMSC CM and cMSC CM on SH-SY5Y neuroblastoma cells were examined using 
the same methodology previously described in Chapter 2 (Section 2.4.1) and Chapter 3. In brief, the 
SH-SY5Y cells were seeded in 24 well plates and incubated for 24 hours to allow for cells to adhere. 
Following medium change and treatment with either hMSC CM, cMSC CM or serum-free medium 
(in control cultures), the plates were incubated in the Cell IQ live cell imaging platform for 3 days 
for digitised image collection (Figure 4.3). At the end of incubation period, these images were 
analysed using the Cell IQ analyser software. 
The data obtained showed that both human and canine MSC CM have a marked neurotrophic effect, 
enhancing neuronal cell growth and neurite outgrowth from SH-SY5Y cells compared to control 
cultures. The results showed that human and canine MSC CM significantly increased the number of 
SH-SY5Y cells present after 3 days in culture compared with control medium (p= 0.0288 for hMSC 
CM and p= 0.0168 for cMSC CM). However, there was no significant difference between the effects 
of human and canine MSC CM in this regard ( p= 0.8865). Also, both human and canine MSC CM 
significantly increased neurite outgrowth of SH-SY5Y cells compared with control medium (p= 
0.0042 for hMSC CM and p= 0.0098 for cMSC CM), but there was no significant difference between 
the effects of human and canine MSC CM ( p= 0.6819) (Figure 4.4). 
Therefore, hMSC and cMSC were shown to have significant neurotrophic activity, which was 
similar.
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Figure 4:3 Human MSC CM and canine MSC CM increased neuronal cell numbers and 
neurite outgrowth in SH-SY5Y neuroblastoma cells.   
Representative digitised images captured by the Cell IQ live cell imaging platform have been shown. 
As shown, hMSC CM and cMSC CM increased neurite outgrowth (arrows) and neuronal cell 
proliferation compared with control medium. Scale bar = 200µm. These images were collected using 
hMSC and cMSC CM from 3 separate donors.
h
M
S
C
 C
M
 
Day 0 Day 3 
cM
S
C
 C
M
 
C
o
n
tr
o
l 
  
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:4 Human MSC CM and canine MSC CM significantly increased SH-SY5Y cell 
numbers and neurite outgrowth. 
The results showed that hMSC CM and cMSC CM had a similar effect of increasing cell proliferation 
and neurite outgrowth of SH-SY5Y cells. Each bar represents the mean±SEM from 3 independent 
experiments (i.e. 3 different donors) of 3 replicates per each individual experiment. *indicates p≤0.05 
(top panel A); and **indicates p≤0.01 (bottom panel B). One way- ANOVA with Tukey's multiple 
comparisons test used to determine the significant differences. 
A 
B 
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4.3.2 hMSC CM and cMSC CM enhanced immunopositivity for the mature neuronal 
marker βIII-tubulin in SH-SY5Y neuronal cells 
βIII-tubulin is a marker of neuronal differentiation (Dwane et al., 2013), which was detected by 
immunocytochemistry. This analysis demonstrated that βIII-tubulin appeared to be present to a 
greater extent in SH-SY5Y cells when they were treated with hMSC CM and cMSC CM compared 
with control medium (Figure 4.5). The proportions of βIII-tubulin immunopositive SH-SY5Y cells 
were significantly increased versus controls when cultured for three days in hMSC CM (p= 0.0018) 
and cMSC CM (p= 0.0013). There was no significant difference in the proportions of βIII-tubulin 
immunopositive SH-SY5Y cells present in either hMSC CM versus cMSC CM (p= 0.4674) (Figure 
4.6). 
Therefore, hMSC and cMSC secreted factors that appeared to induce neuronal differentiation to a 
similar extent.
  
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:5 The effects of hMSC CM and cMSC CM on beta-III tubulin immunopositivity in 
SH-SY5Y cells.  
Representative images are shown of SH-SY5Y cells treated with hMSC CM or cMSC CM or control 
medium for 3 days and immunostained for beta-III tubulin. As shown there was an apparent increase 
in immunopositivity when cultured in the presence of MSC CM. Scale bar = 100µm. Original 
magnification X40. These images were collected using hMSC CM and cMSC CM from 3 separate 
donors. 
h
M
S
C
 C
M
 
cM
S
C
 C
M
 
C
o
n
tr
o
l 
Beta-III tubulin / DAPI 
Beta-III tubulin / DAPI 
Beta-III tubulin / DAPI 
  
133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:6  Human MSC CM and canine MSC CM significantly increased the proportion of 
SH-SY5Y cells that were beta-III immunopositive. 
 The proportion of beta-III immunopositive SH-SY5Y cells present was determined by scoring a 
minimum of 500 cells from digitised images, each collected from 5 randomly selected fields in each 
of three wells per medium tested. Each bar represents the mean±SEM from 3 independent 
experiments, i.e. testing hMSC CM and cMSC CM from 3 separate donors. ****indicates p≤ 0.0001. 
One way- ANOVA with Tukey's multiple comparisons test used to determine the significant 
differences. 
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4.3.3 Assessment of SH-SY5Y viable cell numbers using the MTT assay 
The MTT assay was used to further examine the number of viable SH-SY5Y cells present in cMSC 
CM versus control medium in a 96 well plate format. As shown in Figure 4.7, there appeared to be 
more viable SH-SY5Y cells present after culturing in hMSC CM or cMSC CM for 3 days compared 
with control medium. These cultures were subsequently processed to assess viable cell number using 
the MTT assay, which measures non-specific esterase activity in viable cells (Denizot and Lang, 
1986, Hansen et al., 1989). As shown in Figure 4.8, there was a significantly greater level of 
absorbance, indicative of increased numbers of viable SH-SY5Y cells in hMSC CM (p= 0.0016) and 
cMSC CM (p=0.0060) versus control medium whereas, the absorbances showed no significant 
difference between hMSC CM and cMSC CM (p= 0.3548).  
Therefore, the data suggested that hMSC and cMSC secreted factors appeared to support neuronal 
growth and survival to a similar extent. 
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Figure 4:7 The effects of hMSC CM and cMSC CM on SH-SY5Y neuronal cell proliferation.  
Representative images demonstrate the relative increase in SH-SY5Y cell numbers when cultured 
for 3 days in hMSC CM or cMSC CM versus control medium. Scale bar = 100µm. Original 
magnification X10. These images were collected from hMSC CM and hMSC CM from 3 separate 
donors. 
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Figure 4:8 The MTT assay confirmed that culturing SH-SY5Y neuronal cells in hMSC CM or 
cMSC CM versus control medium significantly increased the number of viable SH-SY5Y cells 
present.  
MTT assays were performed to assess viable cell numbers. The results showed a significant increase 
in the number of viable SH-SY5Y cells in hMSC CM or cMSC CM versus control medium at 3 days. 
Whereas, hMSC CM or cMSC CM had a similar effect. Each bar represents the mean±SEM from 3 
independent experiments, i.e. testing hMSC CM and cMSC CM from 3 separate donors. **indicates 
p≤0.01.  One way- ANOVA with Tukey's multiple comparisons test was used to determine the 
significant differences. 
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4.4 The comparative of effects of hMSC CM and cMSC CM on EA.Hy926 endothelial 
cells. 
4.4.1  Human and canine MSCs CM increased the migration and proliferation of 
EA.hy926 endothelial cells  
The angiogenic effects of human and canine MSC CM on EA.hy926 endothelial cells were examined 
by using scratch assays, and live cell image analysis with the Cell IQ imaging platform (Figure 4.9), 
as described in  Chapter 2 (Section. 2.4.3.1) and Chapter 3. The results showed that both human MSC 
CM (p=0.0001) and canine MSC CM (p= 0.0242) significantly enhanced the rates of scratch wound 
closure compared to control medium. In contrast, there was no significant difference in the rate of 
wound closure between the hMSC CM versus cMSC CM (p= 0.1897) (Figure 4.10). 
 To determine whether MSC CM played a role in stimulating EA.hy926 cell migration versus 
proliferation to induce wound closure, cells from the sides of wound edges were tracked by using the 
Cell IQ analyser software. Each scratch wound assay was performed in triplicate in each of the 3 
independent experiments and a minimum of 3 cells at the edge of the scratch per replicate scratch 
were tracked to plot their movement into the scratch wound area every 15 minutes over a 2 days 
period. This meant a total of 27 cells for each condition (hMSC CM, cMSC CM and control medium) 
were tracked. The total distance each cell had migrated from day 0 to day 2 was measured and 
demonstrated that hMSC CM and cMSC CM significantly enhanced the extent to which cells 
migrated in the wound area compared to control medium (p= 0.0001 in both cases), but that there 
was no significant difference between the human and canine MSC CM (p= 0.3155) (Figure 4.11).
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Figure 4:9 The effects of hMSC CM and cMSC CM on EA.hy926 endothelial cells in scratch 
assays.  
Representative images are shown EA.hy926 endothelial cell scratch assays, which were treated with 
hMSC CM, cMSC CM or serum-free control medium for 2 days after scratching. EA.hy926 cells 
were seeded into multiple wells of 24 well plates and cultured in a standard culture medium until 
confluent and then scratched using a yellow pipette tip. After washing with PBS, the cultures were 
then fed with cMSC CM or serum-free control medium (Control). Scale bars = 200µm. These images 
were collected using hMSC and cMSC CM from 3 separate donors.
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Figure 4:10 Human and canine MSC CM significantly increased the rate of wound closure in 
EA.hy926 endothelial scratch assays. 
 The Cell IQ platform was used for live imaging of wound closure in EA.hy926 endothelial cell 
scratch wound assays in the presence of hMSC CM or cMSC CM versus serum-free control medium. 
Digitised images were generated over 2 days of incubation and Cell IQ imaging software was used 
to measure the extent to which the wound had closed (as a proportion of its original scratch area). 
There was a significant increase in the rate of wound closure in hMSC CM and cMSC CM compared 
to the control medium, whereas no significant difference between hMSC CM and cMSC CM. Each 
bar represents mean±SEM of 3 independent experiments, i.e. using hMSC CM and cMSC CM from 
3 separate donors. *indicates p≤ 0.05, and ****indicates p≤ 0.0001.Blue stars represent hMSC CM 
vs control, and red stars represent cMSC CM vs control. A Two-way ANOVA with Tukey's multiple 
comparisons tests used to determine the significant differences. 
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Figure 4:11 Human and canine MSC CM significantly increased EA.hy926 endothelial cell 
migration.  
Image analysis of the collected digitised images was used to measure the distance that EA.hy926 
endothelial cells migrated from the edge of the scratch towards the centre of the wound over a period 
of 2 days in the presence of hMSC CM or cMSC CM versus serum-free control medium. As shown, 
there was a significant increase in distance travelled in hMSC CM and cMSC CM versus control 
medium during this time. Each bar represents mean±SEM of 3 independent experiments, i.e. using 
hMSC CM and cMSC CM from 3 separate donors. ****indicates p≤ 0.0001. One way ANOVA with 
Tukey's multiple comparisons tests used to determine the significant differences. 
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The numbers of dividing and non-dividing EA.hy926 cells within each of the digitised images 
collected in each of the scratch wound assays were also identified using live cell image analysis. This 
demonstrated that hMSC CM and cMSC CM significantly increased the numbers of dividing and 
non-dividing cells present within the scratch wound assays compared with control medium (p= 
0.0001 for dividing cells in both MSC CM, p= 0.0001 for non-dividing cells in hMSC CM; p= 0.0003 
for non-dividing cells in cMSC CM)  (Figure 4.12). However, there was no significant difference in 
the effects of hMSC CM versus cMSC CM (dividing cells p= 0.1006; non-dividing cells p= 0.9379).  
Moreover, the effects of human and canine MSC CM versus control medium on EA.hy926 cell 
proliferation was further determined by inverted Phase contrast microscopy and by MTT assay to 
determine the number of viable cells present after treatment in 96 well plates. The results showed 
that the hMSC CM (p= 0.0035) and cMSC CM (p= 0.0244) significantly increased the number of 
viable EA.hy926 cells over a 2 day period compared with control medium, but that there was no 
significant difference between the human and canine MSC CM (p= 0.2276) (Figures 4.13 and 4.14).
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Figure 4:12 Human and canine MSC CM increased the numbers of EA.hy926 endothelial cells 
in the scratch wound site.  
The number of dividing versus non-dividing EA.hy926 endothelial cells present in the whole area of 
the digitised images collected of each scratch wound assay was determined over a 2 day period using 
live cell image analysis. As shown, there were marked increases in both dividing and non-dividing 
cells when cultured in the MSC CM versus control medium. Results have been shown as mean±SEM 
from 3 independent experiments, i.e. testing MSC CM harvested from 3 donors versus control 
medium. *** indicates p≤ 0.001 and **** indicates p≤ 0.0001. Blue stars represent hMSC CM vs 
control, and red stars represent cMSC CM vs control. Two-way ANOVA with a Tukey's multiple 
comparisons test used to determine the significant differences. 
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Figure 4:13 Human and canine MSC CM promoted EA.hy926 endothelial cell proliferation.   
Representative images are shown of EA.hy926 cells cultured in 96 well plates in the presence of 
hMSC CM or cMSC CM versus control medium for a 2 day period. As shown, there was an increase 
in the presence of viable EA.hy926 cells with time, which was most marked in cells cultured in MSC 
CM. Scale bars = 100µm. Original magnification X10.This image was collected from hMSC CM 
and cMSC CM from 3 separate donors. 
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Figure 4:14 The MTT assay confirmed that culturing EA.hy926 endothelial cells in cMSC CM 
versus control medium significantly increased the number of viable EA.hy926 cells present. 
 MTT assays were performed to assess viable cell numbers. The results showed a significant increase 
in the number of viable EA.hy926 cells in human and canine MSC CM versus control medium at 2 
days. Whereas, human and canine MSC CM had a similar effect. Each bar represents the mean±SEM 
from 3 independent experiments, i.e. testing hMSC CM and cMSC CM from 3 separate donors. 
*indicates p≤0.05 and **indicate p≤0.01.  One way- ANOVA with Tukey's multiple comparisons 
test used to determine the significant differences.
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4.4.2  Human and canine MSC CM stimulated endothelial tubule formation in 
Matrigel assays 
The angiogenic activity of human and canine MSC CM was further assessed using Matrigel assays 
to examine endothelial tubule formation by EA.hy926 cells, as has been reported in other studies 
testing different angiogenic factors (Ponce, 2001, Ponce, 2009, Khoo et al., 2011).  The extent of 
tubule formation and endothelial tubule branch formation was determined by capturing digitised 
images after EA.hy926 cells had been cultured on Matrigel in hMSC CM, cMSC CM or control 
medium, and using the Cell IQ image analysis software (see Chapter 2, 2.5.4). As shown in Figure 
4.15, human and canine MSC CM induced the formation of tubule-like structures by EA.hy926 
endothelial cells to a markedly greater extent than culturing the cells on Matrigel in control medium. 
Angiogenic activity was quantified by measuring total tubule length and branch point count for each 
of the digitised images captured. The results showed that both the human and the canine MSC CM 
significantly increased these parameters compared to control medium (Figure 4.16). Hence, there 
was a significant increase in total tubule length (hMSC CM versus control, p= 0.0034; cMSC CM 
versus control, p= 0.0080) and the number of branch points (hMSC CM versus control, p= 0.0163; 
cMSC CM versus control, p= 0.0298). In contrast, there was no significant difference between hMSC 
CM versus cMSC CM for either total tubule length or branch point counts (p= 0.6665, p= 0.8611. 
respectively). Taken together, this data demonstrated that human and canine MSC CM had a marked 
and significant stimulatory angiogenic effect on EA.hy926 endothelial cells. 
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Figure 4:15 The effects of human and canine MSC CM on EA.hy926 endothelial cells cultured 
on Matrigel.  
Representative images are shown of EA.hy926 endothelial cells cultured on Matrigel in the presence 
of hMSC CM or cMSC CM versus serum-free control medium. These images were subsequently 
analysed using the Cell IQ imaging software to determine the length (indicated by green lines) and 
the number of branch points (indicated by blue and red dots) seen in endothelial tubule-like 
structures. Scale bars = 200µm. This analysis was performed on hMSC CM and cMSC CM from 3 
separate donors. 
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Figure 4:16 Human and canine MSC CM significantly increased EA.hy926 endothelial tubule 
formation. 
 Image analysis of the collected digitised images (see Figure 4.15) was used to measure both the total 
length of tubules formed (per image) and the number of endothelial tubule branch points (per image). 
As shown, there were significant increases in both of these parameters when EA.hy926 cells were 
cultured on Matrigel for 1 day in hMSC CM and cMSC CM versus control medium. Each bar 
represents the mean±SEM from 3 independent experiments, i.e. testing hMSC CM and cMSC CM 
from 3 separate donors. Top panel: **indicates p≤0.01. Bottom panel: *indicates p≤0.05. One way- 
ANOVA with Tukey's multiple comparisons test used to determine the significant differences.
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4.5 Discussion  
MSCs have been intensively studied for their potential therapeutic activity for a large number of 
conditions, particularly CNS damage such as SCI (Mariani and Facchini, 2012, Oliveri et al., 2014, 
Razeghian Jahromi et al., 2016). Recently it has become more accepted that transplanted MSCs exert 
a therapeutic effect through their paracrine activities on endogenous cells present at the sites of 
injuries (Teixeira et al., 2013, Konala et al., 2016). MSCs have the ability to secrete different kinds 
of reparative proteins including growth factors, cytokines, chemokines as well as extracellular 
vesicles (Kupcova Skalnikova, 2013, Kalinina et al., 2015). However, the translation of research into 
cell-based therapy into the clinic requires a good animal model for SCI, which anatomically, 
physiologically and pathologically resembles human SCI. Dogs, among many other animal models, 
including rodents, are a powerful model for the study of human diseases and pre-clinical and clinical 
research leading therapy (Rowell et al., 2011).  
In the previous Chapter, the results demonstrated that canine MSCs exert paracrine activity by 
stimulating neuronal outgrowth and endothelial growth and migration. To help develop a 
translational pathway from establishing the potential effect of canine MSC transplants in dogs with 
SCI to human MSC transplants in humans with SCI, the aim of this study was to compare the 
paracrine activities of human MSCs with canine MSCs. Having established that the human and 
canine MSCs examined, which were isolated and cultured from adipose tissue, met the minimal 
criteria of the MSC phenotype described by the ISCT (Dominici et al., 2006), the study then 
examined their paracrine activity using MSC CM.  
Results obtained by this study showed that both the human and canine MSC CM similarly promoted 
SH-SY5Y neuronal cell proliferation, cell survival, neurite outgrowth and neuronal differentiation. 
These findings suggest that human and canine MSCs exert neurotrophic effects through their 
secretomes in a similar manner and to a similar extent. 
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Traumatic SCI causes damage and disruption to the blood vessels that supply the spinal cord and the 
early re-establishment of blood vessels can minimise the loss of neuronal tissue after injury (Kundi 
et al., 2013). Therefore, this Chapter, like the studies undertaken in Chapter 3, also compared the 
angiogenic effects of human and canine MSC CM. This demonstrated that both the human and the 
canine MSCs had a significant stimulatory effect on EA.hy926 endothelial cells, indicating an 
angiogenic paracrine activity. Similar to the effects on SH-SY5Y cells, there were no marked or 
significant differences between hMSC CM versus cMSC CM. These findings suggest that human 
and canine MSCs exert angiogenic effects through their secretomes in a similar manner and to a 
similar extent.   
However, a clear caveat to concluding that the human and canine MSCs have similar paracrine 
activity is that the responder cell lines tested, i.e. SH-SY5Y neuronal cells and EA.hy926 endothelial 
cells are of human origin and derived from tumours. This means that the responses of these cells to 
cross-species growth factors may differ from their response to cells of the same species, plus they 
may vary in response from normal primary neurones or endothelial cells. The importance of the 
findings shown in this chapter, including possible areas that require further experimentation and 
validation, will be discussed in more detail in Chapter six.   
In the next Chapter, experiments were performed to examine whether there may be an optimal 
population of human MSCs for CNS repair. This was done again as a part of the translational 
pathway to human clinical trials, e.g. for the treatment of SCI, because of the known heterogeneity 
of MSCs in terms of activity and because of the reported donor-donor variation in the effects of 
MSCs (Sivasubramaniyan et al., 2012, Walter et al., 2015).  The generation of a more 
homogenous MSC population of known paracrine activity would be advantageous as the 
application of these cells goes to the clinic.
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5 Chapter 5: An in vitro examination of the neurotrophic and 
angiogenic paracrine activities of human adipose-derived 
MSC subpopulations 
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5.1 Background and aims  
MSCs are heterogeneous populations of non-haematopoietic multipotent cells. The main sources for 
MSCs are bone marrow or adipose tissue (Hass et al., 2011). The most popular and classical method 
to isolate and generate MSCs from tissues is by plastic adherence. The plastic adherent method is 
used to obtain MSCs after tissue processing, i.e., after using density gradient centrifugation of bone 
marrow to obtain mononucleated cells (Pittenger et al., 1999) or following collagenase digestion to 
obtain the stromal vascular fraction from adipose tissue (Zuk et al., 2002). The isolated cells are then 
put into the culture medium, and those which successfully attach to plastic following isolation are 
then culture expanded (after removal of non-adherent cells) as cell monolayers. These adherent 
monolayer cell populations are recognised as MSCs. However, they are still reported being 
heterogeneous in nature (Ho et al., 2008, Phinney, 2012). 
Cell sorting techniques allow the achievement of more highly purified subpopulations of MSCs 
than their selection based on plastic adherence (Tondreau et al., 2005, Buhring et al., 2007, 
Battula et al., 2009). Furthermore, the identification and purification of MSC subpopulations 
before culturing them may allow for a better understanding of their biological functions (Jones et 
al., 2002, Tormin et al., 2011).  
A popular marker to prospectively isolate MSCs from bone marrow and adipose tissue is CD271. 
The receptor belongs to the tumour necrosis factor superfamily (Quirici et al., 2002, Buhring et al., 
2007). Several studies have revealed that selected CD271+ MSCs have shown high osteogenic and 
chondrogenic differentiation capacities compared with plastic adherent selected cells (Jones et al., 
2010, Cuthbert et al., 2015).  
This suggests that using CD271+ MSCs in orthopaedic cell replacement therapies for damaged bone 
and cartilage may have a more beneficial effect regarding tissue regeneration than plastic adherent 
selected MSCs (Mifune et al., 2013).
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However, there is currently a lack of information regarding the paracrine effects of CD271+ MSCs’ 
on the biological functions of various cell types, including nerves and blood vessels, which may have 
application in other wound repair scenarios, e.g. for CNS damage. Therefore, this study was 
conducted for the first time a comparison investigation to examine the paracrine effects of three 
human adipose-derived MSC subpopulations, including plastic adherent MSCs (i.e., PA MSCs), 
CD271-selected MSCs (i.e., CD271+ MSCs), and those cells which were CD271- , but were selected 
for plastic adherence after the removal of the CD271+ MSCs, i.e. the CD271- MSCs. For further 
purposed of comparison, this investigation of sub-population paracrine activities involved looking 
for the effects of MSC CM on neurogenesis and angiogenesis using the SH-SY5Y and EA.hy926 
cell model systems previously utilised in Chapters 3 and 4. 
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5.2 Characterization of MSC subpopulations  
5.2.1  Morphological appearance and differentiation of PA MSCs, CD271+ MSCs, 
and CD271- MSCs 
As described in Chapter 2 (Section 2.1.3), the human MSC subpopulations were isolated using the 
MACS technique, culture expanded and assessed to see if they matched the ISCT minimal criteria 
for MSC phenotype (Dominici et al., 2006). The PA MSCs, CD271+ MSCs and CD271- MSCs all 
manifested a plastic adherent and fibroblastic appearance during culture expansion (Figure 5.1).  
Furthermore, all three MSC subpopulations differentiated into adipocytes as detected by Oil Red O 
staining (Figure 5.2). Moreover, the amount of Oil Red O accumulation was quantified by releasing 
the dye from lipid droplets using isopropanol 100% (Chapter 2, Section 2.2.3). Results shown in 
Figure 5.3 demonstrate that all three MSC subpopulations significantly increased the amount of lipid 
content in response to adipose-differentiation inductions compared with control cultures, but that 
there were no significant differences in the amount of lipid formation amongst the three MSCs sub-
populations. A Two-way ANOVA with Tukey's multiple comparisons test was used to determine the 
differences amongst these three groups. This data was obtained from three independent experiments, 
i.e. examining each MSC subpopulation from three different MSC donors. 
The three MSCs sub-populations were also assessed for their capacity to differentiate into osteoblasts 
(Chapter 2, Section 2.2.3) by staining and quantifying for ALP activity (Figure 5.4 and Figure 5.5). 
As shown in Figure 5.4, there was a marked increase in the presence of ALP-positive MSCs after 
osteogenic induction compared to control cultures. The results shown in Figure 5.5 demonstrated 
that ALP levels were significantly increased in osteogenic treated PA MSCs and CD271+ MSCs 
versus their respective control cultures.
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There was no significant difference between osteogenic treated PA MSCs and osteogenic treated 
CD271+ MSCs. However, osteogenic treated PA MSCs and CD271+ MSCs had significantly higher 
levels of ALP activity compared with osteogenic treated CD271- MSCs. Furthermore, the osteogenic 
treated CD271- MSCs showed no significant difference when compared with their control cultures. 
A two-way ANOVA with Tukey's multiple comparisons test was used to determine levels of 
differences amongst these three groups. The data was obtained from two independent experiments, 
i.e., examining MSC subpopulations from two different donors with three replicates for each donor 
and each experiment were performed and pooled. 
The three MSCs sub-populations were also assessed for their capacity to differentiate into 
chondrocytes. As described in Chapter 2 (Section 2.2.3), the differentiation capacity was assessed by 
the accumulation of GAGs in the extracellular matrix of pellet cultures which were stained with 
toluidine stain (Figure 5.6). This demonstrated that an apparent increase in metachromatic staining 
within the chondrogenic treated cell pellets versus control cell pellets in all MSC subpopulations. 
The amount of GAGs in digested pellets after 28 days in culture was quantified by using the DMMB 
assay. The resulting data in Figure 5.7 showed that there was an increase in GAG content in the 
chondrogenic treated pellets versus control for all MSC subpopulations, but that there were no 
significant differences amongst the three MSC subpopulations. A Two-way ANOVA with Tukey's 
multiple comparisons test was used to determine the differences amongst these three groups. This 
data was obtained from three independent experiments, i.e., with MSC subpopulations from three 
different donors.
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Figure 5:1 The fibroblastic appearance of MSC subpopulations.  
Representative phase contrast images are shown of PA MSCs, CD271+ MSCs and CD271- MSCs 
growing as plastic adherent cells in culture. Scale bar = 100 µm. Original magnification X10. This 
analysis was performed on MSC subpopulations from three separate donors.
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Figure 5:2 Adipogenic differentiation of MSC subpopulations.  
Representative phase contrast images are shown of PA MSCs, CD271+ MSCs and CD271- 
MSCs. All three MSC subpopulations displayed the ability to differentiate into adipocytes 
after their treatment with adipogenic induction medium. Oil Red O staining was used to 
indicate the accumulation of fat droplets in the cell cytoplasm. Scale bar = 50 µm. Original 
magnification X40. This analysis was performed on MSC subpopulations from three 
separate donors.
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Figure 5:3 The extent of lipid accumulation in MSC subpopulations.  
The amount of lipid accumulated after the differentiation of PA MSCs, CD271+ MSCs and CD271- 
MSCs was quantified by spectrophotometry. Each bar represents the mean±SEM from three 
independent experiments, i.e. testing the MSC subpopulations from three different donors. As shown 
there was an increase in lipid content in MSCs that had been treated with adipogenic induction 
medium versus controls. *indicates p≤0.05. Two way-ANOVA with Tukey's multiple comparisons 
tests were used to determine significant differences. 
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Figure 5:4 Osteogenic differentiation of MSC subpopulations. 
Representative phase contrast images are shown of PA MSCs, CD271+ MSCs and CD271- MSCs 
after differentiating into osteoblasts following treatment with osteogenic induction medium. The 
differentiation capacity was indicated by staining for alkaline phosphatase activity. Scale bar = 100 
µm. Original magnification X10. These images were collected from two independent experiments, 
i.e., examining MSC subpopulations from two different donors. 
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Figure 5:5 Quantification of ALP activity for MSCs sub-populations.  
The amount of ALP activity in PA MSCs, CD271+ MSCs and CD271- MSCs was quantified by 
spectrophotometry. Each bar represents the means±SD from the pooled data of two independent 
experiments, i.e., testing the MSC subpopulations from two different donors where there were three 
replicates per donor for each condition of each experiment. *indicates p≤0.05, ***indicates p≤0.001, 
and ****indicates p≤0.0001. A Two-way ANOVA with Tukey's multiple comparisons test was used 
to determine significant differences. 
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Figure 5:6 Chondrogenic differentiation of MSC subpopulations.  
Representative phase contrast images are shown of PA MSCs, CD271+ MSCs and CD271- MSCs in 
pellet cultures which had been induced to undergo chondrogenesis (treated) versus control and 
stained with toluidine blue stain to identify GAG content. Scale bar = 100 µm. Original magnification 
X10. This analysis was performed on MSC subpopulations from three separate donors. 
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Figure 5:7 Quantification of GAGs in the MSC subpopulations.  
The amount of accumulated GAGs in the extracellular matrix from the differentiated and non-
differentiated pellets of PA MSCs, CD271+ MSCs and CD271- MSCs were measured using the 
DMMB assay. Each bar represents the mean±SEM from three independent experiments, i.e., testing 
the MSC subpopulations from three different donors of three replicates per donor for each 
experiment. ****indicates p≤0.0001. A Two-way ANOVA with Tukey's multiple comparisons test 
was used to determine significant differences.
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5.2.2 Immunophenotypic CD profiling characterization of MSC subpopulations  
The common cell surface markers for MSCs which have been established by ISCT as defining 
markers were quantified for the three MSC subpopulations.  The three MSC subpopulations at 
passage II were processed for flow cytometry analysis. The results showed that all these three MSC 
subpopulations were immunonegative for haematopoietic markers, which were CD34 and CD45 and 
immunopositive for MSC-specific cell-surface antigens which are not expressed by haematopoietic 
cells, these were CD44, CD73, CD90 and CD105 (Figure 5.8). The data gathered by this study 
showed that all three MSC subpopulations were immunonegative for CD34. The percentage of cells 
which were detected as positive for CD34 (mean±SEM) were as the following; PA MSCs 
0.67±0.66%, CD271+ MSCs 3.86±3.84%, and CD271- MSCs 3.45±0.96%. Similarly, the MSC 
subpopulations were showed immunonegative for CD45.  The percentage of cells which were 
detected as positive for CD45 (mean±SEM) were as the following; PA MSCs 0.02±0.02%, CD271+ 
MSCs 1.41±1.38%, and CD271- MSCs 0.10±0.05%. Also, the flow cytometry data showed that the 
three MSCs sub-populations were immunopositive for CD44, CD73, CD90, and CD105. The 
percentage of cells which were detected as positive for CD44 (mean±SEM) were as the following; 
PA MSCs 97.68±0.95%, CD271+ MSCs 97.61± 1.19%, and CD271- MSCs 97.34± 0.42%. The 
percentage of cells which detected as positive for CD73 (mean±SEM) were as the following; PA 
MSCs 95.73±2.50%, CD271+ MSCs 99.48±0.18%, and CD271- MSCs 99.56±0.15%. The 
percentage of cells which detected as positive for CD90 (mean±SEM) were as the following; PA 
MSCs 98.15±1.38%, CD271+ MSCs 99.53±0.12% and CD271- MSCs 99.47±0.23%. The percentage 
of cells which were detected as positive for CD105 (mean±SEM) were as the following; PA MSCs 
92.39±6.38%, CD271+ MSCs 99.19±0.47% and CD271- MSCs 99.13±0.30%. 
Furthermore, the expression of CD271 cell surface marker was examined at the same passage (i.e. 
passage II) for all three MSCs sub-populations PA, CD271+, and CD271-.
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The flow cytometry data showed that although CD271+ selected MSCs were positively selected for 
this marker, they lost the expression of this CD marker at an early passage in expanded tissue culture 
only about 0.06±0.04% were positive for CD271 marker. Additionally, PA MSCs and CD271- MSCs 
were also examined for their capacity to express CD271 cell surface marker. The results showed that 
PA MSCs and CD271- MSCs showed negative immunoreaction for CD271 cell surface marker 
(0.94±0.91% and 0.05±0.02% respectively) (Table 5.4). The data presented mean±SEM was 
obtained from three independent (i.e. three different donors). 
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Figure 5:8 (A) Flow cytometry analysis of CD markers expressed by MSC subpopulations. 
 Representative images are shown of three experiments for CD profiling for MSC subpopulations.   The MSC subpopulations were negative for CD34 and 
CD45, but they were positive for CD44, CD73, CD90 and CD105 (red histograms). IgG1 and IgG2a isotype staining were used as negative controls (blue 
histograms).
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Figure 5:8 (B) Flow cytometry analysis of CD271 marker expressed by the three MSC 
subpopulations. Representative images for CD271 expression of MSC subpopulations are shown 
the expression of CD271 after being culture expanded. The CD271+ MSCs lost the capacity to 
express the CD271 at the early passage of culture expansion. Similarly PA MSCs and CD271- MSCs 
were negative for CD271 (red histogram). IgG1 isotype staining groups were used as negative 
controls (blue histogram; overlap between red and blue appears as magenta). Data were obtained 
from three independent experiments, where the three MSC subpopulations were in passage II. 
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Table 6: Immunoreactivity of the three MSC subpopulations for cell surface markers.   
The table shown is the percentage of cells that are immunoreactive from the three MSC subpopulations for specific CD markers. The cells showed negative 
immunoreaction for CD34 and CD45 and positive immunoreaction for CD44, CD73, CD90 and CD105. Also, the three MSC subpopulations showed negative 
immunoreaction for CD 271. Data shown is mean±SEM of three independent experiments.
  CD34% CD44% CD45% CD73% CD90% CD105% CD271% 
PA MSCs 105 0.01 98.53 0.01 99.78 99.48 99.65 2.76 
PA MSCs 123 1.99 95.78 0.06 91.16 95.4 79.68 0.05 
PA MSCs 126 0.02 98.72 0 96.26 99.57 97.85 0 
mean 
 
0.67 97.68 0.02 95.73 98.15 92.39 0.94 
SEM 
 
0.66 0.95 0.02 2.50 1.38 6.38 0.91          
CD271+ MSCs 105 0.01 99.2 0.06 99.3 99.49 99.88 0.03 
CD271+ MSCs 123 0.02 98.33 0.01 99.31 99.36 98.3 0.15 
CD271+ MSCs 126 11.54 95.29 4.16 99.83 99.76 99.4 0.01 
mean 
 
3.86 97.61 1.41 99.48 99.53 99.19 0.06 
SEM 
 
3.84 1.19 1.38 0.18 0.12 0.47 0.04          
CD271- MSCs 105 1.57 97.88 0.19 99.75 99.1 98.61 0.08 
CD271- MSCs 123 4.67 96.52 0.06 99.26 99.43 99.12 0.04 
CD271- MSCs 126 4.12 97.62 0.04 99.67 99.89 99.65 0.02 
mean 
 
3.45 97.34 0.10 99.56 99.47 99.13 0.05 
SEM 
 
0.96 0.42 0.05 0.15 0.23 0.30 0.02 
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5.3 Neurotrophic effect of MSC subpopulations conditioned medium 
5.3.1 MSC CM from all MSC subpopulations promoted neurite outgrowth and 
neuronal survival of SH-SY5Y cells  
The neurotrophic effects of MSC CM from MSC subpopulations were examined by performing an 
in vitro assay using SH-SY5Y cells. The representative phase contrast images in Figure 5.9 show 
SH-SY5Y that were seeded in 24 well plates as described in  Chapter 2 (Section 2.4.1.1) and treated 
with conditioned medium from either PA MSC CM, CD271+  MSC CM, and CD271- MSC CM or 
serum-free medium as a control. The plates were incubated in the Cell IQ live cell imaging platform 
for three days. At the end of the incubation period, images were analysed by using the Cell IQ 
analyser software. The data obtained showed that the MSC CM from MSC subpopulations has a 
similar neurotrophic effect. The Cell IQ analysis showed that the MSC CM from MSC 
subpopulations significantly increased the neurite outgrowth of SH-SY5Y cells compared with 
control medium (p= 0.0039, p= 0.0006, and p= 0.0014 respectively). However, there was no 
significate differences on promoting neurite outgrowth from SH-SY5Y amongst MSC CM from 
MSC subpopulations (PA MSC CM vs CD271+ MSC CM p= 0.4023, PA MSC CM vs CD271- MSC 
CM p= 0.8096 and CD271+ MSC CM vs CD271- MSC CM p= 0.8673). Also all three MSCs PA, 
CD271+, and CD271- CM significantly increased cell number compared with control medium (p= 
0.0005, p= 0.0008, and p= 0.0016 respectively). There was no significant differences amongst MSC 
CM from MSC subpopulations on increasing the cell number (PA MSC CM vs CD271+ MSC CM 
p= 0.9762, PA MSC CM vs CD271- MSC CM p= 0.7108 and CD271+ MSC CM vs CD271- MSC 
CM p= 0.9037) (Figure 5.10). This data was obtained from three independent experiments, i.e., with 
MSC subpopulations from three different donors.
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Figure 5:9 The effects of the three MSCs sub-populations PA, CD271+, and CD271- CM on SH-
SY5Y cells neurite outgrowth and neuronal cell proliferation.  
Representative images are shown of SH-SY5Y neuronal cells following culture for 3 days in the 
presence of three MSCs sub-populations PA, CD271+, and CD271- CM or in control serum-free 
medium. As shown, there was clear evidence of increased neurite outgrowth (arrows) and cell 
numbers in PA CM, CD271+ CM and CD271- CM compared with control cultures. Scale bar = 
200µm.
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Figure 5:10 Quantitative analysis showing the effect of MSC CM of three MSC subpopulations 
on cell proliferation and neurite outgrowth from SH-SY5Y cells. 
  SH-SY5Y cells were treated with MSC CM of MSC subpopulations or serum-free medium as 
control when digitised phase contrast images were captured and analysed using the Cell IQ imaging 
platform and software. There was a significant increase in both neurite outgrowth and cell numbers 
from SH-SY5Y cells compared with the control medium. However, there was no significant 
difference amongst the three groups. Each bar represents the mean±SEM of three independent 
experiments, i.e., testing the MSC subpopulations from three different donors of three replicates per 
each experiment. **indicate p≤0.01 and ***indicate p≤0.001. One way- ANOVA with Tukey's 
multiple comparisons test used to determine the significant differences.
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5.3.2 Assessment of SH-SY5Y viable cell numbers using the MTT assay 
Cell growth and cell viability rate were determined by the using the colourimetric MTT assay. As 
described in Chapter 2 (Section 2.4.3.) and as the representative images shown in Figure 5.11, the 
SH-SY5Y cells were seeded in 96 well plates and treated with either PA MSC CM, CD271+ MSC 
CM, CD271- MSC CM or serum-free medium as a control for 3 days. The data showed that all three 
MSC CM of MSC subpopulations had a similar effect on SH-SY5Y cell growth and cell viability. 
There was no significant differences in their effect to promote cell growth and to increase the cell 
viability rate of SH-SY5Y cells during the period of incubation (PA MSC CM vs CD271+ MSC CM 
p= 0.6755, PA MSC CM vs CD271- MSC CM p= 0.2030, and CD271+ MSC CM vs CD271- MSC 
CM p= 0.2633). On the other hand, the data showed that the MSC CM of MSC subpopulations effect 
was significantly different when compared with control medium (p= 0.0007, p= 0.0009 and p= 
0.0049 respectively) (Figure 5.12). The data obtained from three independent experiments, i.e., 
testing the MSC CM of subpopulations from three different donors of five replicates per each 
experiment. 
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Figure 5:11 Cell growth and cell viability of SH-SY5Y cells.  
Representative images are shown of the relative increase in SH-SY5Y cell numbers when cultured 
for three days after their treatment with conditioned medium from the three MSC subpopulations 
versus control medium. Cell growth and cell viability were assessed by MTT assay. Scale bar = 
100µm. Original magnification X10. The images were collected from three independent experiments 
(i.e. three different donors).
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Figure 5:12 The MTT assay confirmed that culturing SH-SY5Y neuronal cells in MSC CM of 
MSC subpopulations versus control medium significantly increased the number of viable SH-
SY5Y cells present.  
MTT assays were performed to assess viable cell numbers of SH-SY5Y cells after treating with PA 
MSC CM, CD271+ MSC CM, and CD271- MSC CM versus serum-free medium as a control for three 
days. The conditioned medium from the three MSC subpopulations had the similar influence, and 
they were significantly stronger in promoting cell viability rate as compared with control medium. 
Each bar represents the mean±SEM from three independent experiments, i.e., testing the MSC CM 
of subpopulations from three different donors of five replicates per each experiment. **indicates 
p≤0.01 and ***indicate p≤0.001. A One-way- ANOVA with Tukey's multiple comparisons tests 
used to determine the significant differences. 
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5.4 The effects of MSC CM of MSC subpopulations on EA.hy926 endothelial cells 
5.4.1 MSC subpopulations promoted EA.hy926 endothelial cell migration and 
proliferation to different extents 
The angiogenic effects of the MSC CM of MSC subpopulations on EA.hy926 cells were examined 
by using a scratch assay. The representative images in Figure 5.13 show the confluent layers of 
EA.hy926 cells that were scratched using a yellow pipette tip, and after three repetitive washing steps 
with PBS, the medium was replaced with either PA MSC CM, CD271+ MSC CM, CD271- MSC CM 
or serum-free medium as a control. Then, the migration/ movement and proliferation of the EA.hy926 
cells to close the scratch wound were monitored and quantified using the Cell IQ Imaging Platform. 
The result showed both PA MSC CM and CD271- MSC CM had the same effect of promoting wound 
closure compared with CD271+ MSC CM which showed less effect in promoting wound closure. 
The results showed there was no significant difference between PA MSC CM and CD271- MSC CM 
(p= 0.9991). Whereas, both PA MSC CM and CD271- MSC CM showed significant differences 
when compared with CD271+ MSC CM (p= 0.0204, p= 0.0304 respectively). The PA MSC CM and 
CD271- MSC CM also showed significant differences in increasing wound closure rate when 
compared with control (p= 0.0001 and  p= 0.0001 respectively) while, CD271+ MSC CM showed no 
significant difference when compared with control ( p= 0.1221) (Figure 5.14). To determine whether 
the MSC CM of MSC subpopulations played a role in cell movement and migration to improve 
wound closure, cells from both sides of wound edges were tracked by using the Cell IQ analyser 
software. Three cells per each scratch wound from three replicate per each of three independent 
experiments were randomly selected. This meant a total of 27 cells for each condition (PA MSC CM, 
CD271+ MSC CM, CD271- MSC CM, and control medium) were tracked. Cells were tracked for 
their movement every 15 minutes and over two days, total distance starting from the day 0 to day 2 
was measured. The results showed both PA MSC CM and CD271- MSC CM similarly enhanced 
cells migration in wound area and there was no significant difference in their effect (p= 0.9991). 
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Whereas, both PA MSC CM and CD271- MSC CM showed significant differences in their effect 
when compared with CD271+ MSC CM (p= 0.0367, p= 0.0306 respectively).   
The data obtained in this study also showed that both PA MSC CM and CD271- MSC CM 
significantly increased the cell movements when compared with control (p= 0.0089, p= 0.0075 
respectively) while CD271+ MSC CM showed no significant difference when compared with control 
medium (p= 0.7231) (Figure 5.15). Further analysis has been done using Cell IQ analyser software 
to examine the rate of proliferation of EA.hy926 cells. For the purpose of quantification, cells were 
classified and quantified as dividing and non-dividing. Cells were counted every 15 minutes over 
two days. The results showed all MSC CM of MSC subpopulations similarly promoted cell 
proliferation. The results showed that there was no significant differences in their effect on the rate 
of dividing cells (PA MSC CM vs CD271+ MSC CM p= 0.4809, PA MSC CM vs CD271- MSC CM 
p= 0.4809 and CD271+ MSC CM vs CD271- MSC CM p= 0.9999). But, all MSC CM of MSC 
subpopulations showed significant differences when compared with control medium (p= 0.0001, p= 
0.0094, and p= 0.0094 respectively). However, for non-dividing cells, the results showed there was 
no significant differences between PA MSC CM and CD271- MSC CM (p= 0.9996) but, both PA 
MSC CM and CD271- MSC CM showed significant differences when compared with CD271+ MSC 
CM (p= 0.0228, p= 0.0304 respectively). Moreover, all MSC CM of the three MSC subpopulations 
were significantly higher when compared with control medium (all p= 0.0001) (Figure 5.16). The 
data was obtained from three independent experiments (i.e. three different donors) of three replicates 
per each experiment. The cell viability activities were further determined by using the MTT assay. 
The representative images are shown in Figure 5.17, displaying the EA.hy926 cells which were 
seeded in 96 well plates and treated with either PA MSC CM, CD271+ MSC CM, CD271- MSC CM 
or serum-free medium as a control for two days. The data showed that MSC CM of the three MSC 
subpopulations had the same effect on EA.hy926 cell growth and cell viability and there was no 
significant differences in their effect on promoting cell growth and to increase the cell viability rate 
of EA.hy926 cells during the period of incubation (PA MSC CM vs CD271+ MSC CM p= 0.9717, 
PA MSC CM vs CD271- MSC CM p= 0.9719 and CD271+ MSC CM vs CD271- MSC CM p= 
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0.9999). On the other hand, the data showed that the effect of MSC CM of the three MSC 
subpopulations was significantly different when compared with control medium (p= 0.0382, p= 
0.0211, and p= 0.0212 respectively) (Figure 5.12). The data obtained from three independent 
experiments (i.e. three different donors) of five replicates per each experiment.    
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Figure 5:13 The effect of the three MSCs sub-populations PA, CD271+, and CD271- CM on 
wound closure.  
Representative images of monolayer EA.hy926 cells in scratch assays which were treated with the 
three MSCs sub-populations PA, CD271+, and CD271- CM or control medium for two days. Scale 
bar =200µm. The images were collected from three independent experiments (i.e. three different 
donors).
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Figure 5:14 Effect of MSC CM of the three MSC subpopulations on EA.hy926 cells migration 
and proliferation in closing the scratch.  
The Cell IQ platform was used for live imaging. Images were generated over two days of incubation. 
PA MSC CM and CD271- MSC CM similarly increased wound closure percentage and that was 
significant when they compared with CD271+ MSC CM (blue star and yellow star *indicates p≤ 
0.05). The PA MSC CM and CD271- MSC CM showed significant differences when compared with 
control medium (blue stars and yellow stars ****indicates p≤ 0.0001). Whereas, CD271+ MSC CM 
showed no significant difference compared with control medium. Each bar represents the 
mean±SEM of three independent experiments, i.e., testing the MSC CM of subpopulations from three 
different donors of three replicates per each experiment. A Two-way- ANOVA with Tukey's multiple 
comparisons tests used to indicate the significant differences. 
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Figure 5:15 The MSC CM of the three MSC subpopulations significantly increased EA.hy926 
endothelial cell migration.  
Image analysis of the collected digitised images was used to measure the distance that EA.hy926 
endothelial cells migrated from the edge of the scratch towards the centre of the wound over a period 
of two days in the presence of PA MSC CM, CD271+MSC CM, CD271- MSC CM or serum-free 
control medium. As shown, there was a significant increase in distance travelled in PA MSC CM 
and CD271- MSC CM versus CD271+ MSC CM and control medium during this time. Each bar 
represents the mean±SEM of three independent experiments of three randomly selected cells of each 
three replicates per of each experiment. *indicates p≤0.05 and **indicate p≤0.01. A One-way- 
ANOVA with Tukey's multiple comparisons test used to indicate the significant differences. 
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Figure 5:16 The effect of the three MSCs sub-populations PA, CD271+, and CD271- CM on 
EA.hy926 cells proliferation. 
 This analysis was performed to track the number of dividing and non-dividing cells present in the 
wound area. The data on number of dividing cells showed no significant difference amongst the three 
MSCs populations whereas there was a significant difference when compared with control medium 
( top panel: blue stars ****indicates p≤ 0.0001, red stars and yellow stars** p≤  0.01). The data on 
non-dividing cells showed that PA CM and CD271- CM were significantly higher compared with 
CD271+ CM (bottom panel: blue and yellow star *indicates p≤ 0.05).However, the 3 MSCs 
populations were significantly higher compared with control medium (bottom panel: blue, red, and 
yellow stars ****indicates p≤ 0.0001). Each bar represents the mean±SEM from three independent 
experiments, i.e., testing the MSC CM of subpopulations from three different donors of three 
replicates per each experiment. Two-way- ANOVA with Tukey's multiple comparisons test used to 
indicate the significant differences.
  
180 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:17 The MSC CM of the three MSC subpopulations promoted EA.hy926 endothelial 
cell proliferation in 96 well plates. 
  Representative images are shown of EA.hy926 cells cultured in PA MSC CM, CD271+ MSC CM, 
and CD271- MSC CM or serum-free control medium. As shown, there was an apparent increase in 
the number of EA.hy926 cells present in PA, CD271+, and CD271- CM versus control medium at 2 
days of culture. Scale bars = 100µm. Original magnification X10. The images were collected from 
three independent experiments (i.e. three different donors).
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Figure 5:18 The MTT assay confirmed that culturing EA.hy926 endothelial cells in PA MSC 
CM, CD271+ MSC CM, and CD271- MSC CM versus control medium significantly increased 
the number of viable EA.hy926 cells present.  
MTT assays were performed to assess viable cell numbers. The results showed a significant increase 
in the number of viable EA.hy926 cells in PA MSC CM, CD271+ MSC CM, and CD271- MSC CM 
versus control medium at two days. Each bar represents the mean±SEM of three independent 
experiments, i.e., testing the MSC CM of subpopulations from three different donors of five 
replicates per each experiment. *indicates p≤0.05. A One-way- ANOVA with Tukey's multiple 
comparisons test used to indicate the significant differences. 
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5.4.2 The effect of MSC CM of the three MSC subpopulations to induced 
morphogenesis of EA.hy926 cells in vitro 
The paracrine activity of the three MSC subpopulations to induce tube formation from EA.hy926 
cells was examined. The assessment of the regenerative capacity of the MSC CM of MSC 
subpopulations was performed by establishing an in vitro assay for tube formation using reduced 
growth factors Matrigel. The representative images in Figure 5.19 show the EA.hy926 cells cultured 
on three-dimensional Matrigel and treated with either PA MSC CM, CD271+ MSC CM, CD271- 
MSC CM or serum-free medium as a control for one day. Plates were set in the Cell IQ live imaging 
platform to generate images for the purpose of measurements. The PA MSC CM showed a higher 
ability to induce the formation of tube-like capillaries from EA.hy926 cells as compared with CD271+ 
MSC CM and CD271- MSC CM. The CD271- MSC CM showed stronger ability to induce the 
formation of tubule-like capillaries from EA.hy926 cells when compared with CD271+ MSC CM. 
The results showed that CD271+ MSC CM had the poor effect of inducing the formation of tube-like 
capillaries from EA.hy926 cells. The data was generated by measuring total tubule length and branch 
point count using Cell IQ analyser software as described previously in Chapter 2 (Section 2.5.4). The 
data showed there were significant differences in PA MSC CM effect compared with CD271+ MSC 
CM (for total tube length p= 0.0001, for total branch point count p= 0.0001). Also, the data showed 
significant differences between PA MSC CM and CD271- MSC CM in total tubule length (p= 
0.03209) and in total branch count (p= 0.0001). In addition CD271- MSC CM promoted the tube 
formation as compared to CD271+ MSC CM significantly (for total tube length p= 0.0032, and for 
total branch point count p= 0.0.0365). Moreover, both PA MSC CM and CD271- MSC CM showed 
significant differences when compared with control medium for total tube length (p= 0.0001, p= 
0.0016 respectively) and for branch point count (p= 0.0001, p= 0.0275 respectively). 
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While, CD271+ MSC CM showed no significant difference when compared with control medium for 
both total tube length and branch point count (p= 0.9355, p= 0.9795 respectively) (Figure 5.20). The 
data was obtained from three independent experiments (i.e. three different donors) of five replicates 
per each experiment.  
The amount of VEGF in the MSC CM of the MSC subpopulations was detected by using ELISA. 
The results showed that there were no significant differences amongst the three MSC CM of MSC 
subpopulations regarding containing VEGF in their conditioned medium. The amount of VEGF was 
estimated at a concentration of 307.935 pg/ml for PA MSC CM, 381.018 pg/ml for CD271+ MSC 
CM, and 362.737 pg/ml for CD271- MSC CM (Figure 5.21). This data was obtained from two 
independent experiments (i.e. two different MSC donors). 
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Figure 5:19 The effects of the MSC CM of MSC subpopulations on EA.hy926 endothelial cells 
cultured on Matrigel. 
 Representative images are shown of EA.hy926 endothelial cells cultured on Matrigel in the presence 
of MSC CM of MSC subpopulations or serum-free control medium. These images were subsequently 
analysed using the Cell IQ imaging software to determine the length (indicated by green lines) and 
the number of branch points (indicated by blue and red dots) seen in endothelial tubule-like 
structures. Scale bars = 200µm. The images were collected from three independent experiments (i.e. 
three different MSC donors). 
PA MSC CM CD271+ MSC CM 
CD271- MSC CM Control 
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Figure 5:20 The MSC CM of the three MSC subpopulations significantly increased EA.hy926 
endothelial tubule formation.  
Image analysis of the collected digitised images (see Figure 5.19) was used to measure both the total 
length of tubules formed (per image) and the number of endothelial tubule branch points (per image). 
As shown, PA MSC CM significantly improved the total tubule length and total branch point 
compared with CD271+ MSC CM and CD271- MSC CM. Also, CD271- MSC CM had a significant 
effect compared with CD271+ MSC CM. Each bar represents the mean±SEM of three independent 
experiments, i.e., testing the MSC CM of subpopulations from three different donors of five 
replicates per each experiment. *indicates p≤ 0.05, ** indicates p≤ 0.01, ***indicates p≤ 0.001, and 
****indicates p≤ 0.0001. A One-way- ANOVA with Tukey's multiple comparisons test used to 
determine the significant differences. 
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Figure 5:21 The detection of VEGF in the three MSC subpopulations conditioned medium 
using quantitative ELISA.  
The detection of VEGF in the two donors of MSC subpopulations conditioned medium was 
determined using a quantitative ELISA kit. Using the equation (R2 = 0.9991 as calculated by Excel)  
approximately (means±SD) 306±53 pg/ml of VEGF in PA MSC CM, 380±78 pg/ml of VEGF in 
CD271+ MSC CM and 359±33 pg/ml VEGF in CD271- MSC CM were detected. Each bar represents 
the means±SD of two independent experiments, i.e., testing the MSC CM of subpopulations from 
two different donors of two replicates per each experiment. ****indicates p≤ 0.0001. A One-way- 
ANOVA with Tukey's multiple comparisons test used to indicate the significant differences. 
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5.5 Discussion  
MSCs are a heterogeneous population with regenerative therapeutic activities, which have been 
ascribed to their secretion of paracrine factors (Jayaraman et al., 2013). However, different studies 
have stated that MSCs exhibited donor-donor and intra-population heterogeneity (Méndez-Ferrer et 
al., 2010, Morando et al., 2012). Some studies showed that a CD271 positive purified population of 
MSCs could exert different differentiation potentials related to bone and cartilage repair (Jones et al., 
2010, Cuthbert et al., 2015). Unfortunately, there is a lack of information on understanding the 
functional activities of MSCs at subpopulation levels for their paracrine activities in stimulating 
nerve growth and angiogenesis. 
Therefore, this comparative study was performed to examine the biological differences, if any, in the 
regenerative paracrine activities of PA, CD271+ and CD271- human adipose-derived MSC 
subpopulations on SH-SY5Y neuronal and EA.hy926 endothelial cell model systems.   
The three MSC subpopulations were first examined for their capacity to exert an MSC phenotype 
according to the ISCT criteria (Dominici et al., 2006).  The results showed that all three MSC 
subpopulations were plastic adherent when expanded with a stromal appearance. Furthermore, all 
three MSC subpopulations differentiated into adipocytes, osteoblasts and chondrocytes. There were 
no significant differences in their capacity to differentiate into adipocytes.  However, PA MSCs and 
CD271+ MSCs had a significantly greater level of ALP activity after osteogenic treatment than 
CD271- MSCs. The increased osteogenic capacity of CD271+ BM MSCs has previously been 
reported (Cuthbert et al., 2015), which supports the current observation of adipose-derived CD271+ 
MSCs, although it should be noted that in this previous study the CD271+ MSCs differentiated to 
form osteoblasts to a significantly greater extent even than PA BM MSCs.
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Furthermore, the three MSC subpopulations differentiated to a similar extent, as measured by GAG 
content, into chondrocytes after inducing the culture pellets with induction medium. Some studies 
suggested that CD271+ MSCs have more chondrogenic differentiation capacity compared with PA 
MSCs (Mifune et al., 2013). However, the tissue of origin might be the reason for such differences 
in chondrogenic potentiality as Mifune et al., 2013 used BM MSCs.  
Moreover, the three MSC subpopulations were examined for their ability to express specific cell 
surface markers. The flow cytometry results showed that the three MSC subpopulations shared very 
similar expression levels of standard MSCs markers such as CD44, CD73, CD90, and CD105, but 
lacked expression to haematopoietic cell surface markers such as CD34 and CD45 (Table 5.4). 
Hence, it can be concluded that all three subpopulations of MSCs met the ISCT criteria and can 
justifiably be termed MSCs. Although MSCs from different tissue sources share similar 
morphological appearance and differentiation capacities, their immunophenotype may show 
differences in their expression of CD markers. For example, several studies have suggested that AT 
MSCs have the ability to express CD34 when tissue culture expanded at early passages (Strioga et 
al., 2012, Ammar et al., 2015).This may explain the results of CD profiling for AT MSCs 126 donor 
used in this study as they showed some positivity for CD34.  
This study also examined the expression of CD271 by CD271+ positively selected cells as well as 
the PA MSCs and CD271- cells after cultivation. The flow cytometry data obtained by this study 
showed that all MSC subpopulations were immunonegative for CD271 at passage II. Hence it can 
be concluded that the CD271+ MSCs lost CD271 at early stages of culture expansion. Similarly, 
Churchman et al., 2012 showed that CD271+ BM MSCS also lost the expression of CD271 as they 
were culture expanded (Churchman et al., 2012). Thus, it seems that CD271 is lost from adipose 
MSCs as well as BM MSCs during cell culture expansion. The reasons for the loss of CD271 
expression are currently unknown, although other researchers have suggested that the prevalence of 
CD271+ MSCs in vivo may relate to microenvironmental and physiological factors (Cattoretti et al., 
1993, Churchman et al., 2012). Whilst it would have been advantageous to confirm that the MACS 
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technique has successfully isolated CD271+ cells, it was not possible to test CD271 positivity in the 
freshly isolated cell population due to limitations in cell numbers available after purification. 
However, other studies have demonstrated that the proportion of CD271+ cells yielded after 
purification from BM or adipose tissue was ~ 0.5% of all mononucleated cells present (Jones et al., 
2006, Alvarez-Viejo et al., 2013). 
Various studies have reported that the secretomes of MSCs exert a beneficial impact on damaged 
tissue and have ascribed this effect to a wide range of different bioactive secreted molecules including 
growth factors, cytokines, chemokines and EVs (Lee et al., 2014, Lopatina et al., 2014, Wright et al., 
2014, Kalinina et al., 2015). However, these previous studies have examined the secretomes from 
heterogeneous MSC populations. As alluded to earlier, this study has examined for the first time the 
neurotrophic and angiogenic activities of MSC subpopulations according to their isolation, which 
was based on PA and CD271 immunopositivity. By using in vitro assays with SH-SY5Y cells, it has 
been shown that the MSC CM of all MSC subpopulations significantly stimulated SH-SY5Y neurite 
outgrowth and neuronal cell survival and proliferation.   There were no significant differences 
amongst the three MSC subpopulations in this neurotrophic effect. This finding of enhanced SH-
SY5Y neurite outgrowth was based on the morphological appearance of the cells, and a further 
experimental confirmation to validate the effects of MSC CM in promoting neuronal differentiation, 
e.g., through increased Beta-III tubulin immunopositivity would be beneficial. Nonetheless, the data 
shown in this chapter further supports the hypothesis that MSCs are neurotrophic through their 
secretion of neurotrophic factors and suggests that MSC subpopulations have a similar capacity in 
this regard. Further studies to identify the presence and levels of different known neurotrophic factors 
in the MSC CM, and confirmation of their activity, e.g. through the use of blocking antibodies or 
through gene knockdown strategies, in promoting SH-SY5Y neuronal differentiation and growth are 
also warranted and would help explain potential mechanisms of action. 
Interestingly, the investigations of angiogenic activity amongst these three MSC subpopulations 
conditioned medium have shown very clear variances in their biological effect on endothelial cells. 
  
190 
 
In EA.hy926 endothelial cell scratch wound assays, the results showed that both the PA MSC CM 
and the CD271- MSC CM significantly increasing scratch wound closure rates compared with the 
CD271+ MSC CM and control medium. 
This variance in effects amongst the MSC CM of the MSC subpopulations was examined further by 
tracking cell movements and counting dividing and non-dividing cells in the scratch wound area. The 
conditioned medium from CD271+ MSCs showed a lower biological effect on increasing cell 
movement towards the centre of the scratch wound area compared with PA MSC CM and CD271- 
MSC CM.   This finding may further interpret through the findings of dividing and non-dividing 
cells. Whereas the CD271+ MSC CM had a similar effect on the number of dividing cells, but their 
effect on non-dividing cells was less when compared with the effects of PA MSC CM and CD271+ 
MSC CM. The explanation for such difference could attributed to the fact that the cells might be 
under the influence of other factors that might restrict or inhibited their movement or directed them 
into random directions rather than towards the other side of scratch (i.e. the centre of scratch wound 
area) or could be as a result of the lack of other factors affecting cell movement. Therefore, further 
studies to identify the presence and levels of different known cytokines and growth factors that play 
a role in the mediation of cell migration is required (Chen et al., 2008).   
Furthermore, the results of the tube formation assay using Matrigel reduced growth factors confirmed 
the angiogenic effect of the MSC subpopulation conditioned medium. Whereas the CD271+ MSC 
CM again showed poor enhancement on the formation of tube-like capillaries from EA.hy926 cells, 
meanwhile, PA MSC CM and CD271- MSC CM revealed a stronger effect. In this assay, it is obvious 
that PA MSC CM and CD271- MSC CM showed a different biological effect when compared with 
their effect in the scratch wound assay. Herein the PA MSC CM significantly promoted the tube 
formation compared with CD271- MSC CM, whereas in the scratch wound assay there were no 
significant differences in their effect on EA.hy926 cell proliferation and migration and wound closure 
rate. The explanation of such differences in the biological activities might be related to the fact that 
although the CD271+ population has a poor angiogenic effect but, their presence in the heterogeneous 
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population has a role to direct or regulate the other population to exert their biological effect.  Hence 
these findings support the hypothesis raised in this study where the isolation of a more homogenous 
population could exert differences in their biological effects. Such findings highlight the benefit of 
isolating certain MSCs subsets to treat an injury where specific biological activity is required. This 
finding also further support the findings of  Mifune et al., 2013 findings as they suggested that 
CD271+ MSCs showed better hyaline cartilage repair in vivo, where the lack of neovascularization 
promotion is required. 
Nonetheless, the detection of VEGF in the conditioned medium of the three MSC subpopulations 
using an enzyme-linked immunosorbent assay showed the three MSC subpopulations secreted VEGF 
to a similar extent. This finding may suggest that although VEGF plays the main role in the 
neovascularization process, other factors are required to achieve a fully functional vascularization 
(or lack of inhibitors).  
In conclusion, this study has demonstrated for the first time that the purified MSCs derived from 
adipose tissue culture could exert a different biological effect. The MSCs subpopulations showed 
MSC phenotypes which have been established by the ISCT. The MSC CM of the three MSC 
subpopulations exerted a neurogenic effect to a similar extent, whereas, their angiogenic paracrine 
effect has shown remarkable differences among the three subpopulations. The CD271+ MSC CM had 
a poor effect on enhancing neovascularization by the EA.hy926 cells. The demonstration of poor 
neovascularisation enhancement by CD271+ MSC CM might explain their suitability to repair 
cartilage as the hyaline cartilage is an avascular tissue (Mifune et al., 2013). Finally, the data obtained 
by this study may suggest that the isolation and purification of a certain subpopulation of MSCs 
previously identified in vivo could result in isolation of a subpopulation that has the capacity of 
exerting more tailored biological activities. Also, the consequence of such purification will allow an 
increase in the efficiency of clinical applications of MSCs to treat and repair specific kind of injured 
tissues. 
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6 Chapter 6: Discussion 
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Since the emergence of MSCs in the field of regenerative medicine as a cell-based treatment, 
numerous investigations have been done on their therapeutic capacity to treat a broad range of 
diseases. Such interest can be attributed to their characteristic features including; fewer ethical issues 
than those surrounding ESCs as their extraction does not require destruction of an embryo, relative 
ease of access from patient sources, lack of immune rejection if applied autologously, and lack risk 
of tumour formation (Bongso and Richards, 2004, Larijani et al., 2012). In recent years, MSCs 
derived from adipose tissue have received more attention than those derived from bone marrow in 
terms of regenerative applications for repairing injured and damaged tissues. Such attention can be 
ascribed to the fact that adipose tissue is a more abundant tissue, again ease of access, and the 
harvesting of adipose tissue has a low morbidity rate when compared with the harvesting of bone 
marrow. Also, the number of the cells released from adipose tissue is higher compared to bone 
marrow (Padoin et al., 2008). It also has recently become more accepted that the MSCs exert their 
potential therapeutic activities through their secretomes (Teixeira et al., 2013). The trophic activities 
of secretomes of MSCs have been addressed in different aspects of regenerative medicine including 
SCI. It is well known that the recovery after SCI is elusive. Many experimental studies in animals 
showed encouraging results of recovery and regaining some functions after transplantation of MSCs 
in the injured spinal cord (Lim et al., 2007, Park et al., 2012b, Li and Lepski, 2013, Dasari et al., 
2014). It is worth mentioning that in the absence of an animal model fully reflecting the SCI in 
human, it can be a challenging step to bridge the gap between experimental studies evaluating the 
effects of MSCs in rodent models through the translation research that leads clinical trials in human. 
Therefore, the research described in this study was aimed to evaluate and improve several strategies 
for application of secretomes of MSCs as a treatment for SCI. These strategies were:       
 Examining the secretomesʼ activities of MSCs derived from canine adipose tissue using 
established assays for neurotrophic and angiogenic.  
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 Comparing the neurotrophic and angiogenic activity of canine and human MSCs in a step-
by-step approach to help validate dogs as a clinically relevant large animal model for SCI 
treatments. 
 Examining the regenerative paracrine activities of subset populations of human MSCs to 
increase the likelihood and efficiency of MSC-based clinical applications to treat and repair 
SCI, where avoiding cell heterogeneity is potentially advantageous. 
The MSCs used in this study were derived from canine and human adipose tissue. The investigation 
of canine MSCs in this study was for the following reasons. First, such investigation can bring benefit 
to both human and veterinary regenerative medicine as a means of treating dogs with SCI. This in 
itself is a potential clinical application. Second, dogs represent a better large animal model for human 
treatment than rodents as dogs share some similarities with humans in terms of wound causation, 
pathophysiology and disease presentation and scale (Starkey et al., 2005, Khanna et al., 2006, 
McMahill et al., 2015). Third, if canine MSCs are shown to have a therapeutic effect in dogs with 
SCI, then understanding and comparing their activity with human MSCs may help inform how best 
to apply the human MSCs in the clinical setting. 
The therapeutic potential of MSCs has been widely investigated for various diseases including 
mainly tissue injury and immune disorders (Patel et al., 2013).  Dogs are valuable animal models 
since most of the disease is naturally occurring similar to humans. The transplantation and 
regenerative activities of canine MSCs have been studied in many clinical trials for a naturally 
occurring disease like keratoconjunctivitis Sicca (Villatoro et al., 2015), and SCI (Penha et al., 
2014). Interestingly the research on cMSCs is based on investigations of the potential therapeutic 
effect of the cells only; there is a lack of information about the secretomes’ action of canine 
MSCs. Thus, the study data presented in chapter 3 of results has described for the first time the 
potential therapeutic activities of canine MSCs secretomes for in stimulating neurogenesis and 
angiogenesis, which supports their application as a treatment for SCI in the dog.  
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The canine MSCs were initially examined for their capacity to display MSCs phenotype, according 
to the minimal criteria proposed by the ISCT to define MSCs. These criteria are: i) adherence to 
plastic, ii) specific cell surface antigen expression, for example immunopositivity for CD73, CD90 
and CD105, immunonegativity for CD34, CD45, CD11b, CD14, CD19, CD79a and HLA-DR., iii) 
multipotent differentiation potential into the three mesenchymal lineage cell types of adipocytes, 
osteoblasts and chondrocytes, at least in vitro (Dominici et al., 2006), where the cMSCs have 
matched these criteria. Largely, the canine MSCs have matched these criteria, although there was 
some difference from human MSC phenotypes in that a proportion of canine MSCs were CD34 
immunopositive. This demonstrated that the cells that were isolated and culture expanded from the 
inguinal fat pads of a number of dogs could be classified as MSCs. 
 Recent studies suggested that the mechanism of MSCs therapeutic effects might not work through 
differentiation of transplanted MSCs at the site of injury. In fact, MSCs exert their therapeutic effect 
through their secretomes that have a varied array of proteins including growth factors, cytokines, 
chemokines, metabolites and bioactive lipids (Kupcova Skalnikova, 2013). These secretory 
molecules have a role in tissue repair and regeneration after injury (Pluchino and Cossetti, 2013). In 
experimental studies, MSC CM have demonstrated the activities that required for tissue repair 
(Walter et al., 2010, Isakson et al., 2015). Therefore, MSCs represent one of the most promising cells 
for cell-based therapy application in human and veterinary regenerative medicine (DiMarino et al., 
2013).  
The rational basis of the study presented in Chapter 3 was first to characterise the MSC phenotype, 
as discussed, then to determine the effects of cMSC CM on neurite outgrowth and neuronal cell 
growth and survival, using the SH-SY5Y neuroblastoma cell line, and, on endothelial cell migration, 
proliferation and tubule formation using the EA.hy926 endothelial cell line.  The findings suggested 
that cMSC CM exerted neurogenic and angiogenic effects.   
These findings support the hypothesis raised by this study of considering the trophic activity of cMSC 
CM as potential therapies for SCI. The findings could shed light on the benefits of secretomes of 
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cultured cMSCs as an alternative for cell therapy with a view toward a trial in SCI repair in veterinary 
regenerative medicine since the regain of neuronal survival, axonal growth and revascularisation play 
the main role in repair processes for the injured spinal cord (Quertainmont et al., 2012). However, 
mechanisms of action of cMSCs are still poorly identified and have not been fully addressed in this 
study. Therefore, further investigation is required on the identification of the conditioned medium 
composition. 
The preliminary data (in Appendix Figure 7.1) showed for the first time the isolation of exosomes 
from cMSC CM. Both concentration and diameter of these exosomes were measured using the qNano 
machine.  This preliminary data suggested the requirement for future work including the examining 
of the functionality of these isolated exosomes, as human exosomes have shown a potential effect on 
angiogenesis and neurogenesis (Zhang et al., 2015, Kim et al., 2016). 
In human regenerative medicine, there is an urgent need for a large animal model mirroring the 
phenotype of the target disease and bridging the gap between translation research and human clinical 
trials (Harding et al., 2013). As mentioned earlier in this chapter, dogs are considered as a good 
model to represent SCI in human, for the reasons described above and in Chapter One (Section 1.5).  
These are briefly, long life span, large body mass and naturally occurring diseases. SCI lesions are 
very similar to humans as both SCI occur due to traumatic injuries because of car accidents or non-
traumatic injuries due to IVDD (McMahill et al., 2015). The findings in chapter four of results 
support the proposal of considering dogs with SCI as a model for human SCI. To summarise these 
findings of work, it was clearly demonstrated that both human and canine MSCs underwent tri-
lineage differentiation into adipocytes, osteoblasts and chondrocytes. Although cMSCs showed poor 
adipogenic differentiation, this could be ascribed to the composition of the induction medium 
composition which was more suitable to human MSCs rather than cMSCs. The reason behind the 
chosen human induction medium to induce adipogenesis in cMSCs was to avoid variations of 
experimental conditions. In future using induction medium specific or suitable for cMSCs is 
recommended. Also, both human and canine MSCs have shown a lack of expression of 
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haematopoietic CD markers such as CD34 and CD45, but they showed positive expression to most 
of MSCs’ CD markers such as CD44 and CD90 to a similar extent. Hence, this suggested that cMSCs 
have the capacity to exert an MSC phenotype to a similar extent to hMSCs in culture expanded. 
The comparative examination of MSC CM from both human and canine showed interesting findings 
for their neurogenic and angiogenic paracrine activities as SH-SY5Y cells, and EA.hy926 cells were 
used as a model system to test these two activities respectively. Both morphological analysis using 
Cell IQ analysis software and immunohistochemistry for B-III tubulin staining showed both human 
and canine MSC CM had a neurotrophic effect on neurite outgrowth and neuronal survival from the 
SH-SY5Y cells line to a similar extent.  
Similarly, the examining of angiogenic effects of both human and canine MSC CM in scratch wound 
assay and tube formation assay suggested that human and canine MSC CM exerted their angiogenic 
effect to a similar extent. Due to this similarity in paracrine effects from both human and canine MSC 
CM, a comparison of the protein sequences was performed. The amino acid sequences for NGF and 
VEGF were sought since NGF plays a key role in neurogenesis and VEGF is the key role for 
angiogenesis. This comparison was done to examine the extent of similarity between human and 
canine in terms of protein sequences of these growth factors. Figure 6.1 and 6.2 shows that these two 
human and canine growth factors are homologous. Alignment of human and canine NGF and VEGF 
amino acid sequences revealed a high degree of sequence homology. Interestingly, the detection of 
VEGF in conditioned medium from both human and canine MSCs using a human ELISA kit has 
shown that although the ELISA kit was specific for quantitative determination of VEGF in human 
samples, it has detected VEGF in the canine sample as well. VEGF in cMSC CM was detected at a 
concentration 229.58 pg/ml, and VEGF in human MSC CM was detected at concentration 378.39 
pg/ml (measuring VEGF is a first step toward characterising the secretomes).  
Although the findings in this study could encourage the idea of adopting a dog as a model in 
translation research for cell-based therapy (i.e. treatment using MSCs), however, clearly there is a 
need for an in vivo study to confirm the potential effect of cMSC CM. Also, both cell models, i.e., 
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SH-SY5Y cell and EA.hy926 cells used in this comparative study are of human origin and derived 
from tumours. Thus, responses of these cells to cross-species growth factors may differ from their 
response to primary neuronal and endothelial cells of the same species. Therefore, these findings 
may highlight the importance of establishing neuronal and endothelial cells originating from canine 
as a model system for such investigation. Also and as stated earlier in this section, further 
investigation on the mechanisms of action of cMSC CM is required and also a further proteomic 
profile for cMSC CM is recommended. As described in the introduction (section 1.4) human MSC 
CM is known be composed of various growth factors, cytokines, and ECM (Walter et al., 2010, 
Kupcova Skalnikova, 2013). It is likely that cMSC CM contains similar factors. 
Also, despite these advantages of using cell lines in research they also have their disadvantages, 
represented by the fact that cell lines after continuous passaging over a period of time can show 
genotypic and phenotypic variations. Therefore, researchers should be careful about only relying on 
data generated with cell lines. Hence, the primary cells are believed to be more biologically relevant 
tools than cell lines for studying human and animal biology. Although, primary cells have a limited 
lifespan, they resemble tissue characteristics and their mutation capacity is low compared with cell 
lines that have an infinite life span and that lose tissue characteristics and their mutation capacity is 
high (Hughes et al., 2007).  
Interestingly, primary cells have also been used in the investigation of the potential effect of 
conditioned medium of MSCs. Wright et al 2007 and 2014 tested the MSCs secretomes effect on 
neurite outgrowth using dorsal root ganglia and spinal cord model. Based on their studies they 
suggested that MSCs have impact effect on promoting neurite outgrowth despite the presence of 
inhibitory factors (Wright et al., 2007, Wright et al., 2014). 
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Score Expect Method Identities Positives Gaps 
422 bits(1085) 2e-151 Compositional matrix adjust. 219/241(91%) 223/241(92%) 0/241(0%) 
Canine  1    MSMLFYTLITALLIGIRAEPHPESHVPAGHAIPHAHWTKLQHSLDTALRRARSAPAGAIA  60 
             MSMLFYTLITA LIGI+AEPH ES+VPAGH IP AHWTKLQHSLDTALRRARSAPA AIA 
Human   1    MSMLFYTLITAFLIGIQAEPHSESNVPAGHTIPQAHWTKLQHSLDTALRRARSAPAAAIA  60 
 
Canine  61   ARVTGQTRNITVDPKLFKKRRLRSPRVLFSTHPPPVAADAQDLDLEAGSTASVNRTHRSK  120 
             ARV GQTRNITVDP+LFKKRRLRSPRVLFST PP  AAD QDLD E G  A  NRTHRSK 
Human   61   ARVAGQTRNITVDPRLFKKRRLRSPRVLFSTQPPREAADTQDLDFEVGGAAPFNRTHRSK  120 
 
Canine  121  RSSSHPVFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCR  180 
             RSSSHP+FHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCR 
Human   121  RSSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCR  180 
 
Canine  181  DPTPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAGRR  240 
             DP PVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKA RR 
Human   181  DPNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAVRR  240 
 
Canine  241  A  241 
             A 
Human   241  A  241 
 
Figure 6:1 Alignment of NGF amino acid sequences of canine (NCBI Reference Sequence: 
NP_001181879.1) and human (NCBI Reference Sequence: NP_002497.2).  
Differences are marked in the human sequence by highlighting the residues in yellow. 
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Score Expect Method Identities Positives Gaps 
377 bits(969) 8e-132 Compositional matrix adjust. 205/215(95%) 207/215(96%) 1/215(0%) 
Canine  1   MNFLLSWVHWSLALLLYLHHAKWSQAAPMA-GGEHKPHEVVKFMDVYQRSYCRPIETLVD  59 
            MNFLLSWVHWSLALLLYLHHAKWSQAAPMA GG    HEVVKFMDVYQRSYC PIETLVD 
Human   181 MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVD  240 
 
Canine  60   IFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEEFNITMQIMRIKPHQGQHIGEM  119 
             IFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEE NITMQIMRIKPHQGQHIGEM 
Human   241  IFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEM  300 
 
Canine  120  SFLQHSKCECRPKKDRARQEKKSIRGKGKGQKRKRKKSRYKPWSVPCGPCSERRKHLFVQ  179 
             SFLQH+KCECRPKKDRARQEKKS+RGKGKGQKRKRKKSRYK WSVPCGPCSERRKHLFVQ 
Human   301  SFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVPCGPCSERRKHLFVQ  360 
 
Canine  180  DPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR  214 
             DPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR 
Human   361  DPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR  395 
 
Figure 6:2 Alignment of VEGF amino acid sequences of canine (NCBI Reference Sequence: 
NP_001003175.2) and human (NCBI Reference Sequence: NP_001165095.1).  
Differences are marked in the human sequence by highlighting the residues in yellow.
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It is worth mentioning that MSCs reveal differences in their biological properties based on their tissue 
of source (Elahi et al., 2016). In fact, recently, there is a clear interest in using AT MSCs in different 
aspects of research in regenerative medicine over the BM MSCs. This can be as a result of the fact 
that AT MSCs possess several features that make AT MSCs preferable, these include; ease of access 
and the harvesting of adipose tissue has a low morbidity rate when compared with the harvesting of 
bone marrow (Padoin et al., 2008). Also, for their high quantity of MSCs released from adipose tissue 
compared with yields from bone marrow. Besides, AT MSCs are characterised by their high 
proliferation capacity and secreted proteins (basic fibroblast growth factor, interferon-γ, and Insulin-
like growth factor-1), and immunomodulatory effects (Li et al., 2015). However, AT MSCs are a 
highly heterogeneous population. SVF released from collagenase processed adipose tissue is 
composed of different stem cells subpopulations and fully differentiated cells (differentiated 
endothelial cells, smooth muscle cells and pericytes) (Ho et al., 2008). 
Since CD271 has emerged as a CD marker for isolation of subpopulations within MSCs, many 
studies; have focused on their differentiation capacity regardless of their secretomesʼ activities 
(Quirici et al., 2002). Hence, in Chapter Five of results, and as a continuation in the loop of the 
translational pathway to human clinical trials, the study aimed to highlight the CD271+ MSC CM 
neurogenic and angiogenic activities compared with the whole population of MSCs, i.e., PA MSC 
CM and CD271- MSC CM. The development of homogenous MSC population of known paracrine 
activity would allow an increase in the efficiency of clinical applications of MSCs to treat and repair 
injuries including SCI.  
The MSC subpopulations were first examined to determine if they match the ISCT criteria. The three 
MSC populations had an equivalent capacity to differentiate into adipocytes and chondrocytes. 
Whereas they showed variances in their capacity to differentiate into osteoblasts as the PA MSCs 
and CD271+ MSCs exerted a high level of ALP. This observation was supported by other researchers 
(Cuthbert et al., 2015) although in their study the CD271+ MSCs had greater osteogenic activity even 
when compared to PA MSCs.
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This study has examined the ALP expression from 2 MSC donors following their osteogenic 
induction, therefore, increasing the number of repeat experiment is recommended. As the limited 
number of MSC donors (i.e., 2 MSC donors) used in this experiment could be the reason for 
unmarked differences of osteogenic differentiation between CD271+ MSCs and PA MSCs. 
Moreover, the three MSC subpopulations shared very similar expression levels of standard MSC 
markers such as CD44, CD73, CD90, and CD105, but lacked expression of haematopoietic cell 
surface markers such as CD34 and CD45. Hence, from all above it is possible to conclude that all 
MSC subpopulations exerted the MSCs phenotype.  
Interestingly, CD271+ selected MSCs lost their capacity to express the CD271 cell surface marker 
at an early passage, i.e., passage II. Similarly, Churchman et al., 2012 in their study showed that 
the BM MSCs CD271+ also lost the expression of CD271 as the culture expanded. They assumed 
this may relate to the physiologic requirements for bone remodelling, and hence the production 
of osteoblasts, may stimulate CD271 cells in vivo. Growing as monolayers in culture and in vitro 
environment conditions could also be the reason behind such loss rather than functional 
differences between cells (Tormin et al., 2011). Hence, these findings could suggest that the 
culture expanded MSCs lost the expression of CD271 in even earlier passages.  Although the 
mechanism underlying the loss of expression of CD271 is still unknown, but researchers have 
suggested that the presence of CD271+ MSCs in vivo may relate to microenvironmental and 
physiological factors  (Cattoretti et al., 1993, Churchman et al., 2012). 
As stated earlier the aim of this study was to develop a strategy based on the generation of a 
homogenous MSC population of known paracrine activity which could be advantageous in the 
application of these cells as therapy for SCI. The three MSC subpopulationsʼ conditioned medium 
showed neurogenic effects on SH-SY5Y neuroblastoma cells to a similar extent. However, this 
finding of enhanced SH-SY5Y neurite outgrowth was based on the morphological appearance of the 
cells, therefore, further experimental confirmation to validate the effects of MSC CM in promoting 
neuronal differentiation, e.g., through increased Beta-III tubulin immunopositivity would be 
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beneficial to emphasise the SH-SY5Y cells differentiation. Whereas, the finding of angiogenic 
activity amongst MSC subpopulations conditioned medium showed an interesting observation.  
In the scratch wound assay and tube formation assay, the CD271+ MSC CM showed less angiogenic 
activity. In the EA.hy926 endothelial scratch wound assay, Cell IQ results showed that CD271+ MSC 
CM had a low angiogenic effect compared with PA MSC CM and CD271- MSC CM. This finding 
was a further corroborated by the tube formation assay as the CD271+ MSC CM showed the poor 
angiogenic effect on enhancing formation of tube-like capillaries from EA.hy926 cells in Matrigel 
reduced growth factor assay when compared with PA MSC CM and CD271- MSC CM. Hence, this 
finding may support the hypothesis raised in this study as the homogenous population of MSCs 
exerted different biological effects compared to the heterogeneous population.  
The data in this study indicated that the isolation strategy based on CD271 expression resulted in a 
cell population which has a low paracrine activity of angiogenic activity, although VEGF (which 
plays the main role in angiogenesis) was secreted by these subpopulations at a similar concentration. 
These findings encourage that further understanding of the mechanisms of action of MSC CM could 
be obtained through screening for the presence of other endogenous regulators that are involved in 
the process of angiogenesis. 
 This finding has answered the question raised in this study as to whether the subset of MSCs 
population exhibit a different pattern of action. This supports the idea of selecting specific 
homogenous populations to repair a specific kind of injury. MSCs CD271+ might not be 
recommended for SCI repair, but it could be useful for repairing tissue where the requirement for 
new blood vessels are not necessary such as repairing articular cartilage, as this subpopulation in 
other studies showed a high capacity for chondrogenesis capacity (Mifune et al., 2013). In addition 
to the isolation of subpopulations using CD271 CD marker, on different occasions, many researchers 
have used different CD markers to investigate their biological activities. For example, isolation of 
MSCs subpopulation based on their expression of CD 105. In fact, CD105 is a receptor that plays an 
important role in development and remodelling of blood vessels (Duff et al., 2003).  
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Many studies claimed that CD105 MSCs have more myogenic potentiality. Both in vitro and in vivo 
studies suggested that CD105 MSCs differentiation into myoblast-like cells after myogenic induction 
and differentiation into muscle cells after their transplantation into damaged skeletal muscles in rats 
(Conconi et al., 2006, Ranganath et al., 2012). Another example for CD marker used to sort specific 
subset population of MSCs is CD146. The studies suggested that the localization of this 
subpopulation of MSCs is perivascular (Crisan et al., 2008). 
Conclusion  
In conclusion, from all of the results described above, there are three key findings presented in this 
thesis. In Chapter 3 of results, the study has demonstrated for the first time that the secretomes of 
cMSCs exert neurogenic and angiogenic effects in an in vitro assays. These results highlight the 
desirability of using cMSCs secretomes in further studies of wound healing in dogs, e.g. following 
SCI. These encouraging findings suggested considering dogs with SCI as a model for SCI in human, 
the results in chapter four showed for the first time the similarity in neurogenic and angiogenic 
activities in human and canine MSCs secretomes. Finally, the findings in chapter five of this study 
have demonstrated for the first time that the secretomes of purified cells of MSCs culture could exert 
a different biological effect. Thus this study may suggest that the usage of such purified cells will 
allow an increase in the efficacy of clinical applications of MSCs to treat and repair specific kind of 
injured tissues. 
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7 Appendix  
 
7.1 Quantification of exosomes concentration and measurement of their 
diameters 
 
Figure 7:1 Measurements of the size and quantity of exosomes isolated from the secretomes of 
cMSCs. 
The representative histograms show the concentration (y axis) and the diameter (x axis) of the 
extracellular vesicles from cMSC CM 2000 xg supernatants (left panel) and serum free medium as 
control (right panel, where the histogram show no presences of EVs). cMSC CM or serum free 
medium as controls were processed for EVs isolation by ultracentrifugation. Briefly, cMSC CM or 
control medium was centrifuged at 300 xg for 10 minutes. Then the collected supernatant was 
centrifuged at 2000xg for 20 minutes at 4 ºC. The supernatant was transferred to a special 
ultracentrifugation tube suitable for a SW 40 Ti rotor of optima L-100 ultracentrifuge (Beckman 
Coulter). This final supernatant was then ultra-centrifuged at 100,000 xg for 70 minutes. Then after 
removing the supernatant the pellets were re-suspended in 100 µl of PBS. The nanopore-based 
system q-Nano (IZON Science, Christchurch, New Zealand) was used to determine the size of 
extracellular vesicles in the MSC CM using a 200 nm nanopore membrane (IZON Science). The data 
was analysed using IZON software. Results suggest that cMSCs were secreting EVs in a relatively 
high concentration (1.40x109 particles/mL), where the majority of them fall within the diameter size 
range between 90 and 200 nm, commonly known to correspond to the exosomes (left panel). Serum 
free medium that should be EVs-free was also measured under the same conditions. Acquired data 
demonstrate the lack of characteristic EVs (right pane, l3.26x107 particles/mL) in serum free profiles 
as observed on the left panel, and it is due to the instrumental noise. It can be concluded that 
nanoparticles measured in cMSC CM preparations (left panel) are EVs derived from cells, and not 
from serum free medium (right panel). 
cMSC CM Control 
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